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Abstract 
Even though most of the FDA approved drugs currently out in the market and in the 
process of development are weakly basic drugs, the bioaccumulation and stabilization of these 
drugs are not well understood. For this purpose, we use a model drug, clofazimine (CFZ), which 
is an FDA-approved, weakly basic, and poorly soluble drug that has been used worldwide to 
treat patients with leprosy and tuberculosis diseases, curing over 16 million people in the last 
twenty years, to investigate its bioaccumulation and stabilization properties. During prolonged 
oral administration, CFZ accumulates in macrophages of humans and mice as Crystal Like Drug 
Inclusions (CLDIs), which have been chemically characterized to be composed of hydrochloride 
salts of CFZ (CFZ-H
+
Cl
-
) crystals. However, the mechanism by which the formation and 
stabilization of these insoluble complexes occur in cells is not known. Thus, to address this gap, 
we test the following hypothesis in this dissertation: due to the sufficient proton and chloride 
levels in endolysosomes, we hypothesize that the phase-transition-dependent drug accumulation 
and stabilization processes are occurring inside intracellular compartments of likely 
endolysosomal origin, in macrophages of humans as well as mice.  
To test our hypothesis, we adapt a systems-based mathematical lysosomal ion regulation 
model, which consists of lysosomal membrane proteins, such as the proton-pump known as 
Vacuolar ATPase (V-ATPase), Cl
-
/H
+
 antiporter known as CLC7, and membrane proton leak, in 
order to investigate the key lysosomal parameters that play essential role in the physiological, 
dose-dependent CFZ-H
+
Cl
-
 crystal bioaccumulation. Furthermore, we examine the stabilization 
x 
 
of the free base (CFZ) versus salt form (CFZ-H
+
Cl
-
) of the drug by mathematically fitting an in 
vitro pH-dependent solubility data of CFZ-H
+
Cl
-
 crystal obtained at pH ranging between 
extracellular, cellular, and subcellular pH values, and determining the drug’s solubility 
properties, which include the apparent pKa, intrinsic free base and salt solubility, pHmax, and Ksp 
values. Moreover, we model the cellular and subcellular drug transportation and calculate i) the 
non-membrane and membrane drug accumulation by accounting for the cell-type dependent 
heterogeneous and asymmetric lipid bilayer of the biological membranes ii) the degree of 
supersaturation, which is a measure of thermodynamic propensity of precipitation, of both free 
base CFZ and CFZ-H
+
Cl
- 
salt
 
using the aforementioned solubility properties.  
Collectively, our computational results as well as the CFZ-H
+
Cl
-
 physicochemical 
properties in relation to the ion contents and pH of the microenvironment suggest that the 
physiological and preferential phase-transition-dependent accumulation and stabilization 
mechanisms of CFZ-H
+
Cl
-
 crystals in macrophages, more specifically in macrophage lysosomes, 
are primarily determined by the lysosomal V-ATPase. Moreover, we have shown that the 
alteration of lysosomal physiology due to lysosomal morphological changes induced upon the 
accumulation of intrinsic and extrinsic materials, such as cholesterol and biocrystal drugs, 
respectively can be reversed upon V-ATPase upregulation or inhibition of membrane proton 
permeability. In addition, in terms of characterizing the stabilization of free base CFZ and CFZ-
H
+
Cl
-
 salt, we have found the degree of supersaturation of CFZ-H
+
Cl
-
 salt to be at least 1000-fold 
greater than that of free base CFZ in all of the cellular compartments, including the biological 
membranes; emphasizing the propensity of the formation and stabilization of massive CFZ-H
+
Cl
-
 
salt precipitate in the lysosomal environment even when introducing low (picomolar) total 
extracellular drug concentration.   
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Chapter 1: Introduction 
 
1.1. Introduction 
Nearly 40% of drug failure is attributed to the lack of full understanding of a drug’s 
pharmacokinetic (PK) property, comprised of administration, distribution, metabolism, 
excretion, and toxicity (ADMET)
1
. This jeopardizes the high-risk investment associated with 
drug development from conception to putting the drug out on the market, which therefore 
demands researchers to address drugs’ PK properties from early-on. Moreover, understanding a 
drug’s biodistribution and bioabsorption is essential to minimize potential off-target side effects. 
Even in cases where repositioning of FDA-approved drugs has been favored due to cost and 
time-effective ways of disease treatment, determining and characterizing the PK properties of 
such drugs is very important
2,3
. 
Most drugs that are currently in drug discovery and development pipelines are weakly 
basic molecules and therefore, it is essential to understand ways of improving their solubility
4
. 
Counterion-mediated drug salt formation has been the primary mechanism by which the 
solubility of ionizable drugs that are rather weakly soluble in an aqueous environment is 
enhanced
5
. The most prevalent counterion in salt formation of such drugs is chloride
6
. Solubility 
improvement favors drug bioavailability, which can in turn increase the probability of the drug 
reaching its site of action quickly and effectively. However, there are reported cases where such 
favorable effects are not observed
7
. Although these are generally associated with the poor 
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understanding of the drug’s PK properties prior and/or post administration in relation to the 
physicochemical interactions of the drug with the host environment, post administration phase 
transition of drugs manifesting as drug precipitation remains among the most major factors 
affecting drug bioavailability
8-10
.   
Drugs with poor solubility precipitate out of solution, thereby generally deteriorating 
their chances of reaching their sites of action, which in turn would lead to unwanted off-target 
reactions that could potentially result in toxicity. Attesting to this, structures of toxic insoluble 
drug complexes have been implicated in favoring inflammation by resulting in the destabilization 
of lysosome
11
, which is a subcellular organelle containing various pH-dependent lysosomal 
enzymes involved in digesting unwanted materials delivered from the cytoplasm and 
extracellular environment to the lysosome. To the contrary, there are insoluble drug complexes 
that are not toxic if their bioavailability is physiological, indicating that toxicity can be due to 
dose-response and lack of conducive cellular environment that can withstand the biophysical and 
thermodynamic properties of the drug
12
. Thus, we need to have a better understanding of the 
phase-transition-dependent drug bioaccumulation not only as a separate phenomenon, but in 
conjunction with the cellular environment. This will allow us to distinguish the effective dose-
regimen and cellular conditions that favor insoluble versus soluble drug species in the hope of 
predicting and delineating effective from toxic profile of any given drug.  
Indeed, there have been many efforts in the study of drug accumulation and precipitation 
in vivo as well as in vitro
8-10
. Most studies have been focused on improving drug bioavailability 
by introducing excipients, such as cosolvents and surfactants, that could improve the drug’s 
solubility while minimizing its potential of precipitation
13
. In addition, various formulation 
advancements, such as particle size reduction, solid dispersions, lipid-based formulations, salts 
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and cocrystals are generally used to improve drug solubility and bioavailability
13
. However, the 
complexity of a cellular environment, characterized by ion homeostasis, pH, and lipid content – 
to name few – can change the intended outcome of the formulations. Indeed, consistent with this, 
challenges reported in various in vitro and in vivo correlation studies
13,14
 highlight the gap that 
remains in the field of phase-transition-dependent PK studies in concert with cellular 
environment.  
Among the aforementioned important cellular features, the effect of pH on phase 
transition properties of drugs can be determined using the well-established solubility-pH 
relationship developed by Kramer and Flynn
15
. This is especially important when studying the 
effect of different cellular pH on the accumulation and stabilization of drug species. It is well 
established that when weak base drug molecules enter acidic cellular environment, such as the 
lysosome, they undergo a phenomenon known as lysosomotropism
16
, which is the ionization of 
the drug molecule and its consequent sequestration within the organelle due to its low 
permeability. However, the stability of the drug upon entry into the lysosomes must be well 
understood to avoid unwanted side effects. In fact, while some weak base drug accumulation 
within lysosomes have been associated with favorable effects
17
, some are rather associated with 
the destabilization of the lysosomal physiology which leads to toxicity
18,19
. Thus, elucidating the 
relationship between maintaining the acidic endolysosomal functionality and stabilizing the 
phase-transition-dependent drug accumulation is necessary.  
For this purpose, utilizing a mathematical model
20,21
 that incorporates the biophysics of 
the endolysosomal proton pumping protein and chloride channel, and the electrophysiological 
roles of the chloride ion and membrane potential can greatly benefit the understanding of the 
dynamic subcellular physiology, including its molecular genetics that can accommodate drug 
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accumulation, salt formation, and stability, which is rather challenging—if not impossible—to 
study by solely relying on wet lab experiments. Predictions that arise from hypothesis and 
exploratory-driven mathematical models could potentially bridge the gap between in vitro and in 
vivo drug pharmacokinetic disparities. Furthermore, they can help shed light on the potential of 
repositioning many insoluble complex-forming drugs that have rather been neglected.   
 
1.2. Introduction to model drug: Clofazimine 
Clofazimine (CFZ) is an FDA-approved antibiotic used to treat leprosy
22
, curing over 16 
million people worldwide
23. Even though the exact mechanism of the drug’s action is 
multifaceted, it is likely that bacterial growth hindrance, membrane disruption, and increment of 
antimicrobial reactive oxidant species play important roles
24-26
. Regardless of the mechanism, 
clofazimine’s antibiotic and anti-inflammatory properties have made researchers to-date 
interested in using this drug for various treatments including cancer, respiratory disease, skin-
targeted autoimmune diseases, multi-drug resistant tuberculosis (MDRTB), and TB-HIV co-
infections
27-30
. Along with its definitive antimycobacterial activity in vitro, CFZ has had a 
success rate of 87.9% when administered along with other drugs such as, ethambutol, isoniazid, 
and pyrazinamide to treat MDRTB
31
. MDRTB arises due to the pathogen’s capability of 
perturbing phagosomal maturation process by disrupting endolysosomal acidification in 
macrophages
32
. Thus, possible mechanism through which CFZ reverses the resistance of the 
growing mycobacteria to previously used drugs could be by maintaining endolysosomal pH 
necessary for phagosomal maturation, which facilitates the removal of the mycobacteria from the 
host.   
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Moreover, it has been shown that clofazimine inhibits cathepsins B, H, and L, which are 
lysosomal enzymes involved in the progression of various deadly diseases including cancer, 
arthritis, and Alzheimer’s disease33-39.Tumoricidal properties of clofazimine have also been 
useful in treating cancer patients by possibly increasing lysophospholipids in membranes
40
. 
These findings indicate that although the drug has had tremendous success in treating bacterial 
and non-bacterial diseases, its full potential has not been exploited and demands more studies 
that can capitalize on its efficacy while diminishing its clinically-reported, dose-related 
reversible side effects, such as skin discoloration
41
. Among the interesting features of CFZ is that 
it forms Crystal Like Drug Inclusions (CLDIs) in both humans as well as mice
42-44
. After three to 
four weeks of feeding the drug to mice, our lab has shown that the crystals accumulate in liver, 
spleen, and lung macrophages
45
. Our wet lab studies have indicated that these crystals give rise 
to the drug’s anti-inflammatory property12,46. However, the mechanism of crystal formation is 
unknown. In addition, for the drug accumulation to be sustained and induce effects, the drug 
containing macrophages must go through accommodative process to remain viable and active. 
Thus, it is important to understand the conditions required by macrophages for accumulating 
CFZ crystals as it would lay the groundwork for understanding the mechanisms of 
bioaccumulation, crystallization, and stabilization of CFZ.   
To explain the relatively complex in vivo phenomenon, we initially have to have better 
understanding of in vitro studies that can correspond to in vivo CLDI formation. In support of 
this, previous work in our lab has indicated that the in vitro accumulation and crystallization of 
CFZ is within order of magnitude consistent with that of the in vivo
47
. Moreover, we have shown 
that CLDIs are comprised of CFZ-H
+
Cl
-
 crystals, and that both show similar fluorescence, 1D 
nuclear magnetic resonance (NMR), and powder X-ray diffraction (pXRD) profiles
48
. Thus, we 
6 
 
hypothesize that, due to pH decrement and chloride increment along the endocytic pathway, the 
accumulation, protonation, and subsequent crystallization of clofazimine is coupled with the 
endocytic pathway, more specifically with the endolysosomal organelles based on ion-trapping 
mechanism and chloride sequestration. Ion-trapping mechanism has been implicated in studies of 
subcellular accumulation of other weakly basic amines, with similar solubility and 
hydrophobicity profile to CFZ
49
. Because most weakly basic molecules have ionizable groups 
with high pKa greater than 5, they become mainly protonated upon entering an acidic 
environment, such as the endolysosomes. Once protonated, the molecule will have less 
permeability and therefore, gets trapped in the organelle, consequently inducing change in 
organellar size
50,51
. Such phenomenon could arise due to the phase-transition-dependent 
accumulation and stabilization of insoluble drug complexes upon chloride sequestration by the 
protonated drug, also known as a common-ion effect
5,6
. 
Alternatively, in the event of phagocytosed CFZ crystals, there could be an 
accommodative process in macrophages where the regulation of certain endolysosomal genes 
may contribute for the phase-transition-dependent drug accumulation and crystallization 
processes to not induce toxicity by perturbing phagosomal maturation. It has been shown that the 
transcription factor EB (TFEB) regulates lysosomal biogenesis upon the introduction of a foreign 
material to the lysosome
52
. Thus, we suggest that the expression level of TFEB-regulated 
lysosomal genes will be essential to our understanding of the maintenance of accumulation and 
crystallization of CFZ in the endolysosomes while keeping the integrity of the host cells intact. 
Moreover, the heterogeneous expression of endolysosomal genes will aid our understanding of 
the relationship between different expression levels of genes that are essential for regulating 
proton and chloride ions, and the overall heterogeneous distribution of CLDIs in macrophages.  
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1.3. The role of endolysosomal biogenesis in the cell-type specific phase-transition-
dependent drug bioaccumulation and salt precipitation 
Macrophages are categorized into two based on their induced polarization states in 
response to environmental stimuli. These states are known as M1 and M2 types of macrophages. 
M1 macrophage is characterized by pro-inflammatory responses, such as interferon-gamma-
receptor after induction by lipopolysaccharides (LPS) antagonist; whereas M2 macrophage is 
characterized by anti-inflammatory cytokines, such as, IL-10 and TGM2, after stimulation with 
IL-4 and IL-3 agonists. In addition, macrophages are heterogeneously distributed in vivo
53
. This 
is in agreement with our lab’s observation of the heterogeneously distributed CLDIs in peritoneal 
and alveolar macrophages
42
. Thus, understanding the necessary conditions for various types of 
macrophages to accommodate various amounts of CLDIs require a modeling prediction that 
incorporates analysis of the literature, which elucidate different expression levels of the 
electrogenic, multi-subunit proton pumping protein known as vacuolar-type ATPase (V-
ATPase), and chloride channels and transporters in macrophages, and more specifically in 
endolysosomes. Chloride channels/transporters that dominate the endolysosomes are classified as 
CLC family, where CLCs 3-5 are primarily found in the early stages, and CLCs 6 and 7 are 
localized in the later stages of the endocytic pathway
54
. 
It is suggested that the expression levels of V-ATPase subunits must be regulated by a 
transcriptional and post-transcriptional universal mechanisms. Stat6 is among the transcription 
factors that highly regulates lysosomal genes. In the presence of IL-4 stimulant in Stat6+/+ 
mouse macrophages, some of the V-ATPase subunits are upregulated, indicating that M2 
macrophages have higher V-ATPase expression
55
. Beyond Stat6, transcription factor EB (TFEB) 
is a lysosomal transcription factor that has been shown to play significant role in regulating 
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lysosomal biogenesis, including V-ATPase expression
56-58
. Although TFEB has not been 
associated with CLC7 expression, Microphthalmia transcription factor (MITF), which is in the 
same family as TFEB has been shown to regulate CLC7 expression
59,60
. 
In osteoclasts, where the prevalence of CLC7 is necessary for bone resorption, CLC7 and 
V-ATPase (more specifically, the a3 subunit) expression levels must change with the size of the 
cell
61-64
. This can be due to an increase in TFEB expression, as that has been shown to expand 
lysosomal compartment as well as increase the number of lysosomes per cell in HeLa cells
50
. 
Similarly, we expect the TFEB expression to increase with the size of the lysosome as well, 
because the translocation of TFEB from the cytoplasm to the nucleus has been associated with an 
increase in lysosomal volume upon accumulation of a weakly basic molecule
51
. Not only is 
CLC7 expression level important, but also its Ostm1 subunit
64
, which is required for the role of 
CLC7 in dissipating membrane potential for the V-ATPase to regulate physiological pH. 
Moreover, among the V-ATPase subunits, the ratio of a1 to a3 expression level has been shown 
to vary with different cell types including macrophages and osteoclasts, and have a direct 
relationship with the change in phagolysosomal pH
65-67
. In the case of non-physiological change 
in pH, less localization of V-ATPase a3 subunit in osteoclasts occurs, hence affecting bone 
resorption
66,68
. 
In addition to cell-type specific heterogeneous lysosomal gene expression, lysosomes are 
known to have different morphologies
69
. Although most lysosomes are known to be spherical in 
shape, there have been reports showing lysosomes with tubular and disc-shaped geometries
69,70
. 
While tubular lysosomes are primarily prevalent before the initiation of material uptake by the 
endolysosomes
70,71
, the disc-shaped lysosomes are reported in the case of prolonged material 
accumulation within the lysosomes, such as those in various lysosomal storage disorders 
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(LSDs)
72-74
. Indeed, the non-degradable materials range from intrinsic cellular materials, such as 
cholesterol and lipids, to extrinsic materials, such as weak base drugs
69,75-77
. 
The disc-shaped lysosomes have non-physiological pH
74,78
, which arrests the proper 
functioning of the pH-dependent lysosomal enzymes that induce the timely degradation of the 
accumulating materials. Given physiological lysosomes are important for the degradation of 
cellular materials, recycling of membrane materials, such as membrane proteins, cholesterol, and 
lipids, such perturbation of lysosomal physiology is detrimental to the overall cellular function
58
. 
Therefore, thorough understanding of lysosomal ion homeostasis with respect to drug-induced 
change in lysosomal morphology is important to avoid the negative side effects of prolonged 
material accumulation in lysosomes. Indeed, this is very essential to our understanding of 
physiological cellular drug accumulation, especially in cases where drugs are administered for 
longer periods of time.  
Although there have been studies showing the role of TFEB nuclear translocation to 
remedy lysosomal malfunction observed in LSDs
52,79,80
, the mechanism by which this occurs is 
not well recognized
81
. This could be attributed to the dynamic, interdependent processes of 
lysosomal biogenesis, ion homeostasis, membrane trafficking, and membrane protein expression 
and turnover, all of which are extremely difficult to monitor and investigate in wet lab 
experiments where appropriate experimental techniques lack. Therefore, utilizing a mathematical 
model
20
 that allows us to investigate the interdependence of lysosomal morphology, gene 
expression, and ion homeostasis, is deemed necessary. This will especially be important in our 
understanding of the cell’s mechanistic role in the phase-dependent prolonged accumulation and 
stabilization of CFZ as biocrystalline CFZ-H
+
Cl
-
 salts in macrophages, in vivo
42,47
. 
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1.4. Modeling phase-transition-dependent cellular drug accumulation and stabilization  
Weak base drugs can undergo phase transition depending on their physicochemical 
properties, such as their pKa, intrinsic free base and salt solubility, pHmax (pH at which the free 
base and salt forms of the drug coexist), and salt solubility product (Ksp), as well as the pH and 
ion content of their cellular microenvironments
6,15
, which can affect their distribution profile, 
thereby affecting their overall PK properties. While the precipitation of CFZ into insoluble 
complexes known as CLDIs has not been associated with any major side effects
12,46
, reports have 
shown phase transition of other drugs, such as ciprofloxacin, are linked with adverse drug side-
effects, such as kidney injury known as crystal nephropathy
82,83
. Although alkaline urine is 
suggested to contribute to such side effect, the exact mechanism by which this occurs is not well 
defined
84
. 
Furthermore, there are various weak base drugs which permeabilize the lysosomal 
membrane, thereby inducing cellular toxicity upon the release of lysosomal enzymes from the 
lysosome to the cytosol
19
. However, the relationship between drug accumulation within the 
various cellular compartments, including cell and organelle membranes, such as lysosomal 
membrane and the degree of membrane permeabilization is not well characterized. Moreover, 
whether the amount and type of lipids in the biological membranes contribute to this effect is not 
known. Indeed, the presence of surfactants is known to affect the solubility of most drugs
85
 
including weak base drugs
86
. Thus, whether biological membrane lipids could induce similar 
effects, thereby affecting the overall cellular drug disposition and stabilization remains to be 
investigated.  
However, regarding the knowledge of subcellular drug disposition, it is well known that 
weak base compounds accumulate to a greater extent in the lysosomes as ionized forms
16,51,87
. 
11 
 
However, not much is known regarding the stability of those entrapped, ionized drugs in the 
lysosome. Moreover, although experimental determination of subcellular drug concentrations of 
non-fluorescent compounds has been possible
88
, the subcellular concentration of the phase-
transition-dependent drug species is not accounted for, and remains to be challenging to 
investigate.     
Indeed, in order to address the gap in wet lab experimental techniques, there have been 
multiple mathematical models built to study drug accumulation, which generally follow Fick’s 
first law of diffusion and Nernst-Planck equation
42,89
, and in some more elaborate cases 
incorporate the effect of drug transporters
90,91
. Although these models are very useful in 
predicting drug accumulation in different cellular compartments, they neither elucidate the 
stability of these drugs nor the propensity of these drugs to precipitate out of solution inside the 
organelles and the membranes. This suggests that building a mathematical model that 
investigates the phase transition of drugs in different cellular environments while accounting for 
the effect of biological membrane lipids is important to not only better predict and understand 
the PK properties of a given drug, but also to minimize unwanted, drug-induced adverse side 
effects.  
 
1.5. Dissertation objectives 
Cellular drug disposition, accumulation, and stabilization, collectively remain to be topics 
that are not well characterized in the drug discovery and development fields, which in turn leads 
to drug failure following high-risk time and financial investments, and unwanted adverse drug 
side effects associated with various health complications. Thus, in this dissertation, I first 
investigate the relationship between endolysosomal membrane proteins and endoylsosomal ion 
12 
 
homeostasis, and their roles in physiologically accommodating and stabilizing biocrystal drug 
accumulation (Chapter 2). In concert with this, I study the physicochemical properties of a given 
biocrystal drug, which are important in elucidating the stability of the drug in endolysosomes. 
Second, I investigate the key lysosomal parameters that can explain drug accumulation observed 
in macrophages with respect to changes in lysosomal morphology (Chapter 3), which is 
important for our understanding of the cell-type specific drug accumulation and stabilization 
phenomenon. Third, I investigate how phagosome maturation influences biocrystal 
biocompatibility by studying the phase-transition-dependent accumulation and stability of the 
biocrystal drug in relation to different cellular compartments (Chapter 4). Lastly, I perform 
computational pharmacokinetic analysis of in vivo clofazimine accumulation and efflux 
experiments, which have allowed us to determine the steady-state clofazimine accumulation in 
different macrophage populations (Chapter 5).  
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Chapter 2: Elucidating the Relationship between Endolysosomal Membrane 
Proteins and Endolysosomal Ion Homeostasis and Their Roles in 
Accommodating and Stabilizing Biocrystal Drug Accumulation 
 
This chapter was adapted from submitted manuscript: 
Woldemichael, T., Keswani, R.K., Rzeczycki, P., Murashov, M.D., LaLone, V., Gregorka, B., 
Swanson, J.A., Stringer, K.A., and Rosania, G.R. (2017) Reverse Engineering the Intracellular 
Self-Assembly of a Functional Mechanopharmaceutical Device. 
 
2.1. Relevance to Thesis  
This chapter incorporates the interdependence of lysosomal ion homeostasis and 
biocrystal drug accumulation, and discusses the key lysosomal parameter for the physiological 
accumulation of biocrystal drug in a cell-type dependent manner by i) investigating the 
physicochemical properties of free base CFZ and CFZ-H
+
Cl
-
 salt in relation to different cellular 
and subcellular conditions, such as pH and ion content, ii) modeling the effects of various cell-
type dependent lysosomal features, such as membrane proteins and ion content on biocrystal 
drug accumulation.   
Our findings enabled us to further design and characterize the subcellular accumulation 
of the drug in vitro. Moreover, the combination of wet lab and computational results have 
strengthened our understanding of previously published results from our lab in regards to the 
unique occurrence of the self-assembled, crystal packing of the clofazimine hydrochloride salt in 
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vivo, in macrophages. In addition, the conclusions we have drawn from our findings will allow 
us to design and test new hypothesis-driven studies of physiological drug bioaccumulation.   
Furthermore, given that most drugs that are already FDA approved or in clinical trials are 
weak base compounds, our findings are critical for elucidating the mechanism of a weak base 
drug accumulation and stabilization in cells in a cell-type dependent manner, which is a 
phenomenon closely associated with the drug’s overall pharmacokinetic profile. Thus, our 
findings will further open doors to the fields of drug delivery and drug repurposing where drug 
stability and accumulation, in relation to the biochemical, biophysical, and biomechanical 
features of its natural carriers: cells, play a significant role in the success of a drug development 
process. 
 
2.2. Personal Contribution 
I modeled and analyzed wet lab experimental solubility-pH data to obtain the 
physicochemical properties of free base CFZ and CFZ-H
+
Cl
-
 salt, which are important in our 
understanding of the cellular and subcellular drug disposition and stabilization in concert with 
cellular and subcellular environments.  
In addition, I modeled and performed simulations of the effects of various cell-type 
dependent lysosomal features, such as membrane proteins and ion content on biocrystal drug 
accumulation, which have allowed us to identify the key lysosomal parameter that is essential 
and sufficient to explain the preferential physiological bioaccumulation and stabilization of CFZ 
in macrophages. The findings from the model and simulation results have allowed the design of 
wet lab experiments which have further strengthened our conclusions regarding the mechanistic 
role of lysosomal membrane proteins on the accumulation of clofazimine hydrochloride salt.  
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2.3.  Abstract 
Weakly basic, poorly soluble chemical agents could be exploited as building blocks for 
constructing sophisticated molecular devices inside the cells of living organisms. Here, using 
experimental and computational approaches, we probed the relationship between the biological 
mechanisms mediating lysosomal ion homeostasis and the self-assembly of a weakly basic small 
molecule building block into a functional, mechanopharmaceutical device in macrophage 
lysosomes. Physicochemical considerations indicate that the intralysosomal stabilization of the 
self-assembled mechanopharmaceutical device depends on the pHmax of the weakly basic 
building block
 
and its affinity for chloride, both of which are consistent with the pH and chloride 
content of a physiological lysosomal microenvironment. Most importantly, in vitro and in silico 
studies revealed that high expression levels of the vacuolar ATPase (V-ATPase), irrespective of 
the expression levels of chloride channels, are necessary and sufficient to explain the cell-type 
dependent formation, stabilization, and biocompatibility of the self-assembled 
mechanopharmaceutical device within macrophages.  
 
2.4.  Introduction 
Clofazimine (CFZ) is a weakly basic, poorly soluble, FDA-approved small molecule 
antibiotic that self-assembles
1,2
 into insoluble, biocrystalline structures known as Crystal Like 
Drug Inclusions (CLDIs) in macrophages of both mice and humans
3-5
. In mice, CFZ precipitates 
and accumulates in tissue macrophages as a biocrystalline hydrochloride salt (CFZ-H
+
Cl
-
). 
Remarkably, in Kupffer cells, splenocytes, alveolar macrophages, and peritoneal macrophages, 
the amount of intracellular CFZ-H
+
Cl
-
 typically exceeds that of every other cellular component 
except water
5
. Known factors that contribute to this massive bioaccumulation and self-assembly 
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phenomenon include the drug’s high oral bioavailability, coupled with large daily doses, 
prolonged treatment regimens, and long elimination half-life
6
.  
The observed accumulation, self-assembly, and mechanical properties
7
 of CFZ-H
+
Cl
-  
in 
macrophages inspired our thinking about reverse engineering this weakly basic, small molecule 
chemical agent as a molecular building block for constructing functional mechanopharmaceutical 
devices. These devices constitute the mechanical properties of cells and the pharmaceutical 
agent, and capitalize on the biomechanical synergy between cells and the self-assembled 
biocrystalline salt, inside cells, in vivo
3,5,8
. In macrophages, CFZ-H
+
Cl
-
 forms elastic structures, 
which bend and relax in response to biomechanical forces
7
. Furthermore, the presence of these 
mechanopharmaceutical devices is associated with augmented anti-inflammatory activity
9,10
:  
upon phagocytosis, they lead to changes in cellular function, which include alterations in signal 
transduction pathways that affect the cell’s inflammatory response10. Unlike the soluble form of 
CFZ, which tends to be cytotoxic, phagocytosis of the self-assembled mechanopharmaceutical 
device does not lead to toxicity
8,11
. 
Thus, given that macrophages express high levels of proton pumping vacuolar ATPase 
(V-ATPase) and chloride channels on their lysosomal membranes
12-14
, and that weak bases are 
prone to accumulate inside lysosomes
15
, we probed whether the expression levels of these 
lysosomal membrane proteins in macrophages actively drive the accumulation of CFZ-H
+
Cl
- 
and 
its self-assembly in these cells. Using a well-established and published lysosomal ion regulation 
model
16
, we studied how proton pumping and chloride transport mechanisms influenced cell-
type specific stabilization of CFZ-H
+
Cl
-
 inside lysosomes. In addition to verifying model 
predictions and further refining our understanding of the computational simulation results, we 
performed experiments using pharmacological inhibitors of V-ATPase
17
 and chloride channels
18
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to probe the biological mechanism underpinning the massive accumulation and self-assembly of 
the building block.  
 
2.5.  Materials and Methods 
 
2.5.1.   Solubility measurements.  
Freeze-dried CFZ-H
+
Cl
-11
 samples were weighed and 25 mg was added to each of five 
scintillation vials. Mili-Q water (15 mL) was added to each vial to ensure that CFZ-H
+
Cl
-
 
crystals were in great excess. An aliquot of 0.1 M NaOH was added to each vial to achieve the 
initial equilibration pH measurements as follows: sample vials 1-5 initially contained 0, 40, 80, 
120, and 200 µL of 0.1 M NaOH solution, respectively. After a 24-hour equilibration period, 10 
µL of 0.1 M NaOH was added each day for a period of five days resulting in pH range of 4.5 to 
8.9. The solid phase at equilibrium was qualitatively predicted based on the color of the 
precipitate: orange precipitate for the free base versus dark red precipitate for the salt form of the 
drug. The sample vials were placed on a magnetic stirrer plate in a 25 °C water bath. Each 
sample was allowed to equilibrate for at least 24 hours, after which 500 µL of sample was 
removed and filtered through a Spin-X centrifuge tube filter (0.45 μm cellulose acetate, 2 mL 
polypropylene tubes, non-sterile, Costar®, Cat # 8163) for 4 min @ 10,000 rpm. The pH of the 
filtered sample was determined (UltraBasic pH meter, Denver Instrument, Bohemia, NY), after 
which the sample was subjected to HPLC analysis (see Appendix A.1) (Waters Alliance, 
Separations Module 2695) to determine the total solubility of the drug at the measured pH. For 
each sample, solubility measurement was performed in triplicate, and the average was used to 
construct the total drug solubility-pH profile. The standard curve was generated using CFZ-H
+
Cl
-
 
crystals that were dissolved in the mobile phase at known concentrations (1-50 µM).  
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2.5.2. Thermodynamic equilibrium model of CFZ’s solubility.  
For weak electrolytes such as weakly basic drugs, the protonation state of the drug (B) is 
dictated by the relationship between the drug’s association constant (Ka) and the acidity of its 
environment (H3O
+
). This is represented by the following equilibrium expression: 
B + H3O
+ ⇄ BH+ +  H2O         (1) 
Where BH
+
 is the protonated form of the drug as a result of the interaction of the free base form 
of the drug with hydronium ion, and H2O is the byproduct of the reaction and remains constant. 
Thus, the equilibrium constant (K) is multiplied by H2O to obtain Ka. Therefore, equation (1) is 
re-written using Ka. 
B + H3O
+ ⇄ BH+          (2) 
The mass law equilibrium equation is written as the following, assuming an ideal solution where 
the activity of a given species equals the concentration of the species (represented by the 
brackets):  
𝐾𝑎 =  
[BH+]
[B][H3O+]
         (3) 
By writing the logarithmic form of equation (3), we have the following relationship, which is the 
Henderson-Hasselbach equation:  
pH − p𝐾𝑎 = log
[B]
[BH+]
         (4) 
The equation is re-written as the following to express the concentrations of both the neutral and 
ionized forms of the drug: 
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[B] = [BH+] × 10pH−p𝐾𝑎        (5) 
[BH+] = [B] × 10p𝐾𝑎−pH         (6) 
According to thermodynamic laws of mass action, the total amount of drug is comprised of both 
the neutral and the ionized forms at any given pH of its environment
19
. Thus, the total solubility 
(ST) of the drug is written as: 
ST = [B] + [BH
+]          (7) 
However, depending on the pH of the solution, the total drug solubility equation must be slightly 
modified to account for the distinction of the primary species in the solid versus solution phase
19
. 
For pH < pHmax, the ionized form of the drug is the saturated species that is in equilibrium with 
the salt from of the drug in the solid phase; therefore, its solubility remains constant while the 
solubility of the neutral form of the drug varies with respect to pH. Therefore, by substituting 
equation (5) into equation (7), the total drug solubility for pH < pHmax is re-written as: 
ST = [BH
+]S × ( 1 + 10
pH−p𝐾𝑎)        (8) 
Where the solid phase is denoted by the subscript “s”. 
To the contrary, for pH > pHmax, the neutral form of the drug is in the solid phase; thus, its 
solubility remains constant whereas the solubility of the ionized form of the drug varies with 
respect to pH. Therefore, by substituting equation (6) into equation (7), the total solubility for pH 
< pHmax can be re-written as: 
ST = [B]S × ( 1 + 10
p𝐾𝑎−pH)       (9) 
27 
 
Moreover, at pH = pHmax, both the ionized and neutral forms of the drug are the saturating 
species, where both the salt and free base precipitate forms are in the solid phase. Thus, equation 
(7) can be re-written as: 
ST = [B]S +  [BH
+]S         (10) 
For our purpose, we substituted our model drug CFZ in the above equations (1-10). Rewriting 
equation (7) results in the following total CFZ-H
+
Cl
-
 solubility equation:  
ST = [CFZ]S + [CFZH
+]        (11) 
Where the solid phase, which in this case is the free form of CFZ, is denoted by the subscript “s”, 
and the ionized form of the drug, [CFZH
+
], is in the solution phase, and similar to equation (6), is 
dictated by pKa and pH as follows: 
[CFZH+] = [CFZ]S × 10
p𝐾𝑎−pH       (12) 
Thus, by substituting equation (12) into equation (11), we obtain the following: 
ST = [CFZ]S × (1 + 10
p𝐾𝑎−pH)       (13) 
Furthermore, by using different combinations of any two solubility-pH data points from the 
experimental total solubility-pH measurements, the pKa and the intrinsic free base solubility 
values were simultaneously solved using equation (13). Then, by substituting these values into 
equation (13), the total CFZ-H
+
Cl
-
 solubility was calculated for the given range of pH 4.5 to 8.9, 
and the experimentally obtained total drug solubility-pH curve was fitted. Furthermore, in order 
to generate the total solubility-pH dataset for pH below pHmax, we used the following equation: 
ST = [CFZ] + [CFZH
+]S        (14) 
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Similar to equation (8), equation (14) can be further expressed as:  
ST = [CFZH
+]S × (1 + 10
pH−p𝐾𝑎)       (15) 
However, we first had to determine [CFZH
+
]S. Because we only used one form of the drug 
(CFZ-H
+
Cl
-
 salt) as the starting material in the experimental measurements of total drug 
solubility as a function of pH, we used a mathematical proof approach to determine [CFZH
+
]S 
and thereby pHmax (see Appendix A.1) without necessarily having to experimentally generate a 
total drug solubility-pH curve for pH below pHmax. 
Moreover, the salt solubility product (Ksp) of CFZ-H
+
Cl
-
 is given by the following equation: 
𝐾𝑠𝑝 = [CFZH
+]S × [Cl
−]                  (16) 
However, because of the 1:1 stoichiometric relationship of CFZH
+
 and Cl
-
 in CFZ-H
+
Cl
-7
, the 
Ksp of CFZ-H
+
Cl
-
 in an aqueous media can be expressed as following: 
𝐾𝑠𝑝 = ([CFZH
+]S)
2         (17) 
 
2.5.3. Animal experiments.  
Mice (4 week old, male C57BL/6J) were purchased from the Jackson Laboratory (Bar 
Harbor, ME) and acclimatized for 1 week in a specific-pathogen-free animal facility. 
Clofazimine (CFZ) (C8895; Sigma, St. Louis, MO) was dissolved in sesame oil (Shirakiku, 
Japan) to achieve a concentration of 3 mg/mL, which was mixed with Powdered Lab Diet 5001 
(PMI International, Inc., St. Louis, MO) to produce a 0.03% drug to powdered feed mix, which 
was orally administered ad libitum for up to eight weeks. A corresponding amount of sesame oil 
was mixed with chow for vehicle treatment (control). Mice were euthanized via CO2 
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asphyxiation and exsanguination. Animal care was provided by the University of Michigan’s 
Unit for Laboratory Animal Medicine (ULAM), and the experimental protocol was approved by 
the Committee on Use and Care of Animals (Protocol PRO00005542). All animal experiments 
were done according to the protocol guidelines. 
 
2.5.4. Alveolar macrophage isolation.  
Following euthanasia, the trachea was surgically exposed and cannulated with a 20G 
needle, and the lungs were lavaged by instilling 1 mL DPBS (Life Technologies) containing 0.5 
mM EDTA (Sigma) six times. Approximately 90% of the instilled bronchoalveolar lavage 
(BAL) was retrieved. BAL was centrifuged (10 min at 400 x g, 4 °C), the supernatant removed, 
and the cell pellet was resuspended in RPMI 1640 media (Life Technologies) with 5% FBS (Life 
Technologies) and Penicillin/Streptomycin (Thermofisher). Cells were plated onto 4 or 8 
chamber coverglass (#1.5, Lab-Tek II, Nunc, Rochester, NY) in RPMI for imaging studies. The 
cells were allowed to attach overnight, washed, and imaged in fresh RPMI. 
 
2.5.5. Peritoneal macrophage isolation.  
Following euthanasia, a small incision was made in the lower abdomen. The peritoneal 
cavity was then flushed with 10 mL of ice cold DPBS containing 5% FBS (Sigma) and collected. 
The peritoneal lavage was centrifuged for 10 min at 400 x g, 4 °C, and then re-suspended in 
DMEM media (Life Technologies) with 5% FBS and Penicillin /Streptomycin and counted. The 
cells were plated into Mat-tek dishes overnight in serum-free growth media, and washed five 
times with phosphate-buffered saline (PBS). 
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2.5.6. Macrophage depletion.  
Mice were fed CFZ or control diet continuously for a four-week period. Following two 
weeks of feeding, mice were treated with either liposomes containing either 7 mg/mL of 
clodronate or PBS (FormuMax Scientific Inc., Sunnyvale, CA) for two weeks. Mice were 
initially treated with 200 µL of liposomes followed by 100 µL injections twice per week (or a 
matching volume of PBS) to ensure continual macrophage depletion. Liposomes were injected 
intraperitoneally, as previously described
20
. After completing four weeks of feeding and two 
weeks of liposome treatment, mice were sacrificed and tissues were collected.  
 
2.5.7. Biochemical analysis of CFZ in tissues.  
The concentration of CFZ in the organs of mice was determined spectrophotometrically. 
After four weeks of CFZ- or vehicle-diet treatment, mice were euthanized via CO2 asphyxiation, 
and organs were collected. Tissue (20-30 mg) was homogenized in 500 µL of 
radioimmunoprecipitation assay buffer (Sigma) with added protease inhibitors (Halt protease and 
phosphatase inhibitor cocktail and 0.5 M EDTA; Thermo Pierce, Rockford, IL). Drug was 
extracted from homogenate (350 µL) with three washes with xylenes (1 mL). The drug was then 
extracted from the xylene with three 1 mL passes of 9 M sulfuric acid. The concentration of CFZ 
present in the tissue was determined using a 96-well plate reader (Biotek Synergy 2, Winooski, 
VT) (wavelength 540 nm). To account for extraction yield, untreated liver and spleen samples 
were spiked with known amounts of CFZ prior to extraction, and were analyzed in the same 
plate as the CFZ treated samples. The mass of CFZ per organ was determined using the yield-
corrected concentration of CFZ in the mass of tissue analyzed, as determined through use of a 
standard curve with known concentrations of CFZ, and is reported as mg CFZ/g tissue. 
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2.5.8. Biochemical analysis of CFZ in plasma.  
Blood was collected and centrifuged (7,000 × g for 5 minutes). The resulting supernatant 
serum was extracted with acetonitrile (90% extraction efficiency) for 10 min at 4 °C with 
vortexing. After centrifugation (15,000 rpm, 4 °C), the supernatant was injected into a Waters 
Acquity UPLC H-Class (Waters, Milford, MA) equipped with an Acquity UPLC BEH C18 
column (1.7 μm, 2.1 mm [inner diameter] by 100 mm; Waters, Milford, MA). Mobile phase A 
was 5 mM ammonium acetate, adjusted to pH 9.9 with ammonium hydroxide, and mobile phase 
B was acetonitrile. The flow rate was 0.35 ml/min, with a linear gradient from 50 to 100% phase 
B over 1.5 min, followed by holding at 100% for 1.5 min, a return to 50% phase B, and then re-
equilibration for 2.5 min. Standards were prepared by spiking untreated plasma samples with 
known amounts of clofazimine, ranging from 0 to 30 µM. Peak area was determined using 
Empower 3 Software (Waters, Milford, MA). 
 
2.5.9. Sample preparation for microscopy.  
In preparation for cryosectioning, portions of each organ were removed, immediately 
submerged in OCT (Tissue-Tek catalog no. 4583; Sakura), and frozen (-80 °C). Cryosectioning 
(5 µm) was carried out using a Leica 3050S Cryostat (Leica Biosystems Inc., Buffalo Grove, IL). 
Immunohistochemistry of F4/80 (Abcam, 1:500 dilution) was performed using Alexa-Fluor 488 
(Abcam, 1:500 dilution). 
 
2.5.10.   Deep-etch, freeze-fracture electron microscopy.  
At the time of euthanasia, the liver was collected and kept cold (4 °C). The organ was 
frozen against a copper block, cooled with liquid helium, and stored in liquid nitrogen. The 
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sample was fractured with Balzers 400 nitrogen cooled vacuum evaporator and freeze-etched for 
two minutes (-100 °C). A rotary replica was generated with 2 nm platinum and backed with 10 
nm carbon film support. It was cleaned with chromo-sulfuric cleaning solution (Fisher Scientific, 
cat# SC88) for twelve hours and rinsed with DI water. The sample was picked up on formvar 
coated grids and viewed on a JEOL 1400 electron microscope with an AMT camera (JEOL 
USA, Inc., Peabody, MA). 
 
2.5.11. Spectral confocal microscopy.  
For the preparation of slides, CFZ-H
+
Cl
-
 crystals suspended in PBS (20 µl) were placed 
on a glass slide and a cover-slip was applied onto the sample prior to imaging. Spectral confocal 
microscopy was performed on a Leica Inverted SP5X confocal microscope system with two-
photon FLIM (Leica Microsystems, Buffalo Grove, IL) using excitation wavelengths (470–670 
nm). Image analysis and quantification were performed on Leica LAS AF. Several regions of 
interest of individual crystals were used to obtain fluorescence data, which were imported into 
MS-Excel for further analysis. All fluorescence yields were normalized to the maximum 
fluorescence yield measured across the tested spectral range, and background subtracted using 
data obtained from a blank slide. 
 
2.5.12.   Epifluorescence microscopy of cells incubated with CFZ and Lysotracker® Blue.  
Macrophage-derived RAW264.7 cells (ATCC, Manassas, VA, ATCC Number: TIB-
71
TM
) at a high seeding density of 100,000 cells/well, were grown in 8-chamber multiwell plates 
(Lab-Tek® II, Nunc, Rochester, NY) in Dulbecco’s Modified Eagles Medium (DMEM) + 10% 
Fetal Bovine Serum (FBS) + 1% Penicillin/Streptomycin (P/S) (500 µl/well growth media); cells 
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were pre-incubated with CFZ (20 µM) in DMSO for 24-72 hours. For lysosomal confirmation, 
RAW264.7 cells were seeded at 30,000 cells/well in an 8-chamber multiwell plate (500 µl/well 
growth media). Twenty-four hours later, the growth media was replaced with media containing 
varying concentrations (0, 1, 10, 20 µM) of Lysotracker® Blue DND-22 (Thermo Fisher 
Scientific, Waltham, MA, Catalog No. L7525, excitation/emission maxima ~ 373/422 nm) and 
CFZ (10 µM). Visualization of all samples (cells or crystals) was done on a Nikon Eclipse Ti 
(Nikon Instruments, Melville, NY). Fluorescence filters (excitation/emission) were optimized for 
4,6-diamidino-2-phenylindole dihydrochloride (DAPI) (350/405 nm, exposure - 550 ms, violet), 
fluorescein isothiocyanate (FITC) (490/510 nm, exposure - 100–500 ms, green), Texas Red 
(590/610 nm, exposure - < 500 ms, red), and Cy5 (640/670 nm, exposure - 500 ms, far-red). The 
Pearson’s Co-localization Coefficient (PCC) was computed for each individual cell as ROIs 
using the scatterplot distribution within the Nikon Elements AR software. Brightfield color 
photographs were acquired using a Nikon DS-Fi2 camera, whereas fluorescence photographs 
were acquired using a Photometrics CoolSNAP
TM
 MYO (Photometrics, Tucson, AZ) camera.  
 
2.5.13.   Quantitative cytometric analysis.  
Following macrophage staining, the population of macrophages was determined by 
taking the ratio of the total F4/80 signal to the total nuclear signal across an image. Because of 
the unique Cy5-specific fluorescence property of CLDIs
11
, the prevalence of CLDIs was 
determined by taking the ratio of the total Cy5 signal to the total nuclear signal across an image. 
5 images per mouse per organ were analyzed. 
 
2.5.14.   Drug stability in a lysosomal microenvironment.  
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CLDIs were isolated from spleen and liver of 8-week CFZ treated mice based on 
previously published protocols
10,21
. Free base CFZ crystals were pure CFZ crystals (Sigma-
Aldrich, C8895). A speck (<< 1mg) of isolated CLDIs, CFZ-H
+
Cl
- 
crystals, and free base CFZ 
crystals were placed in 2 mL of each of the stability testing medias: 1x PBS (pH 7.4), lysosomal 
buffer without sodium chloride (LB-, pH 4.5), and lysosomal buffer with sodium chloride (LB+, 
pH 4.5). Lysosomal buffers were prepared according to a previously published protocol
22
. 
Samples were stirred in media for 5-7 days; after which the stability of crystals from each sample 
was monitored using brightfield and fluorescence microscopy using a Nikon Eclipse Ti inverted 
microscope (Nikon Instruments, Melville, NY). Look-up-tables (LUTs) and exposure times were 
maintained the same throughout the samples. 
 
2.5.15.   Multi-parameter microscopy.  
Multi-parameter polarization, brightfield, and fluorescence microscopy was conducted 
using a Nikon Eclipse Ti inverted microscope (Nikon Instruments, Melville, NY). Polarization 
microscopy was performed using the LC-PolScope
23
, with the illuminating light narrowed to 623 
nm by an interference filter (623 ± 23 nm, Semrock Optics, Rochester, NY). Polarization images 
were captured using an Abrio imaging system (Cambridge Research & Instrumentation, Inc, 
Woburn, MA). Brightfield images were captured using the Nikon DS-3 camera (Nikon 
Instruments) and fluorescence images were taken with the Photometrics CoolSnap MYO camera 
system (Photometrics, Tuscon, AZ) under the control of Nikon NIS-Elements AR software 
(Nikon Instruments). Illumination for fluorescence imaging was provided by the X-Cite 120Q 
Widefield Fluorescence Microscope Excitation Light Source (Excelitas Technology, Waltham, 
MA). Images were acquired and analyzed as previously described
24
.  
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2.5.16.   Raman sample preparation and measurements.  
Isolated mouse alveolar macrophages were transferred onto pre-sterilized silicon chips 
(16008; Ted Pella, Inc., Redding, CA) and incubated for 1h (@ 37 
o
C and 5% CO2) to allow 
adherence to chip. The cell-containing chips were washed by brief submersion into isotonic NaCl 
(0.9%) solution followed by DI water, then allowed to air-dry. Raman measurements were 
acquired with the WiTec alpha300R confocal Raman microscope (WITec, Ulm, Germany) 
equipped with two excitation lasers: a 532 nm solid-state sapphire and a 785 nm wavelength-
stabilized diode (0-55 mW and 0-88 mW tunable intensity ranges, respectively). A 100X air 
objective (Zeiss Epiplan-NEOFLUAR, NA (numerical aperture) = 0.9) coupled to a CCD 
detector via a multi-mode fiber of 100 m diameter serving as the confocal pinhole, produced 
0.72 m and 1.06 m illumination spots (for 532 nm and 785 nm lasers respectively). To 
minimize fluorescence background from pure CFZ and CFZ-H
+
Cl
-
 reference crystals, samples 
were excited with 785 nm. The 532 nm laser was utilized for excitation of biological samples 
due to its elicitation of a stronger Raman signal from the microscopic inclusions/CLDIs of 
interest. Point spectra were acquired (n  40 cells/group) by focusing a laser spot on cytoplasmic 
inclusions, CLDIs, or pure reference crystals: at each point, the laser was tuned to optimum 
intensity, and acquired point spectra over an integration time of 25 seconds. Individual raw 
spectra were baseline-subtracted and normalized using a MATLAB® processing algorithm 
developed in-house. For single-cell Raman imaging, the 532 nm excitation laser was raster-
scanned across a 50 × 50 micron area with a step-size of 0.5 microns, yielding spectral datasets 
consisting of 10,000 spectra per cell. Exploiting the dramatic spectral differences arising from 
fluorescence of different CFZ forms, the un-processed Raman spectra were linearly 
deconvoluted via WiTec ProjectFOUR software’s basis component analysis using representative 
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un-processed reference spectra obtained from untreated cells, pure free base CFZ crystals, pure 
CFZ-H
+
Cl
-
 crystals, and the silicon substrate. Dataset acquisition, processing, and image display 
parameters were performed equivalently for each cell specimen. 
 
 2.5.17.   CLDI injection and stabilization assay.  
To determine how macrophages stabilize CLDIs, mice were treated with either liposomal 
PBS or liposomal clodronate, as previously described
25
. 48 hours after liposome administration, 
mice were injected I.P. with 200 µg of CLDIs suspended in 1 mL of PBS (n = 3 mice per group 
per time point). At time points ranging from 0 to 48 hours, the mice were euthanized, the 
peritoneal lavage was collected and pelleted, and the drug content within the pellet was analyzed 
using the previously described spectrophotometric analysis method. Using a simple exponential 
regression with recovered drug content, the half-life was estimated. 
 
2.5.18.   CLDI loading within individual macrophages.  
Using the total recovered mass of CLDIs within the liver and spleen, the CLDI loading 
within individual xenobiotic-sequestering macrophages was estimated using literature reported 
values for macrophage numbers
26
 within the liver and spleen, corrected for the percentage of 
cells which contained a CLDI. For the clodronate depleted organs, the reduction was accounted 
for with the quantified reduction in total F4/80 signal.  
 
2.5.19.   Cell culture and pharmacological treatment.  
For pharmacological inhibition experiments, macrophage-derived RAW264.7 cells 
(ATCC, Manassas, VA, ATCC Number: TIB-71
TM
), at a very high seeding density of 50,000 
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cells/well grown in a 96 well tissue culture plate in 280 µl/well of DMEM + 10% FBS + 1% P/S 
(growth media), were pre-incubated (4h) with varying concentrations of Bafilomycin A1 
(BafA1; Sigma-Aldrich, St. Louis, MO, Cat. No. B1793) (0-10 nM) and NPPB (Sigma-Aldrich, 
St. Louis, MO, Cat. No. N4779) (0-200 µM) after which CFZ (dissolved in DMSO) was added 
to achieve a final concentration range of 0-10 µM. The effect of the treatment on cell viability 
was assessed by an XTT assay (Roche, UK). 
 
2.5.20.   Drug uptake measurements.  
Measurement of CFZ uptake by RAW264.7 cells was performed using a modified 
absorbance spectroscopy method using 9 M H2SO4 (pH << 0.1) to digest the entire cell 
population and extract CFZ from the cells. At two time points (2 and 4h) after CFZ exposure, 
growth media was aspirated from the culture dish and the cells were washed twice with PBS 
before adding 9 M H2SO4 (100 µl/well). The plate was incubated at room temperature for 30 min 
before spectrophotometric quantification of CFZ using a Synergy 2 plate reader (BioTek, 
Winooski, VT) at 540 nm (Abs540) and 750 nm (Abs750) (for background). Standards were 
prepared on the same plate by adding 100 µl/well pre-determined standards of CFZ. Total CFZ 
uptake is reported as total intracellular drug (in picomoles) as measured and calculated using the 
standard curve. Assuming that the doubling time of 50,000 cells/well is ~ 11h
27
, and that no 
compromise of cell viability occurs because of the optimum dose used for both CFZ and the 
pharmacological inhibitors, the total number of cells/well at the time of cellular drug uptake 
measurement is ~ 68,000.  
 
2.5.21.   Experimental lysosomal pH measurements.  
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Lysosomal pH was measured fluorometrically in peritoneal macrophages and 
macrophage-derived RAW264.7 cells, using methods described previously
28
. In brief, 
macrophages were incubated for 40h with CFZ crystals. 20h prior to measuring pH, cells were 
incubated for 15-18h with 150 µg/ml Oregon Green-labeled dextran-10kD (OGDx; Thermo-
Fisher Scientific), and transferred to unlabeled culture medium for 3-5h to allow OGDx to traffic 
fully to lysosomes. Following transfer to Ringer's buffer, cells on Mat-tek dishes were observed 
in a Nikon TE300 microscope equipped for multichannel fluorescence microscopy with a 60X 
objective lens (N.A. 1.4). Phase contrast and three fluorescence images (excitation/emission: 440 
nm/535 nm; 485 nm/535 nm; and 580 nm/630 nm) were collected from each field. The 
580nm/630nm image was used to quantify clofazimine fluorescence. The ratio of the 
485nm/525nm to 440nm/525nm images were used to measure lysosomal pH. Calibration of 
fluorescence ratios was obtained from cells incubated in ionophores and buffers as described in 
Davis and Swanson
28
. Average lysosomal pH was determined for individual cells.   
 
2.5.22.   Modeling lysosomal CFZ-H
+
Cl
-
 accumulation.  
A Lysosomal ion regulation model which incorporates lysosomal membrane proteins, 
such as V-ATPase, CLC7, and membrane proton permeability was utilized
16
, and further 
elaborated and modified (see Appendix A.1) to explore the relationship between lysosomal ion 
homeostasis and lysosomal CFZ-H
+
Cl
-
 accumulation and stabilization. In order to incorporate the 
lysosomal accumulation of CFZ-H
+
Cl
-
 into the model as a function of lysosomal proton and 
chloride ions, the rate of overall drug accumulation obtained from experimental findings
4,29
 was 
used to define the rates of both lysosomal proton (Hsequestered) and chloride (Clsequestered) 
sequestrations by CFZ, in units of molecules per second. We assumed these rates to be equal due 
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to the proposed equal contribution of both proton and chloride ions in the intracellular formation 
and accumulation of CFZ-H
+
Cl
-
 salt precipitates:  
CFZH+Cl− =  Hsequestered = Clsequestered       (18) 
 
2.5.23.   Model parameterization.  
The model incorporated 23 parameters: four were adjustable and the remaining 19 were 
fixed (see Appendix Table A.1). Fixed parameters were given values obtained from the 
literature
16,30-34
, and are associated with physiological lysosomal ion homeostasis. Therefore, 
these parametric values are interchangeably referred hereon as “baseline input values” or 
“physiological baseline input values”. The adjustable parameters are those values that were 
varied from their respective baseline input values in order to investigate their individual as well 
as combined effects on the physiological lysosomal pH, Cl
-
, and membrane potential readout 
values, as discussed in the following subsections. These parameters include the number of active 
V-ATPase and CLC7 molecules per lysosome, as well as the cytoplasmic chloride concentration. 
In addition, the rates of proton and chloride sequestrations by CFZ are considered adjustable 
parameters as they are foreign to the lysosome. 
 
2.5.24.   Simulating lysosomal CFZ-H
+
Cl
-
 accumulation.  
The previously mentioned rates of proton and chloride sequestrations by CFZ were 
adjusted to either 0.01 or 0.1 picomoles/cell/day
4,29
. However, in our model simulations, we 
converted the units of these rates to picomoles/lysosome/day assuming there are ~ 100 
lysosomes in a cell. From here onwards, we interchangeably refer to these rates, 0.01 and 0.1 
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picomoles/cell/day, as 1-fold (1X) and 10-fold (10X) rates of lysosomal CFZ-H
+
Cl
-
 
accumulation, respectively.  
 
2.5.25.   Simulating changes in lysosomal membrane proteins and cytoplasmic chloride 
amounts.  
In order to study the roles of V-ATPase, CLC7, and cytoplasmic chloride concentration 
on lysosomal accumulation of CFZ-H
+
Cl
-
, we varied the total numbers of active V-ATPase and 
CLC7 molecules per lysosome, and the cytoplasmic chloride concentration, while fixing the 
values of other lysosomal parameters at their baseline physiological input values in the presence 
as well as absence of lysosomal CFZ-H
+
Cl
-
 accumulation. More specifically, to simulate the 
simultaneous inhibition of V-ATPase and CLC7, the total number of CLC7 molecules per 
lysosome was varied from 0 to 5,000 (resulting in 7-16 data-generating points) while, one 
parametric simulation at a time, the total number of V-ATPase molecules per lysosome was 
manually varied from 0 to 300 (resulting in 4-7 data-generating points). Moreover, to simulate 
the simultaneous inhibition of V-ATPase and cytoplasmic chloride, the cytoplasmic chloride 
concentration was varied from 0 to 10 mM (resulting in 16 data-generating points) while, one 
parametric simulation at a time, the total number of V-ATPase molecules per lysosome was 
manually varied from 0 to 300 (resulting in 4-7 data-generating points). 
Using the aforementioned ranges of the adjustable lysosomal parameters, the 
corresponding lysosomal parameter inhibition range of 0 to 100% was calculated; where 0% 
represents no change from respective physiological baseline input value, and 100% represents 
the input value set to ~ zero. The inhibition range was calculated as follows by comparing the 
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corresponding input value (Adjusted Input Value) from the aforementioned given range with its 
respective physiological input value (Baseline Input Value): 
% Inhibition =  
 Baseline Input Value−Adjusted Input Value 
Baseline Input Value
× 100%   (19) 
 
2.5.26.   Calculating the effect of lysosomal CFZ-H
+
Cl
-
 accumulation on lysosomal ion 
homeostasis.  
Final lysosomal pH, chloride, and membrane potential were chosen as readout values 
because they are direct indicators of lysosomal ion homeostasis and physiology. Thus, 
parametric simulations of these variables were performed as a function of the aforementioned 
ranges of V-ATPase, CLC7, and cytoplasmic chloride in the absence and presence of lysosomal 
CFZ-H
+
Cl
-
 accumulation at the rate of either 1X or 10X. Then, the readout values in the absence 
of lysosomal CFZ-H
+
Cl
-
 accumulation were subtracted from those in the presence of lysosomal 
CFZ-H
+
Cl
-
 accumulation in order to determine the effect of lysosomal CFZ-H
+
Cl
-
 accumulation 
on lysosomal ion homeostasis.  
 
2.5.27.   Calculating the effects of V-ATPase, chloride channels, and cytoplasmic chloride 
on the physiological lysosomal accumulation of CFZ-H
+
Cl
-
.  
Time-plot simulations, where all of the lysosomal parameters were set to their respective 
baseline values in the absence of lysosomal CFZ-H
+
Cl
-
 accumulation, were performed to obtain 
physiological final lysosomal pH, chloride accumulation, and membrane potential values, which 
from hereon we refer to as “physiological baseline readout values”. Moreover, model parametric 
simulations of final lysosomal pH, Cl
-
, and membrane potential as a function of simultaneous V-
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ATPase-CLC7 and V-ATPase-cytoplasmic chloride inhibitions were performed in the presence 
of lysosomal CFZ-H
+
Cl
-
 accumulation at the rates of 1X and 10X. These were then subtracted 
from the physiological baseline readout values in order to calculate the effects of the 
simultaneous lysosomal parameter inhibitions on the dose-dependent lysosomal CFZ-H
+
Cl
-
 
accumulation.  
 
2.5.28.   Confirmation of steady-state and mass balance.  
For all of the aforementioned simulations, the final readout values were confirmed that 
they were steady state values by performing the simulations for > 24h. We confirmed that mass 
balance was maintained in all of the simulations in the presence and absence of lysosomal CFZ-
H
+
Cl
-
 accumulation as long as a physiological pH gradient of up to 4.6 pH units was maintained 
across the lysosomal membrane.  
 
2.6.  Results 
2.6.1. The weakly basic building block has pH-dependent solubility properties. 
CFZ is a weak base with two amines, which can be protonated depending on the pH of 
the immediate environment (Fig. 2.1a). To study its pH-dependent solubility behavior, we used  
an established approach
19
 (described in Appendix A.1), which allowed an accurate measurement 
of the total solubility of CFZ-H
+
Cl
-
 as a function of pH. From the experimental measurements, 
we calculated the solubility properties of CFZ, in an aqueous media at 25 ºC, which include its 
apparent pKa,2 (pKa’ = 6.08 ± 2.43x10
-3
; 95% Confidence Interval = 6.07, 6.09) and intrinsic free 
base solubility (S0 = 0.48 ± 4.05x10
-6
 µM; 95% CI = 0.48, 0.48) (Fig. 2.1b). Moreover, to 
determine the effect of lysosomal Cl
-
 (Fig. 2.1c) on the stability of the free base versus salt form 
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of the drug, we performed drug stability experiments (Fig. 2.1d) in the presence and absence of 
lysosomal buffer (pH 4.5, Cl
-
 concentration =0-100 mM). We monitored drug stability by relying 
on the unique fluorescence profile of the different forms of CFZ: free base CFZ exhibits green 
and red fluorescence; peak excitation: 540–560 nm, peak emission: 560–600 nm, whereas CFZ-
H
+
Cl
-
 exhibits red and far red fluorescence; peak excitation: 560–600 nm, peak emission: 650–
690 nm
11
. Indeed, the fluorescence of CLDIs resembles the fluorescence of the synthesized CFZ-
H
+
Cl
-
 crystals (peak excitation: 560–600 nm, peak emission: 650–690 nm) (see Appendix Fig. 
A.1).   
 
Figure 2.1 Chemical characterization of CFZ.  
a, Chemical structure of clofazimine (CFZ) with its two protonation sites and corresponding 
predicted (chemi-informatic) pKa values (pKa,1 = 2.31 and pKa,2 = 9.29). b, CFZ-H
+
Cl
-
 solubility-
pH study revealed the solution pH dependence of the stabilization of the free base versus salt 
form of the drug with respect to its solubility parameters; which include the intrinsic free base 
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solubility (So), apparent pKa,2 (pKa’), and pHmax. c, Illustration showing the cellular and 
subcellular accumulation of free base CFZ, its subsequent protonation (CFZH
+
), and ion-ion 
interaction of CFZH
+ 
and cellular Cl
-
 to form CFZ-H
+
Cl
-
. This phenomenon depends on the 
drug’s intrinsic solubility properties as well as the cellular pH and Cl- levels, which are primarily 
regulated by membrane proteins: proton-pump known as V-ATPase and Cl
-
/H
+
 antiporter known 
as CLC7. d, Stability of CLDIs, CFZ-H
+
Cl
-
, and free base CFZ in PBS (pH 7.4), lysosomal 
buffer without sodium chloride (LB-, pH 4.5), and lysosomal buffer with 100 mM sodium 
chloride (LB+, pH 4.5) was monitored via brightfield and fluorescence microscopy. 
 
A low pH environment in the absence of Cl
-
 (LB-) induced the destabilization of both 
CFZ-H
+
Cl
-
 and free base CFZ, without affecting the stability of CLDIs. To the contrary, a low 
pH environment in the presence of a physiological lysosomal Cl
-
 (LB+) induced the stabilization 
of CFZ-H
+
Cl
-
 and CLDIs, whereas the free base CFZ precipitated out as CFZ-H
+
Cl
-
 (Fig. 2.1d). 
Thus, these findings reveal that the precipitation of CFZ as a hydrochloride salt was highly 
sensitive to small, but physiologically relevant variations in pH and chloride concentrations 
(pHmax = 4.5 ± 7.11x10
-15
, 95% CI = 4.5, 4.5; and Ksp = 332.3 ± 3.71 µM
2
, 95% CI = 323.1, 
341.5) (Fig. 2.1b, d); where the pHmax reveals the pH below which CFZ-H
+
Cl
-
 salt formation 
occurs, and the Ksp elucidates the Cl
-
 concentration, which is > (Ksp)
1/2
 µM, that would further 
stabilize the salt form of the drug through a common-ion effect
35
. Thus, at the 
pharmacologically-relevant CFZ concentrations that have previously been measured in serum (1 
to 20 µM), local variations in pH (~ 7.4 extracellular; ~ 7.2 cytosolic and ~ 4.5 lysosomal) and 
chloride concentrations (~ 80 mM extracellular; ~ 10-20 mM in cytosol; and ~ 50-200 mM in 
lysosomes) can lead to a greater propensity of CFZ to precipitate as a hydrochloride salt in the 
lysosomal microenvironment (Fig. 2.1c, d). 
 
2.6.2. The intracellular organization of the self-assembled mechanopharmaceutical device  
Prolonged administration of CFZ results in its accumulation in both human and animals 
as microscopic, insoluble, and membrane-bound aggregates, known as Crystal Like Drug 
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Inclusions (CLDIs), which are primarily found within tissue macrophages
3-5
. CLDIs are 
primarily comprised of a protonated, hydrochloride salt of CFZ (Fig 2.2a)
7
, which forms faceted 
structures possessing three orthogonal cleavage and multiple fracture planes with lamellar 
spacing of 6 nm to 14 nm
21
 (Fig. 2.2b). These orthogonal cleavage and fracture planes 
correspond to the orthogonal crystallographic planes of the CFZ-H
+
Cl
-
 unit cell (Fig. 2.2c). 
When examined under polarized light (623 nm wavelength), the orthorhombic crystal structure 
of the deep red CLDIs
11,29,36
 exhibits dichroism (Fig. 2.2d)
24
. Due to the biological origin of the 
CLDIs
7
, the interaction between the cell and crystal often leads to significant variations in its 
organization, impacting the manner in which it interacts with polarized light (Fig. 2.2d). 
Furthermore, reference spectra of pure CFZ and CFZ-H
+
Cl
-
 identified characteristic Raman 
peaks for clear distinction between the two forms (Fig. 2.2e). Spectra obtained from cytoplasmic 
regions of untreated mouse alveolar macrophages were typical of biological specimens with no 
apparent contributions from drug. However, spectra obtained from cytoplasmic regions of 4- and 
8-week CFZ-fed mouse alveolar macrophages revealed the presence of CFZ-H
+
Cl
-
, which 
dominated any Raman signal associated with biological specimens, and exhibited unique peak 
intensities and peak widths, which attribute to the geometric organization of the supramolecular 
structures: peaks generally become narrower and more intense with higher degree of order in 
samples, which suggests that by 8 weeks, the macrophages have organized the accumulated drug 
into supramolecular crystalline packages of CFZ-H
+
Cl
-
 salt. Moreover, Raman imaging of 
single-cells revealed cytoplasmic accumulation of both forms of the drug after just 1 week and 
continuing through 4 weeks; at 8 weeks CLDI formation was apparent and clearly 
distinguishable from free base CFZ, as evidenced by non-overlapping Raman signals in the 
biocrystal regions of Raman image (Fig. 2.2f). 
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Figure 2.2. Intracellular self-assembled crystal organization of CFZ-H
+
Cl
-
.  
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a, CFZ-H
+
Cl
-
 chemical structure with color coding corresponding to the regions of the structure 
in the crystal arrangement. b, Freeze-fracture electron micrograph of CLDIs within a Kupffer 
cell, showing that the CLDIs are sequestered inside the cell as multiple layered planes with 
lamellar spacing of 6 nm to 14 nm, by a double membrane of biological origin (~ 20 nm in 
thickness)
21
. c, Crystal packing of CFZ-H
+
Cl
-
 showing the three crystallographic planes of the 
crystal: a hydrophobic face in orange (plane 1), a hydrophilic face in blue (plane 2), and an 
amphipathic face (plane 3)
8
. d, CLDIs (100-1.5X magnification) zoomed in (zoom factor of 2) in 
alveolar macrophages show high dichroism and an axis of highest transmittance, with a different 
profile (represented by the different signal intensity associated with the color bar) observed 
specifically around the edges of the crystal. e, Raman spectra of free base CFZ, CFZ-H
+
Cl
-
, 
untreated and treated alveolar macrophages (4 and 8wks CFZ-fed mice) show distinct Raman 
peaks distinguishing between the different forms of the drug (red in the brightfield images): free 
base CFZ (1341 and 1465 cm
-1
), CFZ-H
+
Cl
-
 (1399 cm
-1
). f, Reflected brightfield and Raman 
images of alveolar macrophages from CFZ-fed mice prepared on silicon chip substrates; basis 
spectral fitting was used to show the temporal accumulation and cytoplasmic packaging of CFZ 
into highly ordered CLDIs. 
 
 
2.6.3. Macrophages are necessary for the self-assembly of the mechanopharmaceutical 
device  
To investigate whether macrophages play an active role in stabilizing CLDIs in vivo, 
macrophages were depleted by injecting mice (n = 3-4 per treatment group) intraperitoneally 
with clodronate liposomes. This treatment depletes phagocytic cells without affecting non-
phagocytic cells
20
. Moreover, the aforementioned CFZ’s unique fluorescence characteristics 
were used to monitor the effect of macrophage depletion on the accumulation of CFZ-H
+
Cl
-
 
crystal. Following liposome therapy, the relative number of F4/80 positive macrophages within 
the liver and spleen of each treatment group was quantified using the total ratio of F4/80 to 
nuclear signal, revealing a significant reduction in the total macrophage population in the 
clodronate-CFZ fed group when compared to the PBS-CFZ treated group (p < 0.05, ANOVA, 
Tukey’s HSD) (Fig. 2.3a). Consequently, using the ratio between the intrinsic far-red 
fluorescence of CFZ-H
+
Cl
-37
 and total nuclear signal, there was a significant reduction in the 
accumulation and stabilization of CFZ-H
+
Cl
-
 within the liver and spleen (p < 0.05, ANOVA, 
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Tukey’s HSD) compared to the PBS-CFZ treated group (Fig. 2.3b). More specifically, within the 
PBS-CFZ treated mice, the livers accumulated an average of 0.68 ± 0.27 mg CFZ/g tissue, while 
the clodronate-CFZ livers accumulated an average of 0.23 ± 0.09 mg CFZ/g tissue (p < 0.05, 
two-tailed Student’s t-test); a reduction of nearly 66%. Similarly, the spleens of PBS-CFZ treated 
mice accumulated an average of 2.31 ± 0.40 mg CFZ/g tissue, compared to 0.70 ± 0.12 mg 
CFZ/g tissue in the clodronate-CFZ groups (p < 0.01, two-tailed Student’s t-test); a reduction of 
70%.  
 
 
Figure 2.3 The role of macrophages on the intracellular accumulation of CFZ biocrystals in 
vivo.  
a, Clodronate depletion significantly reduces both hepatic and splenic macrophages in 
Clodronate-CFZ treatment group. b, Depletion of macrophages results in concomitant reduction 
in CLDI loading within the livers and spleens of treated animals. c, Clodronate depletion does 
not significantly reduce the estimated clofazimine loading per macrophage in the livers and 
spleen. d, Clodronate depletion does not significantly impact the serum concentrations of 
clofazimine following four weeks of treatment. e, Depletion of peritoneal macrophages 
significantly increases the rate of degradation of CLDIs injected intraperitoneally, leading to a 
significantly faster half-life. f, Peritoneal exudate of PBS- and clodronate-liposome treated mice 
48 hours following CLDI injection showing brightfield and Cy5 fluorescence (red fluorescence 
and red in brightfield images correspond to CLDIs) (* = p < 0.05, ANOVA or ANOVA, Tukey’s 
HSD when applicable). g, Alveolar lavage from PBS- and clodronate-liposome treated mice. 
Clodronate treatment did not impact CLDI accumulation (red fluorescence and red in brightfield 
images correspond to CLDIs) within alveolar macrophages.  
 
49 
 
The individual drug loading within the macrophages of the liver and spleen was 
estimated based off of literature-reported values for macrophage populations in those two 
organs
26
 and the total recovered drug within each organ, and there was no difference in total drug 
loading within either population of macrophage as a result of clodronate therapy (Fig. 2.3c). 
Furthermore, there was no significant difference in mean plasma concentrations of CFZ at the 
end of therapy (Fig. 2.3d). Taken together, this provides evidence that, while clodronate therapy 
was reducing the macrophage population and subsequent bioaccumulation within the liver and 
spleen, it was not impacting the general bioavailability and absorption of CFZ in the body. To 
determine how macrophages stabilized the self-assembled mechanopharmaceutical devices, 
isolated CLDIs were injected I.P. into clodronate and PBS liposome treated mice and collected at 
time points from 0 to 48 hours (n = 3 mice per group per time point). Without macrophages 
present in the peritoneal cavity to internalize the CLDI, there was a significant reduction in the 
estimated half-life of the biocrystal (p < 0.05, ANOVA) (Fig. 2.3e). This was confirmed via 
microscopic analysis of the peritoneal exudate 48 hours post-injection, with CLDIs becoming 
internalized by the macrophage and retaining their far-red fluorescence in the PBS-treatment 
group, while the clodronate-treated group showed reduced CLDI content within the exudate (Fig. 
2.3f). 
Additionally, in order to confirm that clodronate did not impact drug accumulation within 
other macrophage populations, alveolar macrophages were collected and analyzed. Within the 
alveolar macrophage population, there was no significant difference in total cell number 
collected between the PBS and clodronate-treated groups (p = 0.48, two-tailed Student’s t-test), 
as well as in the ability of the cells to accumulate CFZ in the form of a CLDI; where each 
alveolar macrophage population contained approximately 20% CLDI-positive cells (p = 0.36, 
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two-tailed Student’s t-test) (Fig. 2.3g). Thus, the specific effect of clodronate liposomes on liver 
and spleen CLDIs and CFZ content, as well as the increased rate of CLDI destabilization and 
solubilization in the absence of peritoneal macrophages provide evidence that these cells are 
directly responsible for the in vivo accumulation, self-assembly, and stabilization of CFZ-H
+
Cl
-
. 
 
2.6.4. The intracellular accumulation, protonation, and self-assembly of the building block 
in cytoplasmic vesicles does not interfere with lysosomal pH. 
 Taking advantage of the aforementioned CFZ’s unique fluorescence properties, we 
studied the accumulation of the un-protonated free base and protonated hydrochloride salt form 
of the drug in macrophages. Incubation of  macrophages with CFZ in vitro revealed vesicular 
staining pattern consistent with free base CFZ (peak excitation: 540–560 nm, peak emission: 
560–600 nm) as well as CFZ-H+Cl- (peak excitation: 560–600 nm, peak emission: 650–690 
nm)
11
. Both fluorescent forms were visible in CFZ-treated cells and absent in untreated, control 
cells (Fig. 2.4a and see Appendix Fig. A.2). Based on the observed little overlap of their 
orthogonal fluorescence signals, CFZ-H
+
Cl
-
 did not co-localize with free base CFZ (Pearson’s 
Colocalization Coefficient - PCC between green and far-red fluorescence = 0.30 ± 0.29) (see 
Appendix Fig. A.3). In addition, when cells were co-incubated with both CFZ and Lysotracker 
Blue (LB), LB fluorescence signal (excitation: 373 nm, emission: 422 nm) was inhibited in the 
cytoplasm and displaced
38
 to the nucleus (based on the observed nuclear staining), whereas the 
punctate green and far-red fluorescence of CFZ were clearly visible in the cytoplasm of these 
cells (Fig. 2.4c, see Appendix Figs. A.2 and A.3). As a control experiment, we measured the 
lysosomal pH of macrophages following phagocytosis of CLDIs in macrophage-derived 
RAW264.7 cells as well as in peritoneal macrophages of 8-week CFZ-fed mice (Fig. 2.4d). In 
51 
 
both cases, the lysosomal pH was not physiologically affected by the presence of the CFZ, as 
reflected by < 0.1 pH unit difference between the drug-free and drug-containing peritoneal 
macrophages and RAW264.7 cells. Thus, CFZ uptake in macrophage lysosomes does not perturb 
physiological lysosomal pH homeostasis, which is required for various lysosomal functions such 
as lysosomal trafficking and degradation of intrinsic and extrinsic materials within the lysosome 
by various pH-dependent hydrolytic lysosomal enzymes, which are essential for overall cellular 
homeostasis and viability
39
. Moreover, because the fluorescence signals of Lysotracker® probes 
are pH-independent
40
, we interpret this to mean that intralysosomal CFZ accumulation interferes 
with Lysotracker probe accumulation through a mechanism that is independent of changes in 
lysosomal pH.   
 
 
Figure 2.4. Evidence of lysosomal accumulation of CFZ via fluorescence staining patterns 
in RAW264.7 cells.  
a, Epifluorescence microscopy of RAW264.7 cells (40X magnification) zoomed in (zoom factor 
of 2.5) when incubated with (a) CFZ (10 μM), (b) Lysotracker Blue (LB, 1 μM), and (c) CFZ 
(10 μM) and LB (1 μM) together at t = 24 hours. Green fluorescence spots indicative of CFZ are 
also further annotated using white arrows for cross-referencing with other images. Note the lack 
of any far-red fluorescence positive signal in the direction pointed by the arrows. Vesicular 
staining pattern of LB visible as blue punctate spots in (b) are absent in (c) while nuclear staining 
becomes visible due to LB displacement from the lysosome to the nucleus because of CFZ 
accumulation in the lysosome. Cell boundaries are shown in white in the digitally zoomed 
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panels. d, Lysosomal pH measurements of RAW26.7 cells in the presence and absence of 
CLDIs, and peritoneal macrophages of control versus 8-week CFZ fed mice. Data are mean ± 
S.D. of 29-181 measurements; * p = 0.026; analyzed by unpaired two-tailed Student t-test.  
 
2.6.5. The building block’s self-assembly mechanism is biocompatible with the lysosome.   
To identify the candidate mechanism driving CFZ-H
+
Cl
-
 accumulation and stabilization 
in lysosomes, we used a well-established systems-based mathematical model of lysosomal ion 
regulation. We first performed a simultaneous variation of the number of active V-ATPase and 
chloride channels per lysosome (resulting in 0 to 100% inhibition of both parameters from their 
respective baseline physiological input values of 300 and 5000) in the presence and absence of 
dose-dependent lysosomal CFZ-H
+
Cl
-
 accumulation (0 to 0.01 picomoles/cell/day), as measured 
in vitro
4,29
. The simulation results indicated that CFZ-H
+
Cl
-
 accumulates at the measured rate of 
0.01 picomoles/cell/day exerting a negligible effect on lysosomal pH, Cl
-
, and membrane 
potential from respective physiological baseline readout values (4.53 pH units, 224.6 mM, and 
0.79 mV). Only a significant (≥ 97%) reduction in the total V-ATPase amount per lysosome led 
to changes in these values (Fig. 2.5a). Consistent with this, < 97% V-ATPase inhibition per 
lysosome was required for the physiological accommodation of lysosomal CFZ-H
+
Cl
-
 
accumulating at 0.01 picomoles/cell/day (Fig. 2.5b). However, unlike the number of V-ATPase, 
the number of chloride channel molecules per lysosome did not show any effect on the 
physiological CFZ-H
+
Cl
-
 accumulation unless this chloride current was completely absent (Fig. 
2.5b).  
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Figure 2.5. Model and simulation of the effects of V-ATPase and CLC7 on the lysosomal 
accumulation of CFZ-H
+
Cl
-
.  
a, V-ATPase inhibition showed a more substantial effect than CLC7 inhibition on the 
accumulation of CFZ-H
+
Cl
-
 at the rate of 0.01 picomol/cell/day, as reflected by the changes in 
the lysosomal pH, Cl
-
, and membrane potential values of the CFZ-H
+
Cl
-
 containing lysosome 
from that of the CFZ-H
+
Cl
-
 free lysosome. b, V-ATPase inhibition showed a more substantial 
effect than CLC7 inhibition on the physiological accumulation of CFZ-H
+
Cl
-
 at the rate of 0.01 
picomol/cell/day, as reflected by the changes in the lysosomal pH, Cl
-
, and membrane potential 
values of the CFZ-H
+
Cl
-
 containing lysosome from respective baseline physiological values. 
Arrow signs represent values outside of the axes plot range.  
 
In dose-dependent simulations, CFZ-H
+
Cl
-
 accumulating at a ten-fold greater (non-
physiological) rate of 0.1 picomoles/cell/day led to more pronounced changes in lysosomal pH, 
Cl
-
, and membrane potential (Fig. 2.6a). At least < 68.3% V-ATPase inhibition per lysosome was 
required to sustain physiological ion concentrations in the presence of this 10-fold greater rate of 
CFZ-H
+
Cl
-
 accumulation (Fig. 2.6b). In contrast, variations in the numbers of chloride channels 
did not affect the physiological lysosomal accumulation of CFZ-H
+
Cl
-
 at a rate of 0.1 
picomoles/cell/day, unless there was complete inhibition of the chloride current (Fig. 2.6b).  
54 
 
 
Figure 2.6. Model and simulation of the effects of V-ATPase and CLC7 on the lysosomal 
accumulation of CFZ-H
+
Cl
-
 at a higher dose.  
a, V-ATPase inhibition showed a more substantial effect than CLC7 inhibition on the 
accumulation of CFZ-H
+
Cl
-
 at the rate of 0.1 picomol/cell/day, as reflected by the changes in the 
lysosomal pH, Cl
-
, and membrane potential values of the CFZ-H
+
Cl
-
 containing lysosome from 
that of the CFZ-H
+
Cl
-
 free lysosome. b, V-ATPase inhibition showed a more substantial effect 
than CLC7 inhibition on the physiological accumulation of CFZ-H
+
Cl
-
 at the rate of 0.1 
picomol/cell/day, as reflected by the changes in the lysosomal pH, Cl
-
, and membrane potential 
values of the CFZ-H
+
Cl
-
 containing lysosome from respective baseline physiological values. 
Arrow signs represent values outside of the axes plot range. 
 
2.6.6. V-ATPase is essential in the building block accumulation and self-assembly.  
To verify our model and simulation findings, we performed experiments to detect the 
effects of V-ATPase and chloride channels on the intracellular accumulation of CFZ. All 
experiments regarding the incubation and accumulation of CFZ were performed under conditions 
in which cellular viability was maintained. In the absence of any inhibitor, 8 µM extracellular 
CFZ accumulated at a rate of 0.01 picomoles/cell/day, as previously reported
4,29
. However, 
inhibiting the V-ATPase with BafA1 reduced cellular CFZ accumulation by 80 ± 13% (p < 0.01) 
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in a 4h incubation, relative to control, uninhibited cells (Fig. 2.7a). This observation is consistent 
with our simulation results, where up to 50% V-ATPase inhibition resulted in a lysosomal pH 
increment (Fig. 2.5a), which associates with a reduction in cellular drug accumulation. In 
contrast, when cells were treated with the chloride channel inhibitor NPPB and exposed to CFZ, 
no significant change was measured in the accumulation of CFZ following a 4h incubation (Fig. 
2.7b). This contrasts with the effect observed with BafA1 (Fig. 2.7a), and is consistent with our 
simulation results (Fig. 2.5a), thereby indicating that in the presence of CFZ uptake, lysosomal 
ion homeostasis is insensitive to chloride channel inhibition.  
 
Figure 2.7. Intracellular CFZ accumulation.  
Total intracellular CFZ accumulation in picomoles (pmoles) in RAW264.7 cells when pre-
incubated with (a) BafA1 and (b) NPPB and initial concentration of CFZ = 4, 6, and 8 μM at t = 
4 hours. Significant inhibition of CFZ accumulation was measured at t = 4 hours when cells were 
exposed to BafA1. To the contrary, no such inhibition was measured when cells were exposed to 
NPPB at t = 4 hours. Data are the mean ± S.D. of six experiments. * - p < 0.05, ** - p < 0.01, *** 
- p < 0.001. Each data point was compared in a pair-wise independent Student t-test. 
 
 
2.7. Discussion 
As a weakly basic, poorly soluble small-molecule chemical that is FDA-approved, orally 
56 
 
bioavailable, slowly cleared, and administered at high doses for prolonged periods of time, CFZ 
affords us the opportunity to reverse engineer the construction of a mechanopharmaceutical 
device that was found to form naturally inside cells. We report that, because of its 
physicochemical properties, CFZ is highly prone to precipitation in acidic endolysosomal 
compartments in macrophages, where it self-assembles into a highly ordered CFZ-H
+
Cl
-
 
biocrystalline, possessing many interesting optical and biomechanical features. Consistent with 
its accumulation in macrophage lysosomes, CFZ inhibited Lysotracker Blue fluorescence (Fig. 
2.4). Furthermore, fluorescence imaging revealed that CFZ was present both as a free base and as 
a hydrochloride salt form within intracellular vesicles (Fig. 2.4). Thus, we performed 
computational simulations and experiments to probe the relationship between CFZ’s pH 
dependent solubility properties, the formation of salt and free base crystals, and the molecular, 
ion transport mechanisms responsible for this mechanopharmaceutical phenomenon, which could 
be exploited for developing other weakly basic small molecule building blocks as cell-targeted, 
self-assembling mechanopharmaceutical devices
41,42
.   
Despite the complexities of lysosomal ion homeostasis, computational simulations and 
experimental results provide a straightforward explanation for the observed behavior of CFZ: the 
number of V-ATPase molecules that drive the lowering of macrophage lysosomal pH
43
 plays a 
critical role in determining the intracellular bioaccumulation of CFZ in lysosomes without 
affecting lysosomal ion homeostasis. Our results show that very high levels of V-ATPase 
expression, that are typical of macrophages, are both necessary and sufficient to explain the 
accumulation and stabilization of CFZ-H
+
Cl
-
 salt in these cells because they allow the cells to 
maintain physiological lysosomal pH and membrane potential in spite of the accumulation of the 
drug. In addition, the intrinsic solubility properties of CFZ are such that the protonated form of 
57 
 
the drug strongly interacts with chloride in a concentration range that is typically observed in 
lysosomes, which leads to the physiological accumulation of the drug in its hydrochloride salt 
form. Accordingly, V-ATPase expression establishes the ability of the cell to maintain 
physiological lysosomal pH
44
, which, in relation to the drug’s pHmax and Ksp (Fig. 2.1), can 
sustain the continuous accumulation of the hydrochloride salt form of the drug
19
 in the lysosome.  
More importantly, we found that experimental results
4,29
 were highly consistent with 
model simulation results. First, the inhibition of V-ATPase activity resulted in the reduction of 
the total intracellular CFZ accumulation (Fig. 2.7a), which was consistent with the model 
simulation results (Figs. 2.5 and 2.6). In contrast, NPPB-mediated reduction of chloride channel 
activity did not affect the accumulation and stabilization of the salt form of the drug (Fig. 2.7b), 
which was also consistent with the model simulation results (Figs. 2.5 and 2.6, and see Appendix 
Figs. A.5 and A.6). Furthermore, the measured Ksp of CFZ-H
+
Cl
-
 and our CLDIs/CFZ-H
+
Cl
-
 
stability results (Fig. 2.1) indicate that the physiological lysosomal chloride levels are sufficient 
to stabilize CFZ-H
+
Cl
-
 salt formation through a common-ion “salting-out” mechanism35. 
Therefore, our findings collectively provide the first mechanistic framework that explains the 
accumulation of highly ordered, self-assembled CFZ-H
+
Cl
-
 salt biocrystals in macrophages 
(Figs. 2.2 and 2.3); which depends on the high levels of V-ATPase expression that is unique to 
this cell type
16
.  
It is also noteworthy that macrophages have lysosomes which are an order of magnitude 
greater in size than that of other cell types
45
. This provides them with the capability to 
accommodate massive accumulation of weakly basic drugs
46
. Even in cases where the initial 
lysosomal size is small (< 1 μm, in radius), the macrophage lysosomes can undergo 
biogenesis
47,48
. A master regulator of lysosomal biogenesis and V-ATPase expression is 
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transcription factor EB (TFEB)
39,46,49
. Moreover, given the recent findings regarding the role of 
TFEB in upregulating lysosomal genes during inflammation
50
, the role of TFEB in the 
bioaccumulation and stabilization of CFZ-H
+
Cl
-
 salt in macrophage lysosomes, in relation to 
CFZ’s anti-inflammatory activity9,10, could be further investigated.  
To conclude, we have discovered how lysosomal ion transport pathways play a major 
role in the self-assembly of a biocompatible, cell-targeted supramolecular structure formed by a 
weakly basic, small molecule building block. Together with the physicochemical properties of 
the freely soluble building blocks, these transport pathways can be exploited to develop novel 
types of drug depots and cell-directed drug delivery systems
51-53
. Indeed, interest has been raised 
in macrophages as drug delivery vehicles. As our studies have shown, macrophages may allow 
drugs to be locally stabilized and undergo a sustained release in a site-specific manner, offering a 
strategy for reducing off-target side effects
54,55
. Macrophages are also one of the few cell types, 
which are primarily involved in the phagocytosis of foreign particles of different sizes and 
shapes, including drugs
56,57
, which offer yet another opportunity for loading these cells with 
massive amounts of chemotherapeutic agents. To this end, additional investigations into the 
manner in which these cells mechanically synergize with the self-assembled weakly basic small 
molecule building blocks in order to stabilize functional mechanopharmaceutical devices are 
warranted.   
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Chapter 3: Elucidating the Key Lysosomal Parameters That Can Explain the 
Drug Accumulation Observed in Macrophages with Respect to Changes in 
Lysosomal Morphology 
 
This chapter was adapted from the following publication: 
Woldemichael, T. and Rosania, G.R. (2017) The physiological determinants of drug-induced 
lysosomal stress resistance. PLoS One, 12(11): e0187627. doi: 10.1371/journal.pone.0187627.  
 
3.1. Relevance to Thesis 
This chapter incorporates the effect of heterogeneous lysosomal morphology on 
lysosomal ion homeostasis. This is important to our understanding of the relationship between 
lysosomal physiology of cell-type dependent heterogeneous lysosomal morphology and 
physiological drug bioaccumulation. Given the dynamics of subcellular ion regulation and 
physiology, we utilized a computational approach to dissect out how combinations of different 
factors affecting lysosomal structure and function influence the ability of the organelle to recover 
from perturbations of physiological ion homeostasis. Our results emphasized the key biological 
determinants of sensitivity and resistance to lysosomal stress, which are critical in order to 
understand the cell-type specific toxicological effects of lysosomotropic drugs. Our findings lay 
the groundwork for the design of future wet lab experiments that investigate the physiological 
accumulation of weak base drugs in lysosomes, in a cell-type dependent manner. Moreover, 
because of the multi-faceted impact of our findings, experts from various fields, such as 
Biophysics, Pharmaceutics, Genetics, and Cell Biology could individually or collectively make 
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use of our work to study the biophysical features of lysosomal ion and cholesterol regulations,  
lysosomal morphology with respect to lysosomal membrane biophysics, the upregulation of 
lysosomal genes, and the implications on drug disposition, stabilization, and physiology in a cell-
type dependent manner.  
 
3.2. Personal Contribution 
I used a computational model of lysosomal ion regulation to simulate the manner in 
which intrinsic and extrinsic factors affect the restoration of normal lysosomal physiology 
following perturbation in one or more physiological parameters affecting lysosomal ion 
homeostasis. I varied lysosomal membrane protein levels, lysosomal morphology, and ion 
content in the context of A) extrinsic factors, such as drug-induced changes in lysosomal 
morphology, drug-induced changes in lysosomal cholesterol and ion content, drug-induced 
changes in lysosomal membrane protein activity, and B) intrinsic cellular factors, such as cell-
type dependent lysosomal gene regulation, cell-type dependent change in lysosomal morphology 
as may happen in endocytosis and exocytosis processes, and cell-type dependent ion and 
cholesterol regulation.  
 
 
3.3.  Abstract 
 
Many weakly basic, lipophilic drugs accumulate in lysosomes and exert complex, 
pleiotropic effects on organelle structure and function. Thus, modeling how perturbations of 
lysosomal physiology affect the maintenance of lysosomal ion homeostasis is necessary to 
elucidate the key factors which determine the toxicological effects of lysosomotropic agents, in a 
cell-type dependent manner. Accordingly, a physiologically-based mathematical modeling and 
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simulation approach was used to explore the dynamic, multi-parameter phenomenon of 
lysosomal stress. With this approach, parameters that are either directly involved in lysosomal 
ion transportation or lysosomal morphology were transiently altered to investigate their 
downstream effects on lysosomal physiology reflected by the changes they induce in lysosomal 
pH, chloride, and membrane potential. In addition, combinations of parameters were 
simultaneously altered to assess which parameter was most critical for recovery of normal 
lysosomal physiology. Lastly, to explore the relationship between organelle morphology and 
induced stress, we investigated the effects of parameters controlling organelle geometry on the 
restoration of normal lysosomal physiology following a transient perturbation. Collectively, our 
results indicate a key, interdependent role of V-ATPase number and membrane proton 
permeability in lysosomal stress tolerance. This suggests that the cell-type dependent regulation 
of V-ATPase subunit expression and turnover, together with the proton permeability properties 
of the lysosomal membrane, is critical to understand the differential sensitivity or resistance of 
different cell types to the toxic effects of lysosomotropic drugs. 
 
 
3.4. Introduction 
Alterations in lysosomal structure and function can lead to complex, pathophysiological 
manifestations in living organisms
1,2
. For example, mutations which affect proteins mediating 
lysosomal membrane transport are associated with a variety of inherited diseases and 
developmental disorders which affect multiple organ systems
3-7
. Physiologically, lysosomal ion 
homeostasis is maintained by the action of different transmembrane channels and pumps, such as 
the proton-chloride antiporter known as CLC7
8
, the non-selective cation transporter known as 
TRPML
9
, and the lysosomal proton pump known as vacuolar ATPase (V-ATPase)
10
. In vivo, 
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mutations in CLC7 cause osteoporosis and neurodegeneration in mice, and are associated with 
similar phenotypic effects in humans
11-13
. Similarly, mutations in TRPML are associated with an 
autosomal-recessive lysosomal storage disease known as MLIV
14-16
, whereas mutations in V-
ATPase are associated with osteoporosis, renal tubular acidosis, and deafness in humans, and 
cause similar effects in mice
17-20
. Furthermore, perturbations in vesicular trafficking which affect 
ion transport functions can adversely affect cellular function which leads to muscle 
degeneration
21
.  
Like mutations in proteins affect the ion transport properties of lysosomal membranes, 
many drugs accumulate in lysosomes or interfere with lysosomal ion transport mechanisms, 
which lead to alterations in lysosomal structure and function. At the cellular level, the effects of 
drug accumulation often resemble that of genetic mutations which affect lysosomal ion 
homeostasis, such as lysosomal size expansion
22
 and changes in organelle morphology
23
. 
Furthermore, in vitro experiments have revealed that the accumulation of lipophilic, weakly 
basic drugs in lysosomes can affect lysosomal pH
23
, membrane potential
1
, organelle 
morphology
23
, and changes in transmembrane ion permeability
24-26
. Therefore, it is possible that 
drug-induced lysosomal stress may be manifested as idiosyncratic drug side effects, which 
include increased predisposition to microbial infections
27
, osteoporosis
28,29
, and 
neurodegenerative diseases; such as Alzheimer’s disease, Huntington’s disease, and Parkinson’s 
diseases
11,30,31
.  
Interestingly, cells upregulate the expression of genes that allow lysosomes to recover 
normal physiological function following the disruption of physiological ion homeostasis
32
. At the 
transcriptional level, the transcription factor EB (TFEB) mediates lysosomal stress pathways
33
 by 
upregulating the expression of lysosomal genes, such as V-ATPase
34
 and TRPML
33
. In mice, 
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TFEB reverses expanded lysosomes by upregulating genes that directly or indirectly re-establish 
lysosomal ion homeostasis
33,35,36
. As a regulator of lysosomal biogenesis and stress tolerance, 
TFEB not only affects ion transport functions and membrane trafficking
37,38
, but its activation 
has also been associated with cells’ increased resistance to physiological perturbations induced 
by lysosomotropic drugs
39
.  
In order to further understand how lysosomotropic drugs may affect lysosomal ion 
homeostasis, a physiologically-based, mathematical modeling approach was utilized to shed light 
on key parameters which affect recovery from transient perturbations in lysosomal ion 
regulation. This approach was deemed necessary because pharmacological agents that 
accumulate in lysosomes can exert multiple effects on the molecular mechanisms that influence 
lysosomal pH, membrane potential, and chloride transport. These include inhibitors of the V-
ATPase, such as Bafilomycin A, Concomycin, Salicylihalamide A, and Archazolid
40,41
, chloride 
channel blockers, such as Cystic fibrosis transmembrane regulator (CFTR) inhibitors, which 
include Glibenclamide and Niflumic acid, and ClC channel inhibitor known as Lubiprostone
42
, 
as well as other conditions that affect lysosomal morphology
43,44
 and membrane permeability
45-
49
. Upon simulating transient perturbations, parameter sensitivity analysis was used to reveal the 
most likely mechanistic determinants of the cell’s ability to restore and maintain lysosomal ion 
homeostasis following exposure to one or more drug-induced lysosomal stresses, thereby 
providing important theoretical insights into the mechanistic determinants of drug-induced 
lysosomal stress and stress tolerance. 
 
3.5. Methods 
3.5.1.   Model parameterization. 
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An established, systems-based mechanistic model of lysosomal ion transport, which is 
comprised of differential equations that capture the transmembrane transport properties of ions 
and water across the lysosomal membrane
8,50
 was used to simulate the physiological 
consequences of drug-induced lysosomal stress (Fig. 3.1). 
 
 
Figure 3.1. Modeling the effects of drugs on lysosomal ion homeostasis.  
We utilized an established physiological framework to model lysosomal ion transport (A). 
Accordingly, the V-ATPase actively pumps protons into the lysosome (1) while the proton-
chloride antiporter CLC7 dissipates the ensuing increase in membrane potential by coupling the 
efflux of protons with the influx of chloride (2). Protons escape the lysosomes through diffusion 
across the lysosomal membrane (3), and protons in the lysosome are sequestered through the 
buffering capacity of resident lysosomal components (4). Free protons that accumulate in the 
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lysosomal lumen contribute to the decrease in lysosomal pH. Based on this mechanism, the 
effect of drugs was captured by modeling different lysosomal shapes and volumes (B). 
Concomitantly, the drug-dependent inhibition of V-ATPase function was modeled by varying the 
proton pumping activity (C); the drug-dependent change in membrane proton permeability was 
modeled by varying the proton leak from the lysosome (D); and, the drug-dependent perturbation 
of membrane potential regulation was modeled by inhibiting CLC7 (E) or decreasing 
cytoplasmic chloride (F). 
 
For the purpose of studying the lysosomal stress response, the model (see Appendix B.1) 
contained 22 parameters. Six out of the 22 parameters were varied to capture the effects of drugs 
on lysosomal structure and function, whereas the remaining sixteen were fixed (Table 3.1). Fixed 
parameters were set to published values, which give rise to physiological lysosomal function
50,51
 
and are referred to as “baseline input values”. These parameters include lysosomal radius of 340 
nm with volume and surface area corresponding to a spherical lysosomal vesicle, which was 
obtained from electron microscopy data
52
, and the associated organellar ions and ion 
transporters, which include 300 V-ATPase molecules per lysosome, which was estimated from 
microscope data analysis and wet lab experimental data fitting
50,53,54
, membrane proton 
permeability of 6x10
-5
 cm/s, which was estimated from wet lab experimental data fitting
50
, 
cytoplasmic chloride concentration of 10 mM
55,56
, and initial lysosomal ion concentrations 
estimated to equal that of extracellular ions
56
. A lysosome with the entire model parameters set to 
baseline input values is referred to as an “unperturbed lysosome”.  
 
Table 3.1. Model parameters. 
Symbol Description Baseline 
Input 
Value 
Range of Input Value Units 
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pHC Cytosolic pH 7.2 Fixed pH unit 
pHL Luminal pH 7.4 Fixed pH unit 
[Cl
-
]C Cytosolic chloride 
concentration 
10 1x10
-5
 - 10 mM 
[Cl
-
]L Luminal chloride concentration 110 Fixed mM 
[Na
+
]L Luminal sodium concentration 145 Fixed mM 
[K
+
]L Luminal potassium 
concentration 
5 Fixed mM 
[H
+
]L Luminal proton concentration 0 Fixed mM 
PH
+
 Membrane proton permeability 6x10
-5
 1.38x10
-7
 - 6 cm/s 
V Lysosomal volume 1.65x10
-16
 2.88x10
-17
 - 1.65x10
-16  
 L 
S Lysosomal surface area 1.45x10
-8
 1.45x10
-8
 - 6.28x10
-6
 cm
2
 
C’ Specific bilayer capacitance 1 Fixed μFarad/ 
cm
2
 
β Buffering capacity 40 Fixed mM/pH 
NVATP V-ATPase number 300 1x10
-4
 - 1.3x10
5
  
NClC7 CLC7 number 5000 1x10
-4 
- 5000  
Ψout * Outer surface potential -50 Fixed mV 
Ψin * Inner surface potential 0 Fixed mV 
CLC_Cl CLC7 Cl
-
 stoichiometry 2 Fixed  
CLC_H CLC7 H
+
 stoichiometry 1 Fixed  
R Gas constant 8.314 Fixed J.K
-1
.mol
-1
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T Absolute temperature 0 Fixed Kelvin 
F Faraday's constant 96485 Fixed J/volt 
Nav Avogadro's number 6.02x10
23
 Fixed molecules/
mol 
Model parameters used to simulate various lysosomal stresses and stress tolerance mechanism. 
Baseline input values are literature values
52-56
 representing physiological lysosomes and are in 
agreement with previously published models
50,51
.  
* estimated intrinsic surface potentials for inner, Ψin, and outer, Ψout, leaflets of the lysosomal 
membrane accounted for when modeling membrane transporter mediated dynamic lysosomal 
and cytoplasmic ion concentrations at the surface
51
.  
 
Adjustable parameters are those that were varied from their respective baseline input 
values in order to simulate the effects of lysosomal stressors. Accordingly, lysosomes that are 
modeled by changing one or multiple of these adjustable parameters are referred to as “perturbed 
lysosomes”. Moreover, the lysosomal ion stressors reported here are associated with stressors 
inducing variations in lysosomal membrane proton permeability, cytoplasmic chloride 
concentration, and V-ATPase and CLC7 molecules per lysosome, whereas the lysosomal 
morphology stressors are associated with stressors inducing variations in lysosomal surface area 
and volume.  
 
3.5.2   Simulating drug-induced changes in lysosomal morphology. 
To study how drug-induced changes in lysosomal morphology affect ion homeostasis, 
simulations were performed in lysosomes of different surface areas and volumes. First, 
lysosomes were modeled as perfect spheres. Assuming there are approximately around 100 
lysosomes in a cell, which occupy 1% of cellular volume, the volume of a single lysosome was 
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set to 1.65x10
-16 
L. For a spherical vesicle, this volume corresponds to a lysosomal radius of 0.34 
μm and a surface area of 1.45x10-8 cm2.  
For comparison, tubular lysosomes (Fig. 3.1B) (radius = 40 nm - 270 nm, height = 585 
nm - 5.73 μm) were modeled using a range of volumes (2.88x10-17 L-1.34x10-16 L). The 
dimensional relationship between the tubular radius and height, at constant lysosomal surface 
area of 1.45x10
-8
 cm
2 
(equivalent to the surface area of a spherical lysosome (radius = 0.34 μm), 
as previously mentioned in our study of spherical lysosomes), was calculated using cylindrical 
equation (V =  πr2h, where r is radius and h is height). These morphologies are consistent with 
measurements in other publications
44,57
.  
Next, to mimic disc-shaped lysosomes as have been reported in different cell types under 
other biologically relevant conditions
58-60
, lysosomes (radius = 422 nm-10 μm, height = 0.5 nm-
294.9 nm) were modeled using a rage of lysosomal surface area (1.90x10
-8
 cm
2
 -6.28x10
-6
 cm
2
).  
The dimensional relationship between the disc-shaped lysosomal radius and height, at constant 
lysosomal volume of 1.65x10
-16 
L (equivalent to the volume of a spherical lysosome, 0.34 μm in 
radius), was calculated using cylindrical equation (S = 2πr2 + 2πrh, where r is radius and h is 
height). 
 
3.5.3.   Simulating stress tolerance following drug-induced changes in lysosomal 
morphology. 
To understand how lysosomes possessing different structural and functional 
characteristics may respond differently to drugs, the number of V-ATPase and membrane proton 
permeability were individually varied. When studying the effects of these two particular 
lysosomal parameters on morphologically altered or otherwise stressed lysosome, we referred to 
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them as “stress tolerance inducers”. Thus, the number of V-ATPase molecules per lysosome was 
increased from physiological baseline input value of 300 to 1.3x10
5
 (resulting in 13 data 
generating points), while proton permeability was decreased from physiological baseline input 
value of 6x10
-5 
cm/s to 1.38x10
-7 
cm/s (resulting in 9 data generating points). These ranges of 
input values for both V-ATPase number and proton permeability allowed us to quantitatively 
compare and contrast the relationship of lysosomal surface area to the number of V-ATPase 
molecules and membrane proton permeability per lysosome. For example, we chose different 
fold increments in lysosomal surface area (say, 20- or 400-fold) and one simulation at a time set 
the corresponding lysosomal surface area as an input. So, in the case of a lysosome with a 20-
fold lysosomal surface area expansion, we set the surface area to 2.9x10
-7
 cm
2
. Then, to study the 
effect of the number of V-ATPase molecules on this expanded lysosome, we performed 
parametric simulation for the V-ATPase number ranging 0 to 6000, which corresponds to 0 to 
20-fold increment in V-ATPase number per lysosome. 
 
3.5.4.   Simulating drug-induced lysosomal stress. 
Parametric simulations were performed to study the effects of the following four drug-
induced stresses on lysosomal physiology: V-ATPase inhibition, CLC7 inhibition, lysosomal 
membrane permeabilization, and decreased membrane potential dissipation based on lower 
cytoplasmic chloride concentration (Fig. 3.1). More specifically, membrane proton permeability 
was varied from physiological baseline input value of 6x10
-5 
cm/s to 6 cm/s (resulting in 8 data 
generating points), the number of V-ATPase molecules per lysosome was varied from 0 to 
physiological value of 300 (resulting in 10 data generating points), the number of CLC7 
molecules per lysosome was varied from 0 to physiological value of 5000 (resulting in 25 data 
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generating points), and the cytoplasmic chloride concentration was varied from 0 to 
physiological value of 10
 
mM (resulting in 7-16 data generating points).  
Using the aforementioned ranges of the adjustable lysosomal parameters, the 
corresponding lysosomal parameter inhibition range 0 to 100% was calculated for cytoplasmic 
chloride, V-ATPase and CLC7 number; where 0% represents no change from respective 
physiological baseline input value, and 100% represents the input value set to ~zero. The 
inhibition range was calculated as follows by comparing the corresponding input value (Adjusted 
Input Value) from the aforementioned given range with its respective physiological input value 
(Baseline Input Value): 
% Inhibition =  
 Baseline Input Value−Adjusted Input Value 
Baseline Input Value
× 100%  (1)                                                     
 
3.5.5.   Simulating individual lysosomal ion stressors. 
The effects of the lysosomal ion stressors were individually studied in spherical and 
different sized tubular lysosomes by performing parametric simulation of the four parameters 
mentioned in the previous subsection (using the same ranges of input values with corresponding 
intervals) while setting the lysosomal volume and surface area input values to correspond to 
either a spherical or tubular lysosomal geometry, as indicated in the earlier subsection. For 
example, in the case of introducing CLC7 inhibitor to a spherical lysosome, lysosomal volume 
and surface area were set to 1.65x10
-16 
L and 1.45x10
-8
 cm
2
, respectively. Then, the CLC7 
number was varied from 0 to 5000, as previously indicated. Similar approach was applied when 
studying stressor effect in tubular lysosomes except the input value for lysosomal volume was 
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varied from 2.88x10
-17 
L to 1.65x10
-16 
L (resulting in 4 data generating points), while fixing 
lysosomal surface area at 1.45x10
-8
 cm
2
.  
 
3.5.6.   Simulating combinations of lysosomal ion stressors. 
The effects of the various combinations of the aforementioned lysosomal ion stressors 
were studied in spherical, tubular, and disc-shaped lysosomes. The stressor combinations 
included V-ATPase inhibition-CLC7 inhibition, V-ATPase inhibition-Cytoplasmic Cl
-
 depletion, 
V-ATPase inhibition-membrane proton permeabilization, CLC7 inhibition-Cytoplasmic Cl
-
 
depletion, CLC7 inhibition-membrane proton permeabilization, Cytoplasmic Cl
-
 depletion-
membrane proton permeabilization. The ranges of values, with the associated specific or 
arbitrarily chosen intervals for each parameter mentioned in the previous sections were applied 
here as well. For example, to simulate the administration of V-ATPase inhibition-CLC7 
inhibition to a spherical lysosome, lysosomal volume and surface area input values were set to 
1.65x10
-16 
L and 1.45x10
-8
 cm
2
, respectively to adjust the lysosomal geometry as a sphere. Then, 
the CLC7 number was varied from 0 to 5000, whereas, the V-ATPase number was, one 
simulation at a time, manually set to a value within the range 0 to 300.  
 
3.5.7.   Calculating the effects of lysosomal stressors and tolerance on lysosomal physiology. 
Time-plot simulations were performed to obtain physiological final lysosomal pH, Cl
-
, 
and membrane potential readout values for an unperturbed lysosome, where all of the parameters 
are set to physiological baseline values. These readout values, which from hereon we refer to as 
“physiological baseline readout values”, were specifically chosen as they are direct indicators of 
lysosomal ion homeostasis and physiology. 
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Similarly, when performing each of the aforementioned parametric lysosomal stress and 
stress tolerance simulations, final lysosomal pH, Cl
-
, and membrane potential variables were 
chosen as readouts as a function of either a specific lysosomal stressor or stress tolerance inducer 
in order to generate two-dimensional data. Then, the 2D dataset was exported to Microsoft Excel 
for further analysis. The final lysosomal pH, Cl
-
, and membrane potential values were subtracted 
from their respective physiological baseline readout values mentioned earlier in order to 
determine the net effect of the lysosomal stressor or the stress tolerance inducer on lysosomal 
physiology based on the changes in lysosomal pH, Cl
-
, and membrane potential. 
 
3.5.8.   Confirmation of steady-state and mass balance. 
For all of the aforementioned simulations, the final readout values were confirmed that 
they were steady-state values by performing the simulations for > 24 hours (simulation time). 
Furthermore, we confirmed that mass balance was attained for conditions where the 
thermodynamic limit of V-ATPase proton pump (up to 4.6 pH unit gradient)
61
 was maintained 
across the lysosomal membrane. 
 
3.5.9.   3D Data Visualization. 
Multiple individual 2D datasets associated with the aforementioned parametric 
simulations performed to generate simultaneous inhibitions of various lysosomal parameters 
were obtained. The datasets associated with each simultaneous inhibitions of lysosomal 
parameters were exported from Berkeley Madonna and compiled into three separate matrices in 
an excel spreadsheet, such that the first rows and columns of the matrix correspond to the two 
parameters simultaneously varied in the model simulations to obtain the final lysosomal readout 
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values (lysosomal pH, Cl
-
, and membrane potential), where each makes up the rest of the rows 
and columns of a single matrix. 3D surface plot of the matrix was generated using Sigmaplot®.  
 
3.6. Results 
Using a physiologically-based, mechanistic mathematical model of lysosomal ion 
transport regulation, we performed computational simulations to reveal how drug-induced 
variations in one or more ion transport mechanisms influenced lysosomal physiology, as 
captured by lysosomal pH, Cl
-
, and membrane potential. To facilitate interpretation of these 
results, we separately considered lysosomal ion stressors and lysosomal morphology stressors. 
The earlier directly perturb lysosomal ion transportation, while the latter directly perturb 
lysosomal morphology. As elaborated in the following subsections, the effects of the 
aforementioned lysosomal stressors on lysosomal physiology were considered in the context of 
1) biologically-determined variations in lysosomal morphology, 2) drug induced changes in 
lysosomal volume and surface area, 3) changes in lysosomal volume and surface area as may 
happen during endocytosis or exocytosis.  
 
3.6.1.   The effects of individual alteration of lysosomal proton and chloride transportation 
on lysosomal physiology  
First, the effects of stress inducers that perturb lysosomal ion transporters (V-ATPase, 
CLC7, and membrane proton permeability) and ion content (cytoplasmic chloride) were studied 
in the context of a spherical lysosome (Fig. 3.2A). Among the stressors we modeled, maximum 
reduction in the number of V-ATPase molecule per lysosome induced significant physiological 
perturbation in a spherical lysosome, as evidenced by the changes in lysosomal pH and Cl
-
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accumulation from their respective baseline values of 4.53 pH unit and 224.6 mM of an 
unperturbed lysosome (Fig. 3.2A). We observed a similar physiological perturbation following 
the modeling of the effect of increasing the lysosomal membrane proton permeability on 
lysosomal ion homeostasis (Fig. 3.2B). This indicates that lysosomal stressors that directly affect 
lysosomal proton level by perturbing either proton influx or efflux have similar effect not only 
on lysosomal pH, but also on lysosomal chloride homeostasis. To the contrary, CLC7 and 
cytoplasmic Cl
-
 stressors induced comparatively less perturbation to the overall lysosomal 
physiology (see Appendix Fig. B.1) as they only affected lysosomal pH and membrane potential 
when chloride transport or concentrations were completely abolished. 
            To understand how the same lysosomal ion stressors affect lysosomal ion homeostasis of 
different lysosomal morphologies, the lysosomal ion stressors were each varied along with 
lysosomal volume stressors that simultaneously reduced lysosomal radius and volume from an 
unperturbed lysosomal radius of 340 nm and a corresponding volume of 1.65x10
-16 
L, to 40 nm 
and 2.88x10
-17 
L, respectively. These dimensional changes capture the geometry of tubular 
lysosomes
57
, which are narrower and more elongated than the typical, spherical lysosomes
44
. In 
spite of the lysosomal radius and volume differences, tubular lysosomes have the same surface 
area as spherical lysosomes. This assumption is reasonable because balance in cellular 
membrane material is maintained as a result of the regulation of membrane trafficking upon 
tubular lysosome mediated exocytosis of endocytosed material from the subcellular spherical 
lysosome to the plasma membrane. Notwithstanding, based on our results, the lysosomal ion 
stressors had similar effects on the physiology of tubular lysosome as they had on spherical 
lysosome, based on very similar changes in lysosomal pH, chloride, and membrane potential 
(Fig. 3.2).  
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Figure 3.2 The effects of individual lysosomal ion stressors on spherical versus tubular 
lysosomal physiology.  
(A) The effect of inhibiting the number of V-ATPase molecule per lysosome showed significant 
changes in lysosomal pH and Cl
-
, with minimal change in membrane potential in both spherical 
and tubular lysosomes. (B) The effect of increasing proton-specific membrane permeability per 
lysosome showed significant changes in lysosomal pH and Cl
-
, with minimal change in 
membrane potential in both spherical and tubular lysosomes. In both (A) and (B), only a slight 
difference is observed in the effect of the lysosomal ion stressors on spherical versus tubular 
lysosomal physiology.  
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3.6.2.   The effects of lysosomal swelling on lysosomal ion homeostasis 
Next, we modeled the effect of lysosomal swelling on lysosomal physiology by 
simultaneously increasing lysosomal radius and surface area while maintaining a fixed lysosomal 
volume of a spherical lysosomal morphology (1.65x10
-16 
L in our model, baseline lysosome). 
Starting from a non-perturbed spherical lysosome (radius = 340 nm, surface area = 1.45x10
-8 
cm
2
), the lysosomal radius and the corresponding surface area were expanded up to 10 μm and 
6.28x10
-6
 cm
2
 (433.3 fold change), respectively. Such lysosomal swelling led to changes in 
lysosomal pH, Cl
-
 accumulation, and membrane potential (Fig. 3.3A). Thus, lysosomal 
expansion compromised the maintenance of physiological lysosomal ion homeostasis, similar to 
that of V-ATPase inhibition and membrane proton permeabilization in tubular and spherical 
lysosomes (Fig. 3.2).  
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Figure 3.3 The effects of lysosomal surface expansion and associated stress tolerance on 
lysosomal physiology.  
(A) Simultaneous increment in lysosomal radius and surface area, with a constant volume of 
1.65x10
-16 
L induced progressive perturbation in lysosomal pH, Cl
-
, and membrane potential. (B) 
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Individual effects of varying V-ATPase number and membrane proton permeability on the 
lysosomal physiology of surface area expansion-mediated lysosomal stress. Either increasing V-
ATPase number or reducing membrane proton permeability reduces transient perturbations in 
lysosomal pH, Cl
-
, and membrane potential following the simultaneous increment of lysosomal 
radius and surface area shown in (A).  
 
3.6.3.   The mechanisms of lysosomal stress tolerance in response to lysosomal swelling 
To understand the mechanism by which cells can withstand stress generated from 
simultaneous lysosomal radius and surface area expansion, we identified V-ATPase numbers and 
membrane proton permeability as key parameters that mediate lysosomal stress tolerance; which 
we refer to as “lysosomal stress tolerance inducers”. To illustrate this, V-ATPase number and 
membrane proton permeability were individually increased and decreased, respectively, 0 to 20 
and 0 to 433.3 fold from their respective baseline input values. This was performed in order to 
maintain a constant number of proton influx and efflux mediated by V-ATPase and membrane 
proton permeability, respectively, for a given lysosomal surface area. We observed that 
physiological ion homeostasis was fully restored when either the number of V-ATPase 
molecules or the membrane proton permeability was kept proportional to the lysosomal surface 
area expansion at a fixed lysosomal volume of 1.65x10
-16 
L (Fig. 3.3B).   
 
3.6.4.   The effects of altering multiple lysosomal ion transport pathways on spherical, 
tubular, and disc-shaped lysosomal physiology  
Next, we investigated the mechanism by which various combinations of lysosomal ion 
stressors exert their effects on the physiology of lysosomes with distinct morphology. Thus, we 
used different combinations of various ranges of lysosomal parameters to represent V-ATPase-
CLC7 stressors, V-ATPase-cytoplasmic chloride stressors, V-ATPase -membrane proton 
permeability stressors, and CLC7-cytoplasmic chloride stressors. These stressor combinations 
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were simulated to study their effects on the physiology of spherical, tubular, and disc-shaped 
lysosomes. For all of the lysosomal morphologies, maximum alteration of either CLC7 or 
cytoplasmic chloride parameters in combination with alteration in either V-ATPase number or 
membrane proton permeability generally induced perturbation of lysosomal physiology due to 
the increment of membrane potential by up to > 250 mV (Figs. 3.4B, 3.5, and 3.6). 
 
 
Figure 3.4. The effect of a combination of lysosomal ion stressors in spherical versus 
tubular lysosomes.  
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(A) Dimensions of tubular and spherical lysosomes. (B) The simultaneous inhibitions of V-
ATPase and CLC7 numbers induced changes in both spherical and tubular lysosomes with 
minimal difference between the two lysosomal morphologies. The increment in V-ATPase 
inhibition induced the most significant change while only the complete depletion of CLC7 
induced physiological perturbation which mainly arose from the significant change in membrane 
potential (> 250 mV, as indicated by the black arrow sign). (C) The simultaneous inhibition of 
V-ATPase and membrane proton permeabilization induced very similar and significant changes 
in the overall physiology of both spherical and tubular lysosomes.  
 
 
 
 
Figure 3.5 The effect of a simultaneous inhibition of the transport of chloride and proton 
ions in spherical versus tubular lysosomes.   
(A) Dimensions of tubular and spherical lysosomes. (B) The simultaneous inhibitions of the 
cytoplasmic chloride and V-ATPase number per lysosome induced significant changes in 
lysosomal pH, Cl
-
, and membrane potential. The effect was magnified in the tubular lysosome 
where the > 4 pH unit increment in lysosomal pH, > 150 mM reduction in lysosomal Cl
-
 
accumulation, and > 250 mV increment in membrane potential were observed (as indicated by 
the black arrow signs).  
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Figure 3.6 The effect of a simultaneous inhibition of proton and chloride transport in 
spherical versus various sized disc-shaped lysosomes.  
The simultaneous inhibitions of the cytoplasmic chloride and V-ATPase number per lysosome 
induced significant changes in lysosomal pH, Cl
-
, and membrane potential. The effect was more 
magnified in the disc-shaped lysosomes with lysosomal radius (> 2.2 fold) and height (< 3.7 
fold) than in the spherical lysosome where the > 4 pH unit increment in lysosomal pH, > 150 
mM reduction in lysosomal Cl
-
 accumulation, and > 250 mV increment in membrane potential 
were observed (as indicated by the black arrow signs).  
 
Although such increment in membrane potential was associated with the increment in 
lysosomal pH and reduction in lysosomal chloride accumulation, greater perturbations in both 
variables were observed when at least either the V-ATPase number (Figs 3.4B, 3.4C, 3.5B, 3.6 
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and 3.7) or membrane proton permeability (Figs. 3.4C and 3.7), (see Appendix Figs. B.2 and 
B.3) were maximally altered from their respective baseline values.  
 
 
Figure 3.7 The effect of a simultaneous V-ATPase inhibition and membrane 
permeabilization in spherical versus various sized disc-shaped lysosomes.  
The alterations of the V-ATPase number and membrane proton permeability per lysosome 
induced very similar changes to lysosomal pH, Cl
-
, and membrane potential. For all of the disc-
shaped lysosomes, as the lysosomal radius and height increased and decreased, respectively, 
more increment in the lysosomal pH, more reduction in the lysosomal Cl
-
 accumulation, and a 
slight increment in the lysosomal membrane potential were observed when there were no or very 
minimal alterations in both the V-ATPase number and membrane proton permeability, thus 
indicating the effect that the change in morphology alone has on lysosomal physiology.  
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Following the simultaneous reduction of both V-ATPase and CLC7 numbers, reduction 
of lysosomal chloride accumulation was observed to the extent of chloride efflux, in both 
spherical and tubular lysosomes (Fig. 3.4B). Beyond the perturbation of lysosomal chloride 
level, increment in lysosomal pH was also observed. Moreover, similar perturbation of 
lysosomal physiology was observed when the effect of the simultaneous alteration of membrane 
proton permeability and CLC7 number was simulated (see Appendix Fig. B.2). This indicates 
that the presence of lysosomal ion stressors, such as V-ATPase number and membrane proton 
permeability stressors which directly affect proton homeostasis, alone or in combination with 
lysosomal ion stressors, such as cytoplasmic Cl
-
 and CLC7 number stressors, which directly 
affect chloride homeostasis, perturb lysosomal physiology in a very similar manner.  
Regardless of lysosomal morphology, perturbations of lysosomal pH, Cl
-
 and membrane 
potential were generally greatest when either V-ATPase number or membrane proton 
permeability was simultaneously lowered or increased, respectively, along with the lowering of 
cytoplasmic chloride concentration from baseline values (Figs. 3.5 and 3.6), and (see Appendix 
Fig. B.3). More specifically, the perturbations were greater in tubular (Fig. 3.5) and disc-shaped 
lysosomes with radial expansion > 2 fold (Fig. 3.6) than in spherical lysosome. When comparing 
whether V-ATPase number, membrane proton permeability, or cytoplasmic chloride level 
affected the aforementioned perturbation the most, it is evident that either the lowering of V-
ATPase number or the increment of proton permeability similarly exerted more significant effect 
on lysosomal physiology (including the reduction in lysosomal chloride accumulation) than that 
of the lowering of cytoplasmic chloride concentration. This further corroborates the finding 
regarding the most significant role of net transmembrane proton flux on the regulation of 
lysosomal physiology.  
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3.7. Discussion  
 
Here, a physiologically-based mathematical modeling approach was used to assess the 
toxicological effects of drugs on lysosomes. For this purpose, we simulated the effects of altering 
individual or multiple parameters controlling lysosomal morphology and ion regulation on the 
recovery of lysosomes from a transient perturbation. Related to this, different cell types are able 
to tolerate lysosomal stress to different extents. While lysosomes of different cell types are 
known to vary in size, shape, and the molecular transport phenomena responsible for maintaining 
lysosomal pH, membrane potential, and ion concentrations, computational modeling approach 
enables the probing of the effect of variations of specific parameters on lysosomal physiology in 
a manner that is difficult –if not impossible– to control with pharmacological experiments.  
 
3.7.1.   Simulation of cell-type dependent differences in lysosomal stress response  
Variations in lysosomal morphology
62
 and lysosomal protein expression
21
 are manifested 
among different cell types. Our model simulations probed the mechanism by which such 
variations affected the cells’ ability to maintain lysosomal physiology. In terms of lysosomal 
morphology, our findings indicate that cell types that either have tubular or spherical lysosomes 
have very similar physiological profile characterized by the observed similar changes in 
lysosomal pH, Cl
-
, and membrane potential values following the introduction of various 
lysosomal ion stressors which induced the following lysosomal stresses: V-ATPase inhibition, 
CLC7 inhibition, cytoplasmic chloride inhibition, and membrane proton permeabilization. In 
spite of the difference in lysosomal volume between spherical and tubular lysosomal 
morphologies, as long as the lysosomal surface area is the same in both, their lysosomal 
physiology will only be dictated by the amount of active lysosomal V-ATPase and CLC7 
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proteins, and ion content, including cytoplasmic and lysosomal chloride and protons. Among the 
parameters that vary in a cell-type dependent manner, changes in the V-ATPase number and 
membrane proton permeability showed the most effect on lysosomal physiology as reflected by 
the significant changes in lysosomal pH, chloride, and membrane potential from their respective 
physiological baseline values. In contrast, alterations in CLC7 number and cytoplasmic chloride 
concentration had comparatively minimal effects on lysosomal physiology. This implies that the 
regulation of net proton transportation to and from the lysosome, for a given lysosomal surface 
area, plays a more significant role than that of net chloride transportation in the maintenance of 
lysosomal physiology.  
Upon investigating the effect of simultaneously changing multiple, cell-type dependent 
lysosomal parameters, simulation results revealed that the degree of lysosomal physiology 
perturbation was mainly determined by changes in the V-ATPase number or membrane proton 
permeability. Moreover, varying either of these two parameters along with the level of 
cytoplasmic chloride resulted in distinct, lysosomal morphology-dependent perturbations of 
lysosomal pH, Cl
-
, and membrane potential as the perturbation was heightened in tubular and 
disc shaped lysosomes. Tubular lysosomes are prevalent in cells with less lysosomal contents
44
, 
whereas disc-shaped lysosomes are prevalent in cells with greater lysosomal content than that of 
spherical lysosomes
63-65
. Thus, our findings imply that cell types with tubular or disc-shaped 
lysosomes may be more prone to toxic effects of lysosomotropic agents, in comparison to cell 
types with spherical lysosomes.  
 
3.7.2.   Simulation of the effects of drugs on lysosomal physiology 
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Pharmacologically, various drugs can be used to disrupt lysosomal ion homeostasis, such 
as V-ATPase inhibitor, chloride channel inhibitor, membrane proton permeabilizer, and 
cytoplasmic chloride reducer
29,40,41,48,66,67
. Moreover, there are also drugs that induce changes to 
lysosomal morphology by either affecting lysosomal volume or surface area
39,43,44
. Thus, by 
modeling the effects of altering lysosomal parameters, we have obtained insights into the 
mechanism by which lysosomal stress inducing drugs affect the regulation of lysosomal pH, Cl
-
, 
and membrane potential. Moreover, by altering various combinations of the lysosomal 
parameters, it is possible to obtain insights into the toxicological effects of drugs that exert 
pleiotropic effects on organelle ion homeostasis. Again, our results indicate that drugs that affect 
net proton flux across the lysosomal membrane, either by inhibiting the V-ATPase or by 
permeabilizing the lysosomal membrane to protons, exert the most significant perturbation to 
lysosomal physiology.  
Of noteworthy significance, many lysosomotropic and cationic amphiphilic drugs
39
 
induce lysosomal volume expansion, which can profoundly alter lysosomal physiology in the 
absence of compensatory changes in either V-ATPase number or membrane proton permeability. 
In contrast to drugs that induce lysosomal vacuolation, drugs that reduce lysosomal volume do 
not exert significant physiological perturbations, as reflected by the minimum changes in 
lysosomal pH, Cl
-
, and membrane potential. This emphasizes the necessity of regulation of net 
lysosomal proton flux dictated by the number of V-ATPase, membrane proton permeability, and 
lysosomal surface area.  
In addition, our mathematical model predictions can be tailored to investigate the 
mechanism by which cell-death inducing lysosomal membrane permeabilizers (LMP) affect 
lysosomal physiology based on various factors, such as size of LMP agent, cell-type dependent 
92 
 
lysosomal size, and lysosomal ion content
68
. In the case where perturbed membrane proton 
permeability due to cholesterol imbalance is the causative agent for LMP-mediated cell death, 
the role of V-ATPase upregulation in lysosomal stress tolerance could be experimentally 
studied
69
. Alternatively, the role of cholesterol-mediated changes in the proton permeability of 
membranes could also be investigated in cells expressing varying V-ATPase levels.  
 
3.7.3.   Relationship between lysosomal morphology and stress response  
In order to understand the mechanism by which lysosomal stress response is associated 
with lysosomal morphology
64
, we altered various combinations of lysosomal ion parameters 
together with geometric parameters that determine lysosomal shape. Only under very specific 
conditions was there a distinctively different perturbation in the physiology of tubular lysosome 
versus spherical lysosome (Fig. 3.5). The perturbation of lysosomal physiology following the 
simultaneous presence of a membrane proton permeabilizer and a cytoplasmic chloride stressor 
can be associated with the cytotoxic phenomenon of LMP-mediated cytosolic acidification along 
with lysosomal alkalinization
68,70-72
. This mechanism may be relevant to the selective toxicity of 
lysosomotropic agents to cancer cells
73
, because tubular lysosomes play a significant role in the 
shuttling of V-ATPase to the plasma membrane, which influences the survival and proliferation 
of cancer cells
40,66,74
. Moreover, this finding could shed light on the mechanism by which certain 
cationic amphiphilic drugs which destabilize lysosomal membrane induce anticancer effects
75
.  
 
3.7.4.   Insights into how exocytosis, endocytosis, and cholesterol may affect lysosomal stress 
response 
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Based on our findings, even though exocytosis and endocytosis can affect changes in 
lysosomal volume and surface area, significant effects on lysosomal pH, membrane potential, 
and chloride regulation are only observed in the context of specific number of V-ATPases, 
membrane proton permeability, and cytoplasmic chloride level per lysosome. More specifically, 
the simultaneous inhibitions in V-ATPase number and cytoplasmic chloride resulted in high 
increment in lysosomal pH, reduction in lysosomal chloride accumulation, and increment in 
membrane potential (Figs. 3.5 and 3.6). Endocytosis or exocytosis affect lysosomal morphology 
through changes in membrane surface area, and hence could be linked to specific toxicological 
manifestations of lysosomotropic drugs (Fig. 3.6). The effect of endocytosis or exocytosis on 
lysosomal stress can be offset, either through V-ATPase upregulation or reduction in membrane 
proton permeability. Regulation of membrane proton permeability can be induced by cholesterol 
regulation. Because cholesterol transportation to and from the lysosomes is facilitated by 
Niemann-Pick type C1 (NPC1) proteins
76,77
, these proteins themselves could also contribute to 
lysosomal stress response
78
 during endocytosis or exocytosis. 
 
3.7.5.   Insights into the TFEB lysosomal stress response mechanism 
Our finding suggests that V-ATPase expression plays a critical role in restoring 
lysosomal ion homeostasis following a transient perturbation. Transcription factor EB (TFEB) is 
a major transcriptional regulator of V-ATPase expression
79,80
. Thus, the upregulation of V-
ATPase may be sufficient to explain how TFEB upregulation may confer resistance to 
perturbations of lysosomal physiology. Although previous findings have indicated that ions or 
channels involved in cation transport may explain how TFEB induces its role
79,80
, appropriate 
interpretation of the experiments would depend on knowing any effects on the function of the V-
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ATPase. This is especially important as there have been reports
43,81,82
 showing TFEB mediated 
upregulation of lysosomal genes as a stress tolerance mechanism following the accumulation of 
weakly basic drugs. However, the induced stress tolerance may not necessarily be sufficient 
enough to restore full lysosomal function
81
. Thus, the extent of TFEB nuclear translocation and 
its transcriptional activity following lysosomal stress must be well understood in relation to the 
upregulation of V-ATPase expression. Indeed, additional cell growth regulators, such as 
mammalian target of rapamaycin (mTOR) complex 1 (mTORC1), which is associated with 
TFEB and V-ATPase regulation
34
, could be investigated to quantify the relationship between 
TFEB nuclear translocation, V-ATPase expression, and amount and type of endocytosed or 
internalized lysosomal stress inducer. 
 
3.8. Conclusion 
To conclude, a mathematical model was used to probe the mechanistic determinants of 
drug induced lysosomal stress and stress resistance, in the presence of individual as well as 
combination of lysosomal stressors. By testing the effects of different parameters that determine 
organelle morphology and ion transport, the net proton flux with respect to lysosomal surface 
area emerged as the key parameter affecting lysosomal stress sensitivity and resistance. 
Accordingly, the expression levels of V-ATPase can act in concert with the regulation of 
membrane proton permeability to determine the differential sensitivity of different cell types to 
the toxic effects of lysosomotropic drugs. 
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Chapter 4: Investigating How Phagosome Maturation Influences Phase-
Transition-Dependent Biocrystal Biocompatibility 
 
4.1. Introduction 
Phase transition of drugs is one of the major factors that account for lack of well-defined 
pharmacokinetic properties of drugs in the drug development and discovery processes
1-3
. Given 
most drugs in development are weak base compounds
4
, the phase-transition properties of such 
molecules must be well understood. It is well known that weak base compounds precipitate out 
of solution depending on the pH of the environment
5
. Indeed, the phase-transition properties of 
weak base compounds and their salt forms can be investigated using the well-established pH-
dependent drug solubility studies
6
. Briefly, the total drug solubility is comprised of both the free 
base and the ionized form of the drug, and depending on the pH of the solution in relation to the 
pHmax (which is defined as the pH where both the free base and salt forms of the drug are in the 
solid phase), either the free base or the salt form precipitates out of solution. At high pH (relative 
to the pHmax), the free base precipitates out of solution, and the total drug solubility is primarily 
dictated by the solubility of the ionized drug in solution. To the contrary, at low pH (relative to 
the pHmax), the salt form precipitates out of solution and is further stabilized by the presence of 
counter-ions in the media through a common-ion effect
7
. 
Although most research focus in drug development and accumulation gravitate towards 
understanding the phase transition properties of one form of a drug, i.e. the precipitation of the 
free base or the salt form of a drug, the phase-transition properties of both forms must be well
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understood. While the precipitation of free base drugs is well known to occur at high pH, such as 
the pH of the intestine
2,5
, the stability and effects of the ionized drug once it is in a low pH 
environment, such as the lysosome, is not well known
8
. Thus, the phase-transition of weak base 
drugs with respect to cellular conditions must be well understood. Indeed, the dynamics of the 
cellular environment as well as the lack of experimental techniques that can detect and measure 
subcellular accumulation of different forms of a given drug makes this pursuit rather challenging. 
Thus, to overcome this barrier, various mathematical models have been devised over the years. 
However, these models treat cellular drug accumulation process as a separate phenomenon from 
the phase transition properties of the drug itself in relation to its cellular environment.  
Thus, we adapt a mathematical model previously published from our lab
9
 in order to 
investigate the cellular and subcellular accumulation of the free base and ionized forms of a 
model, weak base drug molecule known as clofazimine (CFZ). Moreover, using the steady-state 
concentration of both drug species in the non-membrane environments, we determine the 
accumulation of the drug species in cell membrane, mitochondrial membrane, and lysosomal 
membrane. In addition, using the physicochemical properties of the free base and hydrochloride 
salt forms of CFZ, which were obtained from mathematical fitting of wet lab pH-solubility 
studies (Chapter 2), we determine the degree of supersaturation, which is a prerequisite for the 
precipitation of drug species, in all of the cellular compartments.   
 
4.2. Materials and Methods 
4.2.1.   Weak base drug species. 
Following the laws of mass balance, the total activity of an ionizable weak base drug is 
the sum of the activities of both the neutral and ionized forms of the drug: 
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aT = an + ad            (1) 
Where a is the activity of the weak base drug molecule, and the subscripts T, n, and d denote the 
total, neutral, and ionized weak base drug molecules, respectively.  
The activities of the neutral and ionized weak base drug species are related to each other 
according to the pKa of the drug molecule and the pH of its environment: 
ad =  an × 10
p𝐾a−pH           (2) 
Moreover, the activity of the neutral drug molecule (an) can be related to the total drug 
concentration (CT) according to the following relationship: 
fn =  
an
CT
=  
1
W
γn
 + 
Kn
γn
 + 
W × 10p𝐾a−pH
γd
 +  
Kd × 10
p𝐾a−pH
γd
       (3) 
Where W is the volumetric water fraction, γ is the activity coefficient, and K is the sorption 
coefficient of the drug species. 
Similarly, the activity of the ionized drug molecule (ad) can be related to the total drug 
concentration (CT) according to the following relationship: 
fd =  
ad
CT
= fn × 10
p𝐾a−pH          (4) 
For both the neutral and ionized drug species, the sorption coefficient of the drug species 
depends on both the lipid content of the subcellular compartment the drug partitions into, and the 
lipophilicity of the drug molecule itself: 
K = L × 1.22 × Kow            (5) 
Where L is the lipid fraction of a given subcellular compartment, and Kow is the octanol/water 
partition coefficient of the drug molecule.  
 
4.2.2.   Governing equations for cellular drug accumulation. 
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In order to calculate phase-transition-dependent drug concentration in different cellular 
compartments, we first adapted a mathematical model
9
, which enables us to calculate the time-
dependent subcellular drug concentration. The time-dependent subcellular accumulation of the 
unionized weak base drug concentration was modeled using Fick’s First Law of Diffusion, 
assuming passive diffusion of the drug molecule across a given biological membrane:  
J = Pn ×  (an,0 −  an,1)            (6) 
Where J is the flux of the drug molecule down its concentration gradient from compartment (0) 
to compartment (1) across a biological membrane and Pn is the membrane permeability of the 
neutral drug molecule. 
We can rewrite equation (6) by accounting for the relationship of neutral drug activity 
and total drug concentration provided in equation (3) as follows: 
J = Pn ×  (fn,0 × CT,0 −  fn,1 × CT,1)          (7) 
Moreover, the time-dependent cellular and subcellular accumulation of the ionized weak 
base drug was modeled using the Nernst-Planck equation
10
, assuming a linear potential gradient 
across the membrane:  
J = Pd × Y × Z ×
ad,0 − ad,1×e
Y×Z 
eY×Z − 1
         (8) 
Where Pd is the membrane permeability of the ionized drug molecule, Z is the valence of the ion 
(+1 for monoprotic weak base), Y= ΨF/RT, where F is Faraday’s constant, T is absolute 
temperature, R is universal gas constant, Ψ is membrane potential and the following sign 
convention is used: Ψ is more positive or negative if there is more cation or anion, respectively, 
in the external compartment than in the internal compartment.   
Thus, by combining equations (7 and 8), the total drug molecule flux can be written as 
follows: 
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J = Pn × (fn,0 × CT,0 −  fn,1 × CT,1) + Pd × Y × Z ×
fd,0×CT,0 − fd,1×CT,1×e
Y×Z 
eY×Z − 1
      (9) 
More specifically, the total drug molecule flux from i) the extracellular to the cytoplasm 
(equation 10), ii) the cytoplasm to subcellular organelles, such as mitochondria (equation 11) and 
lysosome (equation 12) can be represented as follows: 
JE,C = Pn × (fn,E × CT,E −  fn,C × CT,C) +  Pd × Y × Z ×
fd,E×CT,E − fd,C×CT,C×e
Y×Z 
eY×Z − 1
   (10) 
JC,M = Pn × (fn,C × CT,C −  fn,M × CT,M) +  Pd × Y × Z ×
fd,C×CT,C − fd,M×CT,M×e
Y×Z 
eY×Z − 1
   (11) 
JC,L = Pn × (fn,C × CT,C − fn,L × CT,L) +  Pd × Y × Z ×
fd,C×CT,C − fd,L×CT,L×e
Y×Z 
eY×Z − 1
   (12) 
Where subscripts e, c, m, and l represent the extracellular, cytoplasm, mitochondria, and 
lysosome. 
Using the above specific flux descriptions, the time-dependent changes of total drug 
concentrations in the different compartments can be modeled using the following equations: 
dCC
dt
=  
SC × JE,C
VC
−  
SM × JC,M
VC
 −  
SL × JC,L
VC
         (13) 
dCM
dt
=
SM × JC,M
VM
            (14) 
dCL
dt
=
SL × JC,L
VL
             (15) 
Where each flux term is multiplied by S, membrane surface area, in order to obtain the total 
amount of drug transported across the total area of a given membrane (i.e. cell membrane, 
mitochondria membrane or lysosomal membrane), V is the volume of a given compartment used 
to convert the units of drug molecule from mol/s to Molar/second. 
 
4.2.3.   Defining membrane partition coefficient of a drug. 
Membrane permeability of a drug molecule is given by the following relationship: 
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P =  
D×K
l
            (16) 
Where D is the diffusion coefficient of the drug molecule, K is the partition coefficient of the 
drug molecule, and for our purpose, we specifically focused on biological membrane partition 
coefficient of the drug molecule as described below, and l is the thickness of the biological 
membrane. 
In order to estimate the biological membrane partition coefficient of the neutral drug, we used 
the following equation
11
: 
log Km,n = 0.33 × log Kow,n + 2.2         (17)  
Where Km,n is the biological membrane partition coefficient of the neutral drug molecule, and 
Kow,n is the octanol/water partition coefficient of the neutral drug molecule. 
Similarly, we have the following relationship for the biological membrane partition coefficient of 
the ionized weak base drug
11
: 
log Km,d = 0.37 × log Kow,d + 2         (18) 
Where Km,d is the biological membrane partition coefficient of the ionized drug molecule, and 
Kow,d is the octanol/water partition coefficient of the ionized drug molecule, which can be 
determined from the octanol/water partition coefficient of the neutral drug molecule based on the 
following equation
10
: 
log Kow,d =  log Kow,n − 3.7          (19) 
 
4.2.4.   Numerical analysis. 
Equations (13-15) were solved by numerical integration in Virtual Cell® using combined 
stiff solver as a numerical integrator. 
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4.2.5.   Determining concentration of weak base drug species.  
The total drug concentration obtained from model simulation is comprised of the 
concentration of the neutral and ionized forms of the drug: 
CT = [B] + [BH
+]          (20) 
Where CT is the total drug concentration, [B] is the concentration of the neutral drug, and [BH
+
] 
is the concentration of the ionized drug. 
Thus, using equation (20) and the Henderson-Hasselbach equation (equation 21), we calculated 
the concentrations of the neutral and ionized forms of the weak base drug from the total drug 
concentration in the extracellular, cytoplasm, mitochondria, and lysosome: 
pH − p𝐾𝑎 = log
[B]
[BH+]
          (21) 
Moreover, the steady-state drug concentrations in the non-membrane environments, such 
as the extracellular, cytoplasm, mitochondria, and lysosome were used to calculate the steady-
state drug concentration in the biological membranes, such as the cell membrane, mitochondrial 
membrane, and lysosomal membrane, assuming that each biological membrane can serve as a 
micellar surfactant
12
:  
Km,n =  
[B]m,ss
[B]nm,ss
           (22) 
Where Km,n is the biological membrane partition coefficient of the neutral drug, [B]m,ss is the 
steady-state concentration of the neutral drug in a membrane, and [B]nm,ss is the steady-state 
concentration of the neutral drug in a non-membrane environment.  
Thus, we can derive the following equations from equation (22) to calculate the steady-
state concentration of the neutral drug in the cell membrane, mitochondrial membrane, and 
lysosomal membrane: 
[B]cm,ss = (Kcm,n_e ×  [B]E,ss) + (Kcm,n_i ×  [B]C,ss)      (23) 
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[B]mm,ss = (Kmm,n_e ×  [B]C,ss) + (Kmm,n_i × [B]M,ss)      (24) 
[B]lm,ss = (Klm,n_e ×  [B]C,ss) + (Klm,n_i ×  [B]L,ss)      (25) 
Where subscripts cm, mm, and lm refer to cell membrane, mitochondrial membrane, and 
lysosomal membrane, respectively; subscript ss refers to the drug concentration at steady state; 
subscripts e and i refer to external and internal leaflets of each membrane, which account for the 
effect of asymmetric membrane lipid distribution
13-15
 on membrane drug concentration.  
Similarly, we can derive the following equations to calculate the steady-state concentration of the 
ionized drug in the cell membrane, mitochondrial membrane, and lysosomal membrane: 
[BH+]cm,ss = (Kcm,d_e ×  [BH
+]E,ss) + (Kcm,d_i × [BH
+]C,ss)     (26) 
[BH+]mm,ss = (Kmm,d_e × [BH
+]C,ss) + (Kmm,d_i × [BH
+]M,ss)     (27) 
[BH+]lm,ss = (Klm,d_e ×  [BH
+]C,ss) + (Klm,d_i ×  [BH
+]L,ss)     (28) 
 
4.2.6.   Determining the phase transition of drug species. 
Drug concentration above thermodynamic drug solubility leads to supersaturation
5
. Thus, 
using experimentally determined thermodynamic solubility value of the free base drug, we can 
calculate the degree of supersaturation (DS) of the free base as follows
5
: 
 DS =  
[B]
[B]s
           (29) 
Where [B] is the free base drug concentration, and [B]s is the thermodynamic solubility of the 
free base drug, also known as intrinsic free base solubility.  
Similarly, we have the following relationship to calculate the degree of supersaturation for the 
salt form of the drug: 
DS =  
[BH+]×[Cl−]
𝐾sp
           (30) 
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Where Ksp is the solubility product of the salt form of the drug, [BH
+
] is the dissolved 
concentration of the ionized drug, and [Cl
-
] is the chloride concertation that interacts with the 
ionized drug through ion-ion interaction, producing the salt form of the drug. 
 
Table 4.1. Cellular drug accumulation model parameters 
Symbol Description Value Units 
init CT,E 
Initial total extracellular drug 
concentration 10 μM 
init CT,C 
Initial total cytoplasmic drug 
concentration 0 μM 
init CT,M 
Initial total mitochondrial drug 
concentration 0 μM 
init CT,L Initial total lysosomal drug concentration 0 μM 
init CT,CM 
Initial total cell membrane drug 
concentration 0 μM 
init CT,MM 
Initial total mitochondrial membrane drug 
concentration 0 μM 
init CT,LM 
Initial total lysosomal membrane drug 
concentration 0 μM 
pKa'  Apparent pKa 6.08 
 [B]S Intrinsic free base solubility 0.48 μM 
Ksp Salt solubility product 332.3 μM
2
 
[Cl
-
]L Lysosomal chloride concentration 110 mM 
pHE Extracellular pH 7.4 
 pHC Cytoplasmic pH 7.2 
 pHM Mitochondrial pH 8 
 pHL Lysosomal pH 4.5 
 
logKow,n 
Octanol/water partition coefficient of 
unionized weak base 7.66 
 LE Extracellular lipid fraction 0 
 LC Cytoplasmic lipid fraction 0.05 
 LM Mitochondrial lipid fraction 0.05 
 LL Lysosomal lipid fraction 0.05 
 WE Extracellular water fraction 1 
 WC Cytoplasmic water fraction 0.95 
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* activity coefficients of unionized and ionized molecules were obtained from the literature
16
. 
The physicochemical properties were obtained from experimental data fitting elaborated in 
Chapter 2 for CFZ free base and CFZ-H
+
Cl
-
 salt. The diameters of the cellular compartments 
were used to calculate volume and surface area, assuming spherical geometry. The effect of 
asymmetric membrane lipid distribution
13-15
 on drug membrane partition coefficient was 
accounted for based on literature values
17,18
. 
 
4.3. Results 
4.3.1.   Intracellular accumulation of drug species 
We used clofazimine (CFZ) as a model drug to predict its subcellular phase-transition 
dependent accumulation. CFZ is a poorly soluble, weak base drug molecule with two predicted 
ionizable groups (pKa,1 = 2.31 and pKa,2 = 9.29). It is known to form crystal like drug inclusions 
(CLDIs), which are composed of hydrochloride salts of the weak base (CFZ-H
+
Cl
-
), in mice and 
humans. Thus, using predetermined physicochemical properties of the free base as well as the 
salt form of the drug (Table 4.1), we calculated the time-dependent subcellular distribution of 
both drug species as a function of an extracellular total drug concentration of 10 µm, which is 
within the range of a typical drug concentration introduced in in vitro systems. We set the 
extracellular volume to a high value (Table 4.1), so that the extracellular drug concentration (Fig. 
4.1a) would not be a rate-limiting step in the subcellular drug distribution process.  
WM Mitochondrial water fraction 0.95 
 WL Lysosomal water fraction 0.95 
 γn* Activity coefficient of unionized drug 1 
 γd* Activity coefficient of ionized drug 0.74 
 ΨCM Cell membrane potential -70 mV 
ΨMM Mitochondrial membrane potential -160 mV 
ΨLM Lysosomal membrane potential 10 mV 
VE Extracellular volume 1.00E-04 L 
DC Cytoplasmic diameter 12.4 μm 
DM Mitochondrial diameter 5.76 μm 
DL Lysosomal diameter 5.76 μm 
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Figure 4.1 Time-plot simulations of extracellular and intracellular free base drug 
accumulation.  
a, Extracellular drug accumulation of CFZ free base remains constant while most of the 
free base drug is distributed to the cytoplasm (b). c, The lysosomal compartment does not have 
high free base drug concentration due to its low pH. d, The mitochondrial compartment has the 
highest free base drug concentration, consistent with the fact that it has the highest pH. 
 
As expected, the free base concentration was higher in the cytoplasm and mitochondria, 
than in the lysosome (Fig. 4.1b, c, d). Consistent with this, the ionized drug concentration is 
lower in the cytoplasm (Fig. 4.2b) than in the lysosome (Fig. 4.2c), which is explained by the 
lysosomotropic effect of the low lysosomal pH
19
. In fact, it is indeed in the lysosome that the 
highest drug concentration was observed (Fig. 4.2c). Moreover, even though the mitochondrial 
membrane potential was set to a physiological value of -160 mV, which is lower than the cell 
membrane potential (-70 mV), the higher ionized drug accumulation in the cytoplasm (Fig. 4.2b) 
than in the mitochondria (Fig. 4.2d) indicates that the relatively lower pH in the cytoplasm (pH = 
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7.2) than in the mitochondria (pH = 8.0) plays more substantial role than higher negative 
membrane potential in the amount of ionized drug accumulation within the compartments. 
Moreover, we expect both the free base and ionized drug concentrations in all of the 
compartments would proportionally decrease when the total initial extracellular CFZ 
concentration is reduced (sub-micromolar to picomolar) in a large extracellular volume.   
 
 
Figure 4.2 Time-plot simulations of extracellular and intracellular ionized drug 
accumulation.  
a, Extracellular drug accumulation of ionized CFZ (CFZH
+
) remains constant. b, The 
cytoplasmic compartment, due to its high pH, doesn’t protonate most of the free base drug. c, 
The lysosomal compartment has the highest ionized drug concentration due to its low pH. d, The 
mitochondrial compartment, due to its high pH, doesn’t protonate most of the free base drug.  
 
Using the steady-state concentrations in the non-membrane environments, we calculated 
the concentrations of both the free base and ionized forms of the drug in the cell membrane, 
mitochondrial membrane, and lysosomal membrane. The free base drug concentrations in all of 
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the membranes were higher than the ionized drug concentrations (Table 4.2), which attribute to 
the fact that the partitioning coefficient of the neutral drug is greater than that of the ionized 
drug
20,21
. Consistent with the highest free base drug concentration in the mitochondria (Fig. 4.1), 
we observed the highest free base drug concentration in the mitochondrial membrane (Table 
4.2). Surprisingly, the free base drug concentration was greater in the lysosomal membrane than 
in the cell membrane (Table 4.2), which indicates that beyond drug concentration in the non-
membrane environment – from which the drug partitions into its immediate membrane 
environment – the lipid amount on the membrane leaflets plays a substantial role in the amount 
of drug partitioning into the membrane
20
. 
 
Table 4.2. Drug concentration in membrane  
Membrane [CFZ] (μM) [CFZ-H+Cl-] (μM) 
Cell membrane 5.18x10
7
 2.11x10
5
 
Mitochondrial 
membrane 5.04x10
8
 1.29x10
6
 
Lysosomal membrane 1.39x10
8
 3.65x10
7
 
 
 
4.3.2.   Phase transition of drug species in cell 
In order to determine the propensity of the free base and ionized forms of the drug to 
precipitate out in the different cellular compartments, we calculated the degree of supersaturation 
of both forms of the drug using their solubility properties obtained from experimental 
measurements and experimental-data fitting (Table 4.1). Consistent with the high free base drug 
concentration observed in the cytoplasm and mitochondria (Fig. 4.1b, d), high degree of 
supersaturation of the free base was also observed in both compartments (Fig. 4.3b, d), (Table 
4.3). However, the highest degree of supersaturation in the non-membrane environment was 
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observed for the ionized from of the drug in the lysosomal compartment (Fig. 4.4). Indeed, the 
supersaturation of the CFZ-H
+
Cl
-
 salt occurs only within the lysosome (Table 4.3) because of the 
drug’s pHmax in relation to the physiological lysosomal pH. Moreover, the degree of 
supersaturation of CFZ-H
+
Cl
-
 salt in the lysosome exceeds (3-6 orders of magnitude) that of CFZ 
free base in the non-membrane as well as membrane environments (Table 4.3); which suggests 
that the salt form of the drug has greater thermodynamic tendency for precipitation than the free 
base drug even when introducing a low total initial extracellular CFZ concentration (sub-
micromolar to picomolar) in a large extracellular volume.  
 
Figure 4.3 Degree of supersaturation of extracellular and intracellular free base drug.  
a, The degree of supersaturation of the free base drug in the extracellular compartment is 
relatively low due to low free base drug concentration. b, The degree of supersaturation of the 
free base drug in the cytoplasmic compartment is consistent with the high free base drug 
concentration in the compartment. c, The relatively low degree of supersaturation of the free base 
drug in the lysosomal compartment is consistent with the low free base drug concentration in the 
compartment. d, The degree of supersaturation of the free base drug in the mitochondrial 
compartment is consistent with the high free base drug concentration in the compartment. 
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Figure 4.4 Degree of supersaturation of ionized drug in the lysosome.  
High degree of supersaturation of the ionized drug species occurs in the lysosome  
 
 
Table 4.3. Steady-state degree of supersaturation of free base CFZ and CFZ-H
+
Cl
-
 
Compartments 
Steady-state degree of 
supersaturation of free 
base CFZ  
Steady-state degree 
of supersaturation of 
CFZ-H+Cl- 
Extracellular 1.98x101 
 Cell membrane 5.21x103 
 Cytoplasm 4.95x104 
 Mitochondrial 
membrane 5.07x104 
 Mitochondria 5.36x104 
 Lysosomal membrane 1.40x104 
 
Lysosome 2.25x103 1.36x107 
 
 
4.4. Discussion 
CFZ is a weak base compound which is known to accumulate and supersaturate as CFZ-
H
+
Cl
-
 biocrystalline in macrophages of mice and humans
22-24
. Although the exact mechanism by 
which such crystal formation and stabilization occurs in macrophages is not known, possible 
mechanisms that explain the accumulation and precipitation of the CFZ-H
+
Cl
-
 salt gravitate 
towards the interdependence of cellular properties and the physicochemical properties of the 
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drug. In this report, by performing model simulation of the phase-transition-dependent 
distribution and accumulation of both the free base CFZ and CFZ-H
+
Cl
-
 salt in the different 
cellular compartments, we observed that the free base CFZ accumulation was high in 
compartments with high pH (> 7), such as mitochondria and cytoplasm (Fig. 4.1b, d). However, 
the ionized drug concentration was greater than that of the free base in the lysosomal 
compartment due to the lysosomotropic effect (Fig. 4.2c). Moreover, the extent of the ionized 
drug accumulation in the lysosome is within the same order of magnitude to what has been 
previously reported for other weakly basic compounds
25
. However, in this report, we show the 
effect of lysosomal chloride and the Ksp of CFZ-H
+
Cl
-
 salt, in relation to the drug’s pHmax, on the 
precipitation of the ionized drug as a hydrochloride salt, through a common-ion effect.  
Although lysosomotropic effect is common to weak base compounds, the extent of weak 
base drug accumulation in lysosomes varies significantly even for weak base drug molecules 
with similar properties, such as pKa, logP, and intrinsic free base solubility, which are commonly 
used physicochemical properties in drug classification
26
. In fact, the lysosomal accumulation of 
some weak base drugs is associated with toxic effects, such as perturbation of lysosomal ion 
homeostasis and function by increasing lysosomal pH, increasing the lysosomal size, and 
permeabilizing the lysosomal membrane
27-29
. Moreover, it is suggested that the lysosomal 
accumulation of the ionized form of cationic drugs is associated with lysosomal membrane 
permeabilization
28,29
. Indeed, based on our findings, the ionized drug concentration in lysosomes 
can be very high even at low extracellular drug concentration unless the ionized drug precipitates 
out of solution in its salt form. Therefore, in addition to determining the logP and pKa of a given 
weak base drug molecule, the physicochemical properties of its salt form can be insightful in 
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predicting the extent and stability of the drug accumulation in lysosomes, and the associated 
effects on lysosomal physiology.   
In fact, the degree of supersaturation of the free base and salt forms of various weak base 
drugs, including amiodarone, carvedilol, and desipramine could be estimated using their reported 
solubility properties
30-32
, assuming that the extent of accumulation of these drugs in the various 
cellular compartments is within the same order of magnitude to that of CFZ. For weak base 
drugs with pKa values 6.2 – 10.1
30-32
, the estimated degree of supersaturation of the salt form of 
the weak base drugs in a lysosomal environment would be 1 to 12 orders of magnitude fold less 
than that of CFZ-H
+
Cl
-
. This suggests that the propensity of salt precipitation for some, if not 
most, weak base drugs
30-32
 is primarily dictated by their solubility properties than by their logP 
and pKa values. Indeed, hydrochloride salt forms of weak base drugs with high Ksp values (> 8 
orders of magnitude µM
2
) have low tendency to precipitate out even when administered at high 
dose, which does not perturb cellular physiology.     
To the contrary, the estimated degree of supersaturation of the free base drugs would be 
1-5 orders of magnitude fold greater than that of free base CFZ, with the exception of 
amiodarone, which has a low intrinsic free base solubility
32
. This suggests that the weak base 
drugs are more stabilized in their free base forms than in their salt forms, which could have 
implications regarding their physiological cellular disposition and accumulation that in turn 
affects their overall PK profile. Therefore, further studies which incorporate mathematical model 
predictions as well as model-prediction guided wet-lab experiments of the phase-transition 
dependent cellular distribution and accumulation of weak base drugs and their salt forms are 
warranted.  
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4.4.1.   Insights into weak base drug-induced phospholipidosis 
Phospholipidosis, also known as acquired lysosomal storage disorder, is the accumulation 
of lipids in lysosomes, and is caused by weak base drugs such as amiodarone, azithromycin, and 
chloroquine, which are classified as cationic amphiphilic drugs (CADs)
33,34
. One of the 
suggested mechanisms by which weak base drug-induced phospholipidosis occurs is through the 
accumulation of a weak base drug molecule in the lysosomal membrane, which thereby displaces 
lysosomal phospholipase A2 (LPLA2) enzyme that is responsible for the degradation of 
membrane phospholipids, such as phosphatidylcholine and phosphatidylethanolamine
33,35
. Thus, 
it could be useful to predict the dose-dependent relationship of the ionized weak base drug 
accumulation in the lysosomal membrane and LPLA2 inhibition to better understand the effect 
of weak base drug-induced phospholipidosis
34
. Alternatively, the physicochemical properties of 
the hydrochloride salts of such weak base drugs, such as Ksp, intrinsic salt solubility, and pHmax, 
could be investigated in order to stabilize the salt form of the weak base drugs within the 
lysosome as a mechanistic way to reduce the amount of the ionized weak base drug that inhibits 
LPLA2. This would especially be important in the case where most weak base drugs that are in 
development or already in the market, which are known to induce phospholipidosis could be 
repurposed in order to retain their notable efficacies.     
 
4.4.2.   Cell-type dependent phagocytosis of biocrystal 
Our findings are also helpful in understanding the biocompatibility of phagocytosis of 
crystal drugs
22,36-38
. In the case where salt forms of weak base drugs are directly administered to 
cells, the stability and amount of drug distributed across cells can be determined using modeling 
prediction. For our model drug, CFZ, we have observed that although the ionized drug 
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accumulates in all of the cellular compartments, CFZ-H
+
Cl
-
 salt is only stabilized in a lysosomal 
environment. Thus, future studies that further investigate the effect of cell-type dependent 
lysosomal lipid content
13-15,39-41
 on the phase-transition-dependent weak base drug accumulation 
and stabilization could elucidate the previously reported heterogeneous phagocytosed drug 
bioaccumulation and stabilization processes
38
 with respect to the maintenance of cell physiology.  
 
4.5. Acknowledgment and contributions 
This work was supported by National Institutes of Health grant R01GM078200 to GRR and 
Rackham Merit Fellowship to TW. 
T.W. designed, performed, and analyzed computational experiments. T.W. and G.R.R. designed 
the project and G.R.R. directed the research. 
 
 
4.6. References 
1 Augustijns, P. & Brewster, M. E. Supersaturating drug delivery systems: fast is not 
necessarily good enough. J Pharm Sci 101, 7-9, doi:10.1002/jps.22750 (2012). 
 
2 Miller, D. A., DiNunzio, J. C., Yang, W., McGinity, J. W. & Williams, R. O., 3rd. 
Enhanced in vivo absorption of itraconazole via stabilization of supersaturation following 
acidic-to-neutral pH transition. Drug Dev Ind Pharm 34, 890-902, 
doi:10.1080/03639040801929273 (2008). 
 
3 Yalkowsky, S. H., Valvani, S. C. & Johnson, B. W. In vitro method for detecting 
precipitation of parenteral formulations after injection. J Pharm Sci 72, 1014-1017 
(1983). 
 
4 Charifson, P. S. & Walters, W. P. Acidic and basic drugs in medicinal chemistry: a 
perspective. J Med Chem 57, 9701-9717, doi:10.1021/jm501000a (2014). 
 
5 Hens, B., Brouwers, J., Corsetti, M. & Augustijns, P. Supersaturation and Precipitation of 
Posaconazole Upon Entry in the Upper Small Intestine in Humans. J Pharm Sci 105, 
2677-2684, doi:10.1002/jps.24690 (2016). 
 
6 Kramer, S. F. & Flynn, G. L. Solubility of organic hydrochlorides. J Pharm Sci 61, 1896-
1904 (1972). 
 
7 Serajuddin, A. T. Salt formation to improve drug solubility. Adv Drug Deliv Rev 59, 603-
616, doi:10.1016/j.addr.2007.05.010 (2007). 
121 
 
8 Duvvuri, M. & Krise, J. P. A novel assay reveals that weakly basic model compounds 
concentrate in lysosomes to an extent greater than pH-partitioning theory would predict. 
Mol Pharm 2, 440-448, doi:10.1021/mp050043s (2005). 
 
9 Baik, J. & Rosania, G. R. Modeling and Simulation of Intracellular Drug Transport and 
Disposition Pathways with Virtual Cell. J Pharm Pharmacol (Los Angel) 1, 
doi:10.13188/2327-204X.1000004 (2013). 
 
10 Trapp, S. & Horobin, R. W. A predictive model for the selective accumulation of 
chemicals in tumor cells. Eur Biophys J 34, 959-966, doi:10.1007/s00249-005-0472-1 
(2005). 
 
11 Balon, K., Riebesehl, B. U. & Muller, B. W. Drug liposome partitioning as a tool for the 
prediction of human passive intestinal absorption. Pharm Res 16, 882-888 (1999). 
 
12 Kadam, Y., Yerramilli, U. & Bahadur, A. Solubilization of poorly water-soluble drug 
carbamezapine in pluronic micelles: effect of molecular characteristics, temperature and 
added salt on the solubilizing capacity. Colloids Surf B Biointerfaces 72, 141-147, 
doi:10.1016/j.colsurfb.2009.03.027 (2009). 
 
13 van Meer, G., Voelker, D. R. & Feigenson, G. W. Membrane lipids: where they are and 
how they behave. Nat Rev Mol Cell Biol 9, 112-124, doi:10.1038/nrm2330 (2008). 
 
14 van Meer, G. Transport and sorting of membrane lipids. Curr Opin Cell Biol 5, 661-673 
(1993). 
 
15 Bohdanowicz, M. & Grinstein, S. Role of phospholipids in endocytosis, phagocytosis, 
and macropinocytosis. Physiol Rev 93, 69-106, doi:10.1152/physrev.00002.2012 (2013). 
 
16 Zhang, X., Shedden, K. & Rosania, G. R. A cell-based molecular transport simulator for 
pharmacokinetic prediction and cheminformatic exploration. Mol Pharm 3, 704-716, 
doi:10.1021/mp060046k (2006). 
 
17 Calderon, R. O. & DeVries, G. H. Lipid composition and phospholipid asymmetry of 
membranes from a Schwann cell line. J Neurosci Res 49, 372-380 (1997). 
 
18 Horvath, S. E. & Daum, G. Lipids of mitochondria. Prog Lipid Res 52, 590-614, 
doi:10.1016/j.plipres.2013.07.002 (2013). 
 
19 de Duve, C. et al. Commentary. Lysosomotropic agents. Biochem Pharmacol 23, 2495-
2531 (1974). 
 
20 Williams, H. D. et al. Strategies to address low drug solubility in discovery and 
development. Pharmacol Rev 65, 315-499 (2013). 
 
122 
 
21 Jain, N., Yang, G., Tabibi, S. E. & Yalkowsky, S. H. Solubilization of NSC-639829. Int J 
Pharm 225, 41-47 (2001). 
 
22 Baik, J., Stringer, K. A., Mane, G. & Rosania, G. R. Multiscale distribution and 
bioaccumulation analysis of clofazimine reveals a massive immune system-mediated 
xenobiotic sequestration response. Antimicrob Agents Chemother 57, 1218-1230, 
doi:10.1128/AAC.01731-12 (2013). 
 
23 Desikan, K. V., Ramanujam, K., Ramu, G. & Balakrishnan, S. Autopsy findings in a case 
of lepromatous leprosy treated with clofazimine. Lepr Rev 46, 181-189 (1975). 
 
24 Lewis, J. T., Candelora, J. N., Hogan, R. B., Briggs, F. R. & Abraham, S. C. Crystal-
storing histiocytosis due to massive accumulation of charcot-leyden crystals: a unique 
association producing colonic polyposis in a 78-year-old woman with eosinophilic colitis. 
Am J Surg Pathol 31, 481-485, doi:10.1097/01.pas.0000213420.46127.9c (2007). 
 
25 Fu, D. et al. Imaging the intracellular distribution of tyrosine kinase inhibitors in living 
cells with quantitative hyperspectral stimulated Raman scattering. Nat Chem 6, 614-622, 
doi:10.1038/nchem.1961 (2014). 
 
26 Ohkuma, S. & Poole, B. Cytoplasmic vacuolation of mouse peritoneal macrophages and 
the uptake into lysosomes of weakly basic substances. J Cell Biol 90, 656-664 (1981). 
 
27 Moruno-Manchon, J. F. et al. TFEB ameliorates the impairment of the autophagy-
lysosome pathway in neurons induced by doxorubicin. Aging (Albany NY) 8, 3507-3519, 
doi:10.18632/aging.101144 (2016). 
 
28 Boya, P. & Kroemer, G. Lysosomal membrane permeabilization in cell death. Oncogene 
27, 6434-6451, doi:10.1038/onc.2008.310 (2008). 
 
29 Boya, P. et al. Lysosomal membrane permeabilization induces cell death in a 
mitochondrion-dependent fashion. J Exp Med 197, 1323-1334, 
doi:10.1084/jem.20021952 (2003). 
 
30 Avdeef, A. et al. Equilibrium solubility measurement of ionizable drugs - Consensus 
recommendations for improving data quality. Vol. 4 (2016). 
 
31 Avdeef, A. Solubility of sparingly-soluble ionizable drugs. Adv Drug Deliv Rev 59, 568-
590, doi:10.1016/j.addr.2007.05.008 (2007). 
 
32 Bergstrom, C. A., Luthman, K. & Artursson, P. Accuracy of calculated pH-dependent 
aqueous drug solubility. Eur J Pharm Sci 22, 387-398, doi:10.1016/j.ejps.2004.04.006 
(2004). 
 
33 Shayman, J. A. & Abe, A. Drug induced phospholipidosis: an acquired lysosomal storage 
disorder. Biochim Biophys Acta 1831, 602-611, doi:10.1016/j.bbalip.2012.08.013 (2013). 
123 
 
 
34 Bauch, C., Bevan, S., Woodhouse, H., Dilworth, C. & Walker, P. Predicting in vivo 
phospholipidosis-inducing potential of drugs by a combined high content screening and 
in silico modelling approach. Toxicol In Vitro 29, 621-630, doi:10.1016/j.tiv.2015.01.014 
(2015). 
 
35 Abe, A. et al. Lysosomal phospholipase A2 is selectively expressed in alveolar 
macrophages. J Biol Chem 279, 42605-42611, doi:10.1074/jbc.M407834200 (2004). 
 
36 Baik, J. & Rosania, G. R. Macrophages sequester clofazimine in an intracellular liquid 
crystal-like supramolecular organization. PLoS One 7, e47494, 
doi:10.1371/journal.pone.0047494 (2012). 
 
37 Baik, J. & Rosania, G. R. Molecular imaging of intracellular drug-membrane aggregate 
formation. Mol Pharm 8, 1742-1749, doi:10.1021/mp200101b (2011). 
 
38 Yoon, G. S. et al. Phagocytosed Clofazimine Biocrystals Can Modulate Innate Immune 
Signaling by Inhibiting TNFalpha and Boosting IL-1RA Secretion. Mol Pharm 12, 2517-
2527, doi:10.1021/acs.molpharmaceut.5b00035 (2015). 
 
39 Andreyev, A. Y. et al. Subcellular organelle lipidomics in TLR-4-activated macrophages. 
J Lipid Res 51, 2785-2797, doi:10.1194/jlr.M008748 (2010). 
 
40 Murakami, T. & Yumoto, R. Role of phosphatidylserine binding in tissue distribution of 
amine-containing basic compounds. Expert Opin Drug Metab Toxicol 7, 353-364, 
doi:10.1517/17425255.2011.548805 (2011). 
 
41 Spector, A. A. & Yorek, M. A. Membrane lipid composition and cellular function. J 
Lipid Res 26, 1015-1035 (1985). 
 
 
 
 
 
 
 
124 
 
Chapter 5: The Adaptive Cargo Carrying Capacity of Macrophages Expands 
the Drug Volume of Distribution 
 
The content of this chapter will be included in the following reference: 
Rzeczycki, P., Baik, J., Woldemichael, T., Keswani, R.K., Yoon, G.S., Stringer, K.A., Rosania, 
G.R. The Adaptive Cargo Carrying Capacity of Macrophages Expands the Drug Volume of Drug 
Distribution. (2017), In Preparation.  
 
5.1. Relevance to Thesis  
This chapter incorporates computational pharmacokinetic analysis of in vivo clofazimine 
accumulation and efflux experiments, which have allowed us to determine the steady-state 
clofazimine accumulation in different macrophage population. Our findings have elucidated the 
mechanistic role of macrophages in accommodating and stabilizing massive drug 
bioaccumulation in a physiological manner.  
In addition, our findings and conclusions would enable us to design future experiments to 
better understand the difference in the accommodation and stabilization processes of drug 
bioaccumulation within different macrophage population. Moreover, our model predictions 
would allow us to design experiments that can better capture the biochemical and biophysical 
features of the different macrophage types, especially in relation to the macrophage lysosomes, 
that can explain the stabilization of the prolonged internalization of the drug by the cells.     
 
5.2. Personal Contribution 
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Using experimentally determined CFZ uptake (assumed to be zero order) and release 
rates (assumed to be 1
st
 order exponential decay) by peritoneal and alveolar macrophages, I 
modeled and performed simulations of the time-dependent drug accumulation in both peritoneal 
and alveolar macrophages using ordinary differential equations in Berkeley Madonna® software.  
 
5.3. Abstract 
Through phagocytosis or fluid phase pinocytosis, cultured macrophages are capable of 
internalizing massive amounts of solids and solutes from the extracellular medium (‘massive’ 
defined as surpassing every other cellular component, except water). Nevertheless, the cargo 
carrying capacity of macrophages has never been measured in vivo. Here, we used an orally 
bioavailable drug -clofazimine- as a molecular reporter of the extent of macrophage loading. 
Upon increasing the whole-body drug cargo load, macrophages adjusted their size, number and 
membrane organization to accommodate an increasing cargo volume. Ultimately, the total 
volume of intracellular cargo exceeded 5% of the total cell volume across the entire macrophage 
population. Most interestingly, macrophages adaptively maximized their cargo capacity, not only 
by stabilizing and reshaping the intracellular cargo space, but also by remodeling their 
intracellular membrane architecture to minimize the surface area of the cargo space while 
maximizing the cargo volume. By stabilizing a solute-to-solid phase transition, the apparent 
volume of distribution of the reporter probe continuously increased through treatment, and 
exceeded the cell volume by more than ten thousand-fold. As expected from an active 
sequestration mechanism, experimentally depleting macrophages in liver and spleen reduced the 
total amount of drug cargo accumulated in those organs, without affecting the loading of the 
remaining cells. Altogether, the results indicate a coordinated, immunological response 
126 
 
mechanism across the entire macrophage population, which expands their endolysosomal cargo 
carrying capacity to accommodate an increasingly massive load of drug cargo. 
 
5.4.  Introduction 
Throughout the body, macrophages are especially equipped to internalize extracellular 
solutes and particles through pinocytosis and phagocytosis, respectively. This allows them to 
carry out a number of critical cellular immune functions ranging from destruction of pathogens 
to removal and recycling of dead cells and aged tissue components
1-3
. In addition to being highly 
phagocytic, the endolysosomal system of the macrophage is especially capable of 
accommodating and degrading foreign material due to higher expression levels of lysosomal 
acidification mechanisms
4
, particularly the vacuolar-type proton ATP-ase (V-ATPase)
5
. Little is 
known about the in vivo phagocytic capacity of macrophages, with the majority of work having 
been performed in vitro using fluorescent tracer molecules
6
 or inert beads of varying sizes
7
. For 
example, Cannon et al performed a study to determine the extent to which murine bone marrow 
macrophages were able to phagocytose polystyrene beads of various sizes, revealing that the 
phagocytic capacity of these cells is limited by the amount of membrane that is available to 
spread out and engulf the particle, rather than the volume of the cell
8
.  
Even though the macrophage is a major immune regulator, its role as a determinant of 
drug distribution is underappreciated. Due to their high rates of endocytosis, pinocytosis and 
phagocytosis, and because of their ubiquitous presence throughout the body, they are poised to 
impact the performance and efficacy of many therapeutic agents. For example, liposomal 
formulations must be optimized to avoid phagocytosis of particles and removal of drug from the 
systemic circulation, increasing therapeutic efficiency
9,10
. The action of macrophages may also 
127 
 
impact small molecule drugs, such as antibiotics
11-13
. Many antibiotics will display large volumes 
of distribution and long elimination half-lives
14
, causing them to linger within the body for 
extended periods of time. The accumulation of weakly basic, hydrophobic drug molecules within 
acidic subcellular compartments is a well-documented phenomenon, referred to as ion-trapping 
15
. Cationic, amphiphilic molecules, particularly weakly basic molecules, tend to become trapped 
within lysosomes following protonation within the acidic lysosomal microenvironment
15-17
. 
Because macrophages have very active endolysosomal systems and express high levels of 
biomolecular ion transporters, they could significantly impact the volumes of distribution of 
many weakly basic drugs.  
Here, in order to study both how macrophages impact the volume of distribution of a 
therapeutic agent, and to determine the in vivo cargo carrying capacity of the macrophage, the 
FDA-approved and biocompatible antibiotic clofazimine was chosen as a reporter probe. 
Clofazimine is an anti-mycobacterial agent clinically used to treat leprosy and multi-drug 
resistant tuberculosis
18-20
. It exhibits extensive accumulation throughout the body following oral 
administration, in both humans and in animal models
21-23
. Because clofazimine is both highly 
lipophilic (LogP > 7) and contains a weakly basic, ionizable amine group, it is expected to 
accumulate in adipose tissue, intracellular membranes and in acidic organelles, such as 
lysosomes. In both human and animal models, it has been shown that following prolonged oral 
dosing, CFZ accumulates extensively within macrophages
24
.  
Previously, we have shown that the accumulation of clofazimine within macrophages 
leads to the formation of large, insoluble crystal-like drug inclusions (CLDIs) within these cells 
comprised of highly organized domains of clofazimine hydrochloride
25,26
. In this manner, CLDIs 
can provide a solid, stable volume marker to assess the macrophage’s cargo carrying capacity 
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and its contribution to the drug’s volume of distribution. Because of the crystallinity and low 
solubility, CLDIs are easily isolated and are readily detectable through a variety of analytical 
techniques
24,26
. Thus, we proceeded to study the cargo loading capacity of different macrophage 
populations to probe the patterns of macrophage loading in different organs, and to determine 
how the macrophages impact the volume of distribution. Additionally, the effects of macrophage 
depletion on cargo loading was probed, and the theoretical macrophage loading capacity within 
different tissues was calculated and related to the measured, tissue-specific variations in 
macrophage loading and its contribution to the volume of distribution.  
 
5.5. Materials and Methods 
5.5.1. Clofazimine administration to mice.  
Animal care was provided by the University of Michigan’s Unit for Laboratory Animal 
Medicine (ULAM), and the experimental protocol was approved by the Committee on Use and 
Care of Animals (Protocol PRO00005542). Mice (4 week old, male C57Bl6) were purchased 
from the Jackson Laboratory (Bar Harbor, ME) and acclimatized for 1 week in a specific-
pathogen-free animal facility. Clofazimine (C8895; Sigma, St. Louis, MO) was dissolved in 
sesame oil (Shirakiku, Japan) to achieve a concentration of 3 mg/ml, which was mixed with 
Powdered Lab Diet 5001 (PMI International, Inc., St. Louis, MO) to produce a 0.03% drug to 
powdered feed mix, and orally administered ad libitum for up to eight weeks. A corresponding 
amount of sesame oil was mixed with chow for vehicle treatment (control). For washout 
experiments, mice were fed the vehicle-containing diet for eight weeks, after an eight-week 
loading period with the CFZ-containing diet. Mice were euthanized via carbon dioxide 
asphyxiation and exsanguination. 
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5.5.2. Alveolar macrophage isolation.  
Following euthanasia, the trachea was surgically exposed and cannulated with an 20G 
needle and the lungs were lavaged by instilling DPBS (Life Technologies) containing 0.5 mM 
EDTA (Sigma) in 1 ml aliquots for a total of 6 ml. Approximately 90% of the bronchoalveolar 
lavage (BAL) was retrieved. The BAL was then centrifuged for 10 min at 400 x g, 4 °C, 
resuspended in RPMI 1640 media (Life Technologies) with 5% FBS (Life Technologies) and 
Penicillin/Streptomycin (Thermofisher), macrophages were counted, and an aliquot of cells were 
then plated onto 4 or 8 chamber coverglass (#1.5, Lab-Tek II, Nunc, Rochester, NY) for imaging 
studies. The cells were allowed to attach overnight and then washed with media. The remaining 
cells were analyzed for drug content. 
 
5.5.3. Peritoneal macrophage isolation.  
Following euthanasia, a small incision was made in the lower abdomen. The peritoneal 
cavity was then flushed 10 mL of ice cold DPBS containing 5% FBS (Sigma) and collected. The 
peritoneal lavage was centrifuged for 10 min at 400 x g, 4 °C, and then resuspended in DMEM 
media (Life Technologies) with 5% FBS and Penicillin /Streptomycin, macrophages were 
counted, and an aliquot of cells were then plated onto 4 or 8 chamber coverglass (#1.5, Lab-Tek 
II, Nunc, Rochester, NY) for imaging. The cells were allowed to attach overnight and then 
washed with media. The remaining cells were analyzed for drug content. 
 
5.5.4. Bone marrow monocyte isolation.  
Following euthanasia, an incision was made above the hip bone and the skin was 
removed down the entire leg. The femur was then cut from the knee joint and the hip, the muscle 
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was removed, and the bone was placed in ice cold DPBS. The tips of the femur were then cut, 
and the bone was flushed with 5 mL of ice cold PBS to collect the bone marrow monocytes. The 
suspension was centrifuged for 10 min at 400 x g, 4 °C, and resuspended in RPMI 1640 media 
with 5% FBS and Penicillin/Streptomycin, counted with a hemocytometer, and an aliquot of 
cells were plated onto 4 or 8 chamber coverglass  (#1.5, Lab-Tek II, Nunc, Rochester, NY) for 
imaging. The cells were allowed to attach overnight and then washed with media. The remaining 
cells were analyzed for drug content. 
 
5.5.5. Kupffer cell isolation.  
Following euthanasia, the portal vein was injected with 10 mL of 1 mg/mL Collagenase 
D (Worthington Biochemical Corporation, Lakewood, NJ) in DMEM-low glucose (Life 
Technologies) with 15 mM HEPES (Life Technologies). The tissue was then removed, placed in 
a sterile petri dish, and minced into small (2-4 mm) pieces using a sterile scalpel blade. 15 mL of 
the Collagenase solution was added, and the tissue was incubated for 40 minutes at 37 °C, with 
occasional pipetting to dissociate tissue. The suspension was then filtered through a 100 µm cell 
strainer (Fisher Scientific, Waltham, MA) and centrifuged at 200 x g for 5 minutes. The 
supernatant was discarded, and the cells were resuspended in 15 mL DMEM-low glucose with 
15 mM HEPES, and centrifuged at 200 x g for 5 minutes. This was repeated for two additional 
washes. After the final wash, the cells were suspended in DMEM: F/12 (1:1) (Life Technologies) 
with 10% FBS and Penicillin/Streptomycin, macrophages were counted, and an aliquot was 
plated onto 4 or 8 chamber coverglass(#1.5, Lab-Tek II, Nunc, Rochester, NY) coated with 
Collagen 1 (Corning, Corning, New York) for imaging. The cells were allowed to attach 
overnight and then washed with media. 
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5.5.6. Multi-parameter microscope imaging and analysis of xenobiotic sequestering 
macrophage populations.  
Multi-parameter polarization, brightfield, and fluorescence imaging and analysis were 
performed using the imaging method previously described by Rzeczycki et al
26
. Briefly, cells 
were plated on chamber slides and allowed to attach overnight. Following attachment, cells were 
imaged with brightfield, fluorescence, and polarization imaging modalities. Images were then 
analyzed using ImageJ software
27,28
. Values for dichroism and optical density are reported as an 
average signal per cell, from 0-1. At least 150 cells of each type were analyzed at each time 
point. Following loading with 7 and 14 mg of cargo, macrophages were classified as xenobiotic 
sequestering based on whether or not they contained a detectable Cy5 signal from clofazimine 
hydrochloride
24
 using a K-means clustering analysis, with the clusters set to 2 based off of the 
Log10(Intracellular Cy5 fluorescence). 
 
5.5.7. Biochemical analysis of clofazimine in cells.  
The concentration of clofazimine in cells was determined after measuring clofazimine 
content in isolated macrophage populations and organ homogenates using established methods 
22,24,25,29
. For isolated macrophage populations, cells were counted within each cell sample using 
a hemocytometer to determine the total recovered macrophage population. The cells were then 
centrifuged and the media was removed. The cell pellet was suspended in 1 mL of DI water, and 
the drug was extracted with three passes of 1 mL of xylenes. The drug was then extracted from 
the xylene with three 1 mL passes of 9 M sulfuric acid. The concentration of clofazimine present 
in the cell sample was then determined using a plate reader (Biotek Synergy 2, Winooksi, VT) at 
wavelength 450 nm, and background corrected at wavelength 750 nm, with the concentration 
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determined using a standard curve made of standards with known concentrations of clofazimine, 
and is reported as fmol clofazimine/xenobiotic sequestering cell. 
 
5.5.8. Sample preparation for microscopy.  
Cryosectioning was carried out using a Leica 3050S Cryostat (Leica Biosystems Inc., 
Buffalo Grove, IL). Samples were sectioned to 5 µm. In preparation for cryosectioning, portions 
of the organ were removed, immediately submerged in OCT (Tissue-Tek catalog no. 4583; 
Sakura), and frozen (-80 °C). For transmission electron microscopy, organs were submerged in 
fixative and cut into small (< 1 mm) sized pieces. The organs were preserved in a glass vial with 
fixative and stored at 4 °C. After three rinses with Sorensen's buffer (0.1 M), tissues were stained 
with 1% osmium tetroxide in Sorensen's buffer and washed three times in Sorensen's buffer. 
Dehydration was carried out with a graded ethanol-water series (50, 70, and 90% and two 
changes of 100%) for 15 min each. After washing with three changes of propylene oxide, the 
tissues were treated with Epon resin (Electron Microscopy Sciences) and polymerized at 60 °C 
for 24 hours. The blocks were then sectioned to 70 nm using an ultramicrotome and mounted on 
a copper EM grid (Electron Microscopy Sciences), which was then stained with uranyl acetate 
and lead citrate before imaging. Immunohistochemistry of F4/80 (Abcam, 1:500 dilution) was 
performed using Alexa-Fluor 488 (Abcam, 1:500 dilution). 
 
5.5.9. Clofazimine volume occupancy.  
The volume that clofazimine occupies within the macrophage was determined using the 
reported crystal-packing density of 1.36 g/mL
25
 for CFZ-H
+
Cl
-
, which was then converted to a 
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molar volume of 0.377 µm
3
/ fmol. Cellular volume occupancy was then estimated using the 
measured drug loading per cell and this calculated molar volume. 
 
5.5.10. Determination of vesicle size and shape.  
Vesicle loading per cell was performed using the Cy5 fluorescence of the alveolar 
macrophage. Using ImageJ
27,28
, the radius of each vesicle was determined. Vesicles which 
showed Cy5 fluorescence were counted as clofazimine sequestering. Volume of the vesicle for 
3.5 and 7 mg treated cells was estimated assuming spherical shape, while CLDI volume was 
estimated assuming a cylindrical shape. 
 
5.5.11. Macrophage expansion analysis.  
To determine the expansion in macrophage population in lung, liver, and spleen from 
animals treated with clofazimine, cryosections were obtained of the same thickness. The relative 
number of macrophages in a volume of tissue was determined by dividing the total F4/80 signal 
staining intensity between 8 week clofazimine-treated sample by the total F4/80 signal staining 
intensity of a vehicle-treated sample (the area and thickness of the sections analyzed were kept 
the same). The expanded macrophage population was then determined by multiplying literature 
reported (baseline) macrophage population values for each organ
30
 by the relative  expansion 
factor. To determine the percentage of xenobiotic sequestering cells, the total number of cells 
which showed Cy5 fluorescence and F4/80 staining were determined using a mask of the F4/80 
staining. 5 images per organ per animal were analyzed for each measurement. 
 
5.5.12. Measurement of CLDI mass within tissues.  
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The CLDI mass present in lung, liver, and spleen tissues at eight weeks of treatment was 
determined using established protocols
29
. Tissues (n = 3) were removed, weighed, and placed in 
a sterile petri dish, where they were manually minced and homogenized using a scalpel and 
syringe plunger. The tissue homogenate was filtered through a 40 µm cell strainer to remove 
larger cellular debris. The filtrate was then centrifuged for 10 min at 300 x g to pellet the CLDIs. 
The supernatant was removed and the pellet was resuspended in 10% sucrose in DPBS (Life 
Technologies, Carlsbad, CA) without calcium chloride or magnesium chloride, pH=7.4. CLDIs 
were further purified using a 3-layer sucrose gradient (50%, 30%, and 10% sucrose in DPBS) 
centrifugation method (3200 x g for 60 minutes). The pelleted CLDIs were then dissolved in 9 M 
H2SO4 and the mass of drug was determined using a plate reader (Biotek Synergy 2, Winooksi, 
VT) at wavelength 450 nm, and background corrected at wavelength 750 nm, with the aid of a 
standard curve made with solutions of known concentration. 
 
5.5.13. CLDI loading within individual macrophages.  
Using the total recovered mass of CLDIs within the liver, lung, and spleen, the CLDI 
loading within individual xenobiotic-sequestering macrophages was estimated using the total 
expanded macrophage population, which was corrected for the percentage of CLDI containing 
cells. The percentage of cellular volume that is occupied by the CLDI was estimated using 
literature reported values for the cellular volume of macrophages
31
. 
 
5.5.14. Macrophage depletion.  
To deplete tissue macrophages, mice were treated with liposomes containing either 7 
mg/mL of clodronate or phosphate-buffered saline (PBS) (FormuMax Scientific Inc., Sunnyvale, 
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CA). Liposomes were injected intraperitoneally, as previously described
32
. Mice were initially 
treated with 200 µL of liposomes followed by 100 µL injections twice per week to ensure 
continual macrophage depletion. Mice were fed clofazimine or control diet continuously for a 
four-week period. Following two weeks of feeding, liposome administration began for two 
weeks. After completing four weeks of feeding and two weeks of liposome treatment, mice were 
sacrificed and tissues were collected. 
 
5.5.15. Biochemical analysis of clofazimine in tissues.  
After loading with clofazimine, mice were euthanized via CO2 asphyxiation, and organs 
were removed and weighed. Tissue (20-30 mg) was homogenized in 500 µL of 
radioimmunoprecipitation assay buffer (Sigma) with added protease inhibitors (Halt protease and 
phosphatase inhibitor cocktail and 0.5 M EDTA; Thermo Pierce, Rockford, IL), and 350 µL of 
homogenate was removed. The drug was then extracted from the xylene with three 1 mL passes 
of 9 M sulfuric acid. The recovery yield was determined by spiking samples with a known 
concentration of clofazimine. The concentration of clofazimine present in the tissue was then 
determined using the plate reader assay (Biotek Synergy 2, Winooksi, VT) at wavelength 450 
nm, and background corrected at wavelength 750 nm, with the aid of a standard curve made with 
solutions of known concentration. 
 
5.5.16. Biochemical analysis of clofazimine in plasma.  
Blood was collected and centrifuged (7,000 × g for 5 minutes). The resulting supernatant 
serum was extracted with acetonitrile (90% extraction efficiency) for 10 min at 4 °C with 
vortexing. After centrifugation (15,000 rpm, 4 °C), the supernatant was injected into a Waters 
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Acquity UPLC H-Class (Waters, Milford, MA) equipped with an Acquity UPLC BEH C18 
column (1.7 μm, 2.1 mm [inner diameter] by 100 mm; Waters, Milford, MA). Mobile phase A 
was 5 mM ammonium acetate, adjusted to pH 9.9 with ammonium hydroxide, and mobile phase 
B was acetonitrile. The flow rate was 0.35 ml/min, with a linear gradient from 50 to 100% phase 
B over 1.5 min, followed by holding at 100% for 1.5 min, a return to 50% phase B, and then re-
equilibration for 2.5 min. Standards were prepared by spiking untreated plasma samples with 
known amounts of clofazimine, ranging from 0 to 30 µM. Peak area was determined using 
Empower 3 Software (Waters, Milford, MA). 
 
5.5.17. Determination of the volume of distribution of clofazimine at various stages of drug 
loading.  
Following treatment with 5.25 or 14 mg of clofazimine, mice (n = 3 per time point) were 
euthanized and the liver, spleen, small intestine, fat, kidney, and lung were removed, weighed, 
and the mass of clofazimine within each tissue and concentration within plasma was determined 
using the previously described protocols. The volume of distribution of the drug within 
macrophages, tissue, and the whole body at the different loading amounts was determined using 
the ratio between the total drug within tissues or individual cells and the measured plasma 
concentration, and is reported as L/kg tissue or L/kg body weight, assuming a 25 gram mouse. 
 
5.5.18. CLDI injection and stabilization assay.  
To determine how macrophages stabilize CLDIs, mice were treated with either liposomal 
PBS or liposomal clodronate, as previously described
32
. 48 hours after liposome administration, 
mice were injected I.P. with 200 µg of CLDIs suspended in 1 mL of PBS (n = 3 mice per group 
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per time point). At time points ranging from 0 to 48 hours, the mice were euthanized, the 
peritoneal lavage was collected and pelleted, and the drug content within the pellet was analyzed 
using the previously described spectrophotometric analysis method. Using a simple exponential 
regression with recovered drug content, the half-life was estimated. 
 
5.5.19. Statistical analysis.  
All data are expressed as means ± the standard deviations (SD). For multiple 
comparisons, statistical analysis was performed with one-way analysis of variance (ANOVA) 
and Tukey's post hoc comparisons. The half-life of injected CLDIs was determined using a 
simple, first order exponential regression of the recovered drug mass. All statistical analyses 
were performed using IBM SPSS Statistics version 24.0 (IBM Software, Armonk, New York). P 
values less than 0.05 were considered statistically significant. 
 
5.6. Results 
5.6.1 Macrophages adjusted internal membrane arrangement to maximize cargo loading. 
Experimentally, a moderate, whole-body cargo load (3.5 mg, Fig. 5.1) mostly led to 
accumulation in alveolar macrophages (Fig. 5.1a). This cargo was associated with red, optically 
dense cytoplasmic vesicles which exhibited little dichroism signal, corresponding to a 
disordered, amorphous supramolecular organization
33,34
 (Fig. 5.1b). A larger cargo load resulted 
in a modest increase in accumulation in the alveolar macrophages (Fig. 5.1c), plus a fraction of 
peritoneal and liver macrophages were also loaded. However, the structure of the intracellular 
cargo became more organized (Fig. 5.1b) as reflected in the elevated optical density and 
dichroism of peritoneal and liver macrophages (Fig. 5.1b-d). Doubling the whole-body cargo 
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load caused all macrophages to redistribute their internal cargo loads into large, highly ordered 
CLDIs exhibiting strong dichroism signals (Fig. 5.1b). Under all loading conditions, the less 
mature bone marrow monocytes were free of cargo. At a population level, these trends were 
confirmed by multi-parameter image-based cytometric analyses (Fig. 5.1c, d). 
 
Figure 5.1 Microscopic imaging cytometry reveals variations in cargo loading of 
macrophage and monocyte populations. 
a, Brightfield images of isolated macrophage and monocytes following increasing whole-body 
cargo loading. b, Linear diattenuation images of isolated macrophage and monocytes following 
increasing whole-body cargo loading. c, Mean optical density of alveolar macrophage (black), 
peritoneal macrophage (red), bone marrow monocyte (green), and Kupffer cell (blue) at 
increasing cargo loading. d, Mean linear diattenuation of alveolar macrophage (black), peritoneal 
macrophage (red), bone marrow monocyte (green), and Kupffer cell at increasing cargo loading. 
e, Mean cargo loading per xenobiotic-sequestering cell at increasing cargo loading. f, Percentage 
of maximal cargo loading within each cell type at increasing cargo loading. Error bars represent 
standard deviation. (n = 150 cells per time point for imaging studies, n = 3 mice per cargo 
treatment for drug accumulation, * = p < 0.05, ANOVA, Tukey’s HSD). Scale bar is 10 µm. 
 
The results of chemical analyses confirmed the observed, uneven distribution of cargo 
amongst the different macrophage populations. At low (3.5 mg) cargo loading, alveolar 
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macrophages sequestered 29.9 ± 12.4 fmol of cargo/cell, with the other populations showing 
minimal loading (Fig. 5.1e). Within the alveolar macrophages, after a whole-body load of 3.5 
mg, less than 0.3% of the maximal phagocytic capacity of the cells was reached (Fig. 5.1f). At a 
larger (7 mgs) whole-body cargo load, alveolar macrophages accumulated 34.0 ± 20.3 fmol 
cargo/cell, which primarily remained in disordered form as reflected in the low dichroism signal 
(Fig. 5.1b, d). Peritoneal and liver macrophage populations, due to their differential 
accumulation pattern (Fig. 5.1b), increased their cargo loading per cell to 105.7 ± 10.0 and 63.5 
± 16.2 fmol/cell, respectively. At the highest loads of cargo (14 mgs), alveolar, peritoneal, and 
liver macrophage populations showed similar levels of cargo loading (Fig. 5.1e). By 
accumulating cargo as CLDIs, the macrophages maximized intracellular cargo loading. The 
highest cargo volume corresponded to ~ 1% of the reported, maximal phagocytic capacity of 
macrophages (Fig. 5.1f)
8
. Thus, with CLDI formation, only a small fraction of the potential, 
intracellular cargo space was occupied at the highest loading capacity measured in vivo. 
In order to efficiently accommodate this massive cargo load, macrophages also adjusted 
their intracellular membrane organization. At low levels of loading (3.5 mgs), the alveolar 
macrophage population accumulated an average of 21.6 ± 5.0 vesicles per cell, with each vesicle 
occupying a mean volume of 0.43 ± 0.29 µm
3
 (Table 5.1). Transmission electron micrographs of 
alveolar macrophages revealed numerous dark, lipid bound inclusions within the cytoplasm (Fig. 
5.2a). An even larger (7 mgs) whole-body cargo load resulted in the cytoplasmic vesicles 
increasing to 32.6 ± 6.8 per cell (n = 30 cells, p < 0.05, ANOVA, Tukey’s HSD), with the 
vesicular volume slightly increasing to 0.97 ± 0.96 µm
3
 (Table 5.1). Nevertheless, at 14 mg of 
cargo loading, the AMΦ’s membrane bound cargo compartment was visibly expanded (Fig. 
5.2b). At this point, the number of loaded vesicles per cell dropped to 18.4 ± 11.1 and their 
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volume increased to 13.8 ± 10.4 µm
3
. The larger, solid, membrane bound compartments were 
stable and remained within the macrophage even after an eight-week cargo washout period (Fig. 
5.2c). 
 
Table 5.1 Changes in vesicle number, size, and volume occupancy in cargo-treated alveolar 
macrophages. 
Cargo Loading Mean number of 
vesicles per cell 
(n=30 cells) 
Mean vesicle 
volume (n=50 
vesicles) 
Mean total volume 
occupied by 
vesicles (n=50 
vesicles) 
3.5 mg 21.6 ± 5.0 0.43 ± 0.29 µm
3 
9.2 ± 6.7 µm
3 
7 mg 32.6 ± 6.8* 0.97 ± 0.96 µm
3 
31.7 ± 32.1 µm
3 
14 mg 18.4 ± 11.1 13.8 ± 10.4 µm
3
* 253.8 ± 244.5 µm
3 
(* = p < 0.05, ANOVA, Tukey’s HSD). 
 
 
 
 
Figure 5.2 Cargo accumulation induces reorganization in the internal membrane 
architecture of macrophages. 
a, Following whole-body loading of 3.5 mg of the cargo volume marker, macrophages of the 
lung are loaded with small vesicles that fill the cytoplasm. b, Increasing doses of the marker 
results in the accumulation of crystal-like drug inclusions (CLDIs) throughout the cytoplasm. c, 
These larger aggregates remain stable intracellularly even following an eight-week washout 
period. Black arrows denote cargo-laden vesicles and red arrows denote cavities left from CLDIs 
removed during sample preparation. Scale bars are 2000 nm. 
 
5.6.2 Insoluble cargo accounts for majority of intracellular loading, and leads to 
increased volume of distribution. 
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Of noteworthy significance, the amount of cargo in the isolated macrophage populations 
effectively accounted for most of the total cargo load measured in whole organ homogenates 
(Table 5.2). Based on the amount of cargo within each organ, the volume of blood that was 
cleared by the macrophages in the different organs was estimated (the organ-specific Volume of 
Distribution, VoD; Table 5.3). In pharmacokinetic terms, the whole body VD of a molecule is the 
ratio between the amount of drug in the organism and the plasma concentration of the drug
35
. VD 
represents the extent of tissue distribution
36
 as reflected in the theoretical volume required to 
contain an administered amount of drug, at the same concentration as found in the plasma. With 
an increasing cargo load, each macrophage population significantly contributed to the increase in 
VOD and hence, to VD (Table 5.3). Given that the volume of a single macrophage is ~ 1 pL, the 
macrophages’ contribution to VD was mostly due to the solute-to-solid phase transition that 
accompanied CLDI formation. At the whole organ level, there was a nearly 100-fold increase in 
the VOD within the liver and small intestine, a 60-fold increase within the spleen, and a 10-fold 
increase within the lung upon increasing the whole-body cargo loading from 5.25 to 14 mg 
(Table 5.4). Within the fat and kidney, which do not contain the large populations of tissue 
macrophages typical of the previously mentioned organs, there were modest increases in the 
VOD, but nowhere near the increases in VOD observed in liver, spleen, lung and intestine (Table 
5.4). 
 
Table 5.2 Estimated cargo loading within liver, spleen, and lung macrophages following 14 
mg of cargo loading. 
Macrophage 
Population 
Cargo mass 
(mg) 
Percent 
Xenobiotic 
Sequestering 
Total Xenobiotic 
Sequestering 
Population 
Fmol 
Cargo/Xenobiotic 
Sequestering Cell 
% Cell Volume Occupied 
by Cargo 
Liver 4.57 ± 0.78 88.5 ± 3.3% 8.0 x 107 ± 1.9 x 
107 
120.9 ± 35.3 2.11 ± 0.62%  
Spleen 3.23 ± 0.27 83.9 ± 12.5% 2.2 x 107 ± 5.9 x 
106 
310.5 ± 86.9 5.42 ± 1.52% 
Lung 0.32 ± 0.06 81.1 ± 3.2% 3.7 x 106 ± 1.7 x 183.2 ± 91.5 3.20 ± 1.60% 
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Table 5.3 Volume of distribution of cargo marker in liver, lung, and spleen macrophage, at 
5.25 and 14 mg of whole-body loading 
 
Macrophage Population 5.25 mg cargo VOD (nL/macrophage) 14 mg cargo VOD (nL/macrophage) 
Liver 0.66 ± 9.8x10-5 33.51 ± 0.01* 
Lung 5.51 ± 9.5x10-5 42.73 ± 0.01* 
Spleen 0.49 ± 2.5x10-4 64.25 ± 0.01* 
(* = p < 0.05, Two-Tailed Student’s T-Test) 
 
 
Table 5.4 Volume of distribution of cargo marker in various organs, at 5.25 and 14 mg of 
whole-body loading 
 
Tissue (n=3 per treatment) 5.25 mg cargo VOD (L/kg tissue) 14 mg cargo VOD (L/kg tissue) 
Liver 33.9 ± 13.1 2232.5 ± 958.2* 
Spleen 118.8 ± 85.4 6139.3 ± 2637.0* 
Fat 91.8 ± 15.2 129.1 ± 61.1 
Jejunum and Ileum 11.1 ± 6.3 1085.2 ± 606.2* 
Lung 91.2 ± 12.0 902.3 ± 524.1 
Kidney 31.1 ± 7.3 125.6 ± 55.5 
(* = p < 0.05, Two-Tailed Student’s T-Test) 
 
5.6.3 Macrophages are necessary to acquire and stabilize intracellular cargo 
Interestingly, the number of macrophages in various organs increased following loading 
with the maximum cargo treatment (Fig. 5.3a). Thus, to test whether macrophages played an 
active role in determining cargo accumulation and distribution, liposomal clodronate injections 
were used to deplete hepatic and splenic macrophages
32
. Following clodronate treatment, the 
cargo carrying capacity of liver and spleen was significantly reduced. However, within the 
kidney, which did not undergo depletion, there was no significant reduction in cargo load (Fig. 
5.3b). Quantitatively, due to the reduction in macrophage numbers (Fig. 5.3c), there was a 
concomitant reduction in CLDI accumulation within the liver and spleen (Fig. 5.3d). Most 
interestingly, cargo loading within liver and spleen macrophages was similar between the two 
treatment groups (Fig. 5.3e). Furthermore, the serum concentration of clofazimine was similar 
between the groups (Fig. 5.3f), indicating that the effects of clodronate on cargo accumulation 
106 
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were specifically due to macrophage depletion, and not to a decrease in circulating drug 
concentrations or an associated decrease in drug bioavailability, absorption or macrophage 
loading, which would have been apparent as a decrease in drug accumulation in the remaining 
macrophages. Finally, injecting CLDIs directly into the peritoneal cavity of macrophage-
depleted mice led to a significant reduction in half-life compared to their control, PBS-treated 
counterparts (Fig. 5.3g). The peritoneal macrophages imparted stability to the injected CLDI by 
internalizing them via phagocytosis, while extracellular CLDIs degraded more rapidly (Fig. 
5.3h). These results indicate that the macrophages are actively involved in the sequestration and 
stabilization of cargo as insoluble, highly organized, and biocompatible supramolecular 
complexes. 
 
 
Figure 5.3 Macrophages increase in number and actively sequester cargo (primarily by 
stabilizing it in an insoluble form).  
a, Comparison of total F4/80 macrophage signal in untreated (grey) and 14 mg cargo loading 
(red) tissue sections. b, Total cargo loading in PBS- (red) and clodronate-liposome (green) 
tissues. c, Quantification of tissue macrophage population in PBS-vehicle diet (grey), clodronate-
vehicle diet (black), PBS-cargo diet (red), and clodronate-cargo diet (green) using F4/80 signal. 
d, Quantification of insoluble cargo accumulation in PBS-vehicle diet (grey), clodronate-vehicle 
diet (black), PBS-cargo diet (red), and clodronate-cargo diet (green) using Cy5 fluorescence. e, 
Individual macrophage cargo loading in PBS-cargo diet (red) and clodronate-cargo diet (green). 
f, Serum concentration of clofazimine in clodronate- and PBS-cargo diet treatment groups. g, 
Estimated half-life of injected CLDIs within peritoneal cavity of clodronate and PBS liposome 
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treated mice. h, Peritoneal lavage of PBS and clodronate treated liposome groups 48 hours post 
injection. Scale bar is 50 µm. Error bars represent standard deviation (* = p < 0.05, Student’s 
Two-tailed T-test or ANOVA, Tukey’s HSD). 
 
 
5.7. Discussion 
While the volume of distribution of most hydrophobic drugs is typically ascribed to drug 
partitioning into adipose tissue, the experimental results presented in this study indicate how 
macrophages can account for most of the accumulation and distribution of the reporter probe in 
vivo, with macrophage cargo carrying capacity increasing in parallel to the increase in whole 
body load. In the experiments reported in this study, the mass and volume of cargo per cell was 
nowhere near the maximal cargo capacity of macrophages, as determined in vitro following 
phagocytosis of spherical beads of increasing size
8
. When macrophages of the liver and spleen 
were depleted, there was a reduction in the whole-organ cargo carrying capacity in proportion to 
the decrease in the macrophage population, but the cargo carrying capacity of the remaining 
macrophages was unaffected. There has been extensive research in the past on how therapeutic 
agents can impact the immune system
37
. However, few, if any, small molecule drugs have been 
shown to have their ADME properties dependent on the action of macrophages or other specific 
populations of immune cells. Using clofazimine as a weakly basic reporter molecule
38
, we found 
that the extent of tissue distribution was actively impacted by the action of tissue macrophages. 
Lung and liver macrophages are often where bacteria reside during persistent bacterial infections 
(particularly with infections of Mycobacterium tuberculosis
39
 and Mycobacterium leprae
40
). By 
extension, the efficacy of many of the antibiotics used to treat these infections may be dependent 
on a synergistic interaction between the macrophages, which harbor these intracellular 
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pathogens, and the antibiotic, which is sequestered by these cells and ultimately destroys these 
pathogens. 
Most interestingly, our results indicate that macrophage-mediated small molecule drug 
sequestration can have a profound impact on pharmacokinetics. While it is often assumed that 
the volume of distribution of a therapeutic is a constant, and is only significantly impacted by 
disease states affecting organ function
41,42
, our measurements indicate that this is not necessarily 
the case. Rather, in the case of drugs that show significant levels of bioaccumulation, undergo 
phase transitions (solute-solid or solute-amorphous), or are able to become concentrated within 
particular cellular populations, it is possible that the volume that the drug distributes can change 
significantly as treatment progresses. With clofazimine, this remarkable phenomenon was first 
evident as a significant reduction in the plasma concentration of the drug from weeks 3 to 8 in 
treatment
22
. Concurrently, in this study we found a ~100-fold increase in the organ-specific 
volume of distribution (VOD) within the liver and spleen, and a ~10-fold increase of VOD within 
the lung. The blood volume cleared by different organs corresponded to the extent of loading of 
the macrophages in those organs, with the spleen showing the highest loading per unit tissue 
weight, followed by liver and lung
22
. The preferential accumulation of the cargo in spleen was 
primarily associated with the accumulation of drug molecules as an insoluble, ordered 
supramolecular aggregates
43
. By depleting the macrophages of the liver and spleen with 
clodronate, we deduce that this phenomenon is largely due to the action of macrophages. Beyond 
clofazimine, it is known that the intracellular sequestration of other hydrophobic, cationic drugs 
such as amiodarone
44
 or quinacrine
45
 is highly dependent on the proton pump V-ATPase, which 
is expressed at higher levels within macrophages
5
. Thus, beyond clofazimine, this mechanism is 
likely to impact the pharmacokinetics of other therapeutic agents. 
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In terms of the biological mechanisms that underpin their ability to sequester an 
increasingly massive load of cargo, the macrophage endolysosomal system is particularly adept 
at accommodating an increasing cargo load due to the low pH and high chloride environment of 
their lysosome (Chapter 2)
43
. The high levels of V-ATPase expressed in macrophage lysosomes 
are a likely explanation for the active solute to solid transition that seems to occur selectively 
within these cells. Due to the active concentrative proton and chloride pumping
46
 within the 
endolysosomal system, massive amounts of solid cargo can be sequestered and accommodated 
within membrane bound intracellular compartments. In addition to the activity of lysosomal 
proton and chloride transporters present in macrophage lysosomes, these cells can also alter their 
internal membrane architecture to maximize the volume of cargo within a minimal amount of 
membrane surface area. As our results indicate, at low levels of cargo treatment, macrophages 
acquired soluble cargo in the form of small, spherical vesicles. Continued accumulation of cargo 
led to the formation of larger volume vesicles and to the disappearance of the smaller vesicles. 
We infer that, by expanding the volume of intracellular vesicles, macrophages maximized the 
available cargo space while minimizing the overall membrane surface area delimiting the cargo 
compartments
47,48
, allowing for increased cargo accumulation within the cell, and consequently, 
an increase in VOD. 
In addition to the adaptive changes that were observed to occur at the level of the 
individual macrophages, measurements of the entire cell population of liver, lung, and spleen 
indicated an increase in the number of macrophages occurring in parallel to the increase in cargo 
loading. Pathologically, an expansion in the macrophage population is typically associated with a 
pro-inflammatory response
49,50
. However, the accumulation of insoluble intracellular drug cargo 
in macrophages of clofazimine-treated animals was accompanied by the activation of anti-
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inflammatory signaling pathways and was not associated with obvious toxicological 
manifestations
29,51
. As a candidate anti-inflammatory signaling mechanism, it is possible that the 
lysosomal accumulation of weakly basic molecules may induce activation of transcription factor 
EB (TFEB)
52,53
. Increased cargo loading can therefore lead to TFEB becoming chronically 
activated, resulting in increased lysosomal biogenesis, which would reduce lysosomal stress and 
actively allow for increased intracellular cargo sequestration. Nevertheless, because this 
macrophage-mediated drug sequestration phenomenon is also linked to concomitant changes in 
organ mass (e.g. splenomegaly
22
) and histological organization (e.g. granuloma formation
22,54
), 
these results warrant additional studies into the functional sequelae of the pro- and anti-
inflammatory signaling mechanisms that are activated in response to a massive intracellular 
cargo load. 
 
5.8. Conclusion 
To conclude, the results presented in this study point to a stimulus-dependent, 
macrophage-mediated biological response mechanism that is activated by the extent of cargo 
accumulation in these cells. In this process, macrophages actively stabilize intracellular drug as 
insoluble complexes that are trapped within membrane-bound compartments. To accommodate 
increasingly massive loads of cargo, macrophages increase in numbers and adapt their 
intracellular membrane organization so as to maximize the intracellular cargo space. While 
resident macrophages of different organs demonstrated significant variations in their response to 
increasing loads of cargo, all differentiated macrophage populations were capable of 
sequestering large loads of cargo. The adaptive cargo carrying capacity of macrophages 
ultimately accounted for the observed increment in the drug volume of distribution, which was 
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directly measured based on the amount of drug cargo sequestered within each organ. Of 
noteworthy significance, to our knowledge, this is the first time that the volume of distribution of 
a small molecule drug has been directly measured and associated with an adaptive, immune 
system-mediated biological response. 
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Chapter 6: Conclusions and Future Outlook 
 
6.1 General Conclusions 
In this dissertation, we have investigated two of the key features of pharmacokinetic 
properties of drugs: the phase-transition-dependent subcellular accumulation and stabilization 
processes. We specifically focused on weak base compounds as they are the most developed and 
marketed drugs. Moreover, we chose clofazimine (CFZ), an FDA-approved, weakly basic and 
poorly soluble antibiotic used as part of the standard treatment of leprosy
1
, as our model drug.  
Upon prolonged oral administration, CFZ accumulates in macrophages of mice as well as 
humans in the form of insoluble complexes known as Crystal-Like Drug Inclusions (CLDIs)
2-4
. 
These insoluble complexes have been chemically characterized to contain hydrochloride salts of 
CFZ (CFZ-H
+
Cl
-
) crystals
5
. However, little is known regarding the biomolecular mechanisms 
that determine the intracellular formation and stabilization of drug salt crystals in a physiological 
manner
2
.  
Thus, based on the well-established lysosomotropic
6
 phenomenon of weak base drugs, 
which elaborates that weak base drug accumulation occurs in cells, more specifically in 
lysosomes based on the low lysosomal pH environment that ionizes the weak based drug and 
sequesters it within the lysosomes, we hypothesized that the physiological cellular drug 
bioaccumulation and stabilization of CFZ is highly interconnected with endolysosomal ion 
homeostasis and function. Accordingly, we confirmed the physiological lysosomal accumulation 
of CFZ-H
+
Cl
-
 in relation to the drug’s physicochemical properties, such as pHmax, Ksp, intrinsic 
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free base solubility, intrinsic salt solubility, and apparent pKa. Furthermore, we investigated the 
roles of lysosomal proton and chloride transporters, which regulate cellular ion homeostasis, and 
their potential involvement in the formation and stabilization of CFZ-H
+
Cl
-
 crystal in 
macrophage lysosomes (Chapter 2). 
Using a mathematical modeling and simulation approach, the experimentally measured7,8 
rate of intracellular CFZ-H+Cl- salt formation in macrophages (0.01 – 1 picomol/cell/day) was 
investigated in relation to the maintenance of physiological conditions with respect to different 
numbers of V-ATPase molecules/lysosome (0 - 300), chloride channels/lysosome (0 - 5000), 
lysosomal membrane proton permeability (6x10-5 to 6 cm/s), and cytoplasmic chloride 
concentration (0 - 10 mM). The simulation results were further confirmed in wet lab experiments 
where pharmacological inhibitors of proton and chloride channels were used to observe their 
individual effects on CFZ-H+Cl- accumulation. Moreover, drug accumulation and formation of 
CFZ-H+Cl- was confirmed using CFZ’s bathochromic shift in fluorescence upon protonation and 
epifluorescence microscopy.  
Collectively, our modeling and simulation results, as well as wet lab experimental 
findings point to a critical role of the number of lysosomal V-ATPases in the formation of a 
hydrochloride salt form of a weak base drug in macrophage lysosomes, as has been reported with 
clofazimine. While the V-ATPase proton-pump is needed to maintain lysosomal physiology in 
the presence of CFZ-H
+
Cl
-
 crystal formation, pharmacological experiments reveal that agents 
inhibiting its function influence the rate of intracellular CFZ-H
+
Cl
-
 crystal formation to a much 
greater extent than agents inhibiting chloride transport mechanisms. Thus, the variations in the 
number of V-ATPases present on lysosomal membranes suffice to explain the differences in the 
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phase-transition-dependent accumulation and stabilization of CFZ-H
+
Cl
-
 crystals in macrophages 
vs. other cell types in a manner that is consistent with the drug’s physicochemical properties.    
Moreover, given the heterogeneous size and shape of lysosomal morphologies
6,9,10
, and 
the pleiotropic effects of weak base drugs on lysosomal structure and function
11,12
, we 
investigated the relationship between the different lysosomal morphologies and lysosomal 
physiology, and how perturbations of lysosomal physiology
12-14
 affect the maintenance of 
lysosomal ion homeostasis to elucidate the key factors which determine the toxicological effects 
of lysosomotropic agents, in a cell-type dependent manner (Chapter 3). Accordingly, we used a 
computational approach to explore the mechanisms of drug-induced lysosomal stress and stress 
tolerance. For this purpose, we utilized a well-established physiological model of lysosomal ion 
regulation, and transiently altered the model parameters, both individually and in combination. 
We assessed the effects of these perturbations on lysosomal physiology by monitoring the 
downstream dynamics of lysosomal pH, chloride, and membrane electrical potential. The results 
point to variations in proton transport properties as the main mechanistic determinant of 
lysosomal stress sensitivity and resistance. Furthermore, we discuss the effects of drugs that are 
known to inhibit lysosomal membrane channels and accumulate in the lysosomes, such as 
lysosomotropic and cationic amphiphilic drugs in relation to cell-type specific variations in the 
mechanisms of stress tolerance. 
In Chapter 4, we broaden our studies regarding phase-transition-dependent drug 
accumulation and stabilization by using a cellular model with various subcellular compartments, 
comprised of key cellular features, such as pH, membrane potential, and lipid content, all of 
which impact drug accumulation and stability within cells. Using our model drug, CFZ, we 
investigated the subcellular distribution and stability of the different species of the drug as a 
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function of a total extracellular drug concentration. The distribution of the soluble drug species 
in the non-membrane environments were primarily dependent on pH and non-membrane lipid; 
whereas the phase transitions of free base CFZ and CFZ-H
+
Cl
-
 salt were dictated by the 
physicochemical properties of the drug in relation to the cellular environment. Indeed, the degree 
of supersaturation of free base CFZ was observed in the membrane as well as non-membrane 
environments, whereas that of the CFZ-H
+
Cl
-
 salt was substantial and specific to the lysosomal 
environment, suggesting that the precipitation of CFZ-H
+
Cl
-
 salt is likely to occur in the 
lysosomes even at low (sub-micromolar to picomolar) initial total extracellular drug 
concentration. 
 
6.2 Future Outlook 
 Characterization of pharmacokinetic properties of weak base drugs remains to be the 
most challenging and costly process in drug development and discovery. In this dissertation, we 
have highlighted the importance of mathematical modeling approach to monitor and investigate 
the dynamic changes in cells and subcellular compartments, which are essential to our 
understanding of the behavior of weak base drugs in regards to their extent of accumulation, 
disposition, and stabilization in concert with the different cellular environments. Indeed, such 
approach can be done in conjunction with wet lab experiments to strengthen findings and 
conclusions. Moreover, results and conclusions from modeling and simulation experiments 
would aid the design of wet lab experiments, which are essential for understanding and 
characterizing PK properties of drugs in a cell-type dependent manner.  
 As we have observed from our findings (Chapter 2), cell-type specific protein levels, 
such as the Vacuolar ATPase (V-ATPase) do play significant role in the accumulation of weak 
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base drugs within subcellular organelles, such as the lysosome. Thus, designing wet-lab 
experiments that monitor key lysosomal protein levels in the presence of weak base drug 
accumulation in various cell types could help elucidate the physiological accommodation of 
drugs within cells. Indeed, this would be beneficial in classifying weak base drugs based on their 
physicochemical properties and their extent of cell-type dependent cellular accumulation. 
Furthermore, the study of cellular morphological rearrangement upon drug accumulation could 
be conducted to better characterize the relationship between drug-dose and cellular 
morphological changes that will be important in determining effective drug-dose regimen in a 
cell-type specific manner. Key cellular features, such as the translocation of Transcription Factor 
EB (TFEB) and the downstream lysosomal genes it regulates
15,16
, could be monitored to 
understand their roles in drug-dose dependent cellular accumulation
17,18
. This is especially 
necessary to avoid the toxic effect of unregulated cellular expansion, which is implicated in 
various lysosomal storage diseases
19,20
. 
 Furthermore, our findings emphasize the importance of understanding the phase-
transition-dependent cellular accumulation and stabilization of weak base drugs. Given the 
various cellular properties such as pH, ion and lipid content within subcellular environments, 
including organelles and membranes, it is essential to understand the individual as well as 
combinatorial effects of these properties on the disposition and phase transition of drugs within 
cells. Our mathematical model (Chapter 4) could be used to perform further studies on phase-
transition-dependent drug accumulation and stabilization in a cell-type dependent manner by 
varying certain model parameters. Indeed, this would establish the importance of cell-type 
dependent membrane and non-membrane lipids on drug disposition and stabilization in 
subcellular environments, which is a very novel and necessary arena that must be investigated. 
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Moreover, it would help not only experts in Pharmaceutical Sciences, but also in Biophysics, 
Cell Biology, and Genetics, to understand the relationship between membrane and non-
membrane lipid and protein regulations, and their individual as well as combined effects on 
phase-transition-dependent drug accumulation and stabilization. Such understandings would be 
applicable to the mechanistic elucidation of drug-induced phospholipidosis and its impact on 
overall cell physiology and drug PK properties.  
 However, it is important to note the wet-lab experimental challenges associated with 
determining and simulating biological membranes with their corresponding lipid content 
(including lipid type). Thus, various combinations of lipid type as well as lipid amount must be 
considered when studying their impacts on drug accumulation and stabilization. Indeed, this is 
beneficial in understanding the stability and extent of cellular and subcellular drug accumulation 
in the pursuit of improved drug-targeting and efficacy. In addition, it would enable further 
investigation of drugs that have rather been neglected due to lack of full understanding of their 
physicochemical properties in relation to the physiology of their cellular environment. Thus, the 
interdisciplinary approach of phase-transition-dependent cellular drug accumulation and 
stabilization studies is warranted in current and future drug discovery and development fields. 
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Appendix A 
Supporting Information for Chapter 2 
 
A.1. Additional Experimental Methods: 
A.1.1.   HPLC analysis.  
For the HPLC assay, the mobile phase was methanol: water (80:20) with 0.1% 
trifluoroacetic acid (1 ml/min flow rate). The stationary phase (column) was a C18 (unbonded 
silica particles) column (Atlantis® T3, 5 µm, 100Å), and the HPLC was equipped with a UV 
detector (Waters, Photodiode Array Detector 2996) @ 285 nm detection for CFZ. The retention 
time for CFZ was determined to be 4.75 min. 
 
A.1.2.   Determination of solubility parameters.  
We used a mathematical proof approach to determine [CFZH
+
]S as detailed below:  
First, we calculated [CFZH
+
] using the total solubility (ST) at each pH value and the constant 
intrinsic free base solubility, [CFZ]S, using the following equation, which was obtained by 
rearranging the terms in equation (14) (see Chapter 2): 
[CFZH+] =  ST − [CFZ]S      (Supplementary Equation 1) 
Then, we chose a value, say “y”, from the list of the computed [CFZH+] values, and let “y” equal 
[CFZH
+
]S. By substituting “y’ in place of [CFZH
+
]S, we calculated for total solubility at the 
different pH values using equation (15) (see main article). Then, we compared this total 
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solubility-pH dataset to that obtained using equation (13) (see Chapter 2). Then, we checked if 
there was the same total solubility value at a given pH in both datasets, which would represent 
the intersection point of the two solubility-pH curves mentioned previously. This can be 
represented by the following equation:        
ST′ = [CFZ]S + [CFZH
+]S      (Supplementary Equation 2) 
Where ST
’
 is the total solubility value at the intersection of the two solubility-pH curves, and 
both forms of the drug, CFZ and CFZH
+
, are present in equilibrium with their respective solid 
forms in the solid phase denoted by the subscript s. 
Moreover, to prove if our earlier assumption (“y” is equal to [CFZH+]S) was valid, we 
calculated the total solubility by plugging “y” in place of [CFZH+]S , supplementary equation (2), 
and checked if it was equal to ST
’
. Furthermore, by definition, the pH where both the intrinsic 
free base and salt forms of the drug are in the solid phase is known as pHmax. Thus, the pH 
associated with ST
’
 was deduced to be pHmax.  
 
A.1.3.   Modeling proton influx.  
V-ATPase is an electrogenic proton-pump, which inserts protons from the cytoplasm into 
the lysosome against an electrochemical gradient upon ATP hydrolysis
1,2
. The rate at which a 
proton molecule is inserted per second (JHVATP) was obtained from published experimental 
studies
1
 as a function of transmembrane pH gradient (Δ pH) in units of pH unit and membrane 
potential difference, which is also interchangeably known as membrane potential (ΔΨ), in units 
of mV. This rate was multiplied by the total number of active V-ATPase molecules per lysosome 
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(NVATP) to obtain the total amount of proton molecules inserted into the lysosome in units of 
molecules per second, as follows:  
Hpump = NVATP × JHVATP  (ΔpH ,ΔΨ)   (Supplementary Equation 3) 
Where lysosomal ΔΨ is dictated by the total net change in lysosomal ion content and is 
represented by the following relationship
3
:  
ΔΨ =  
F×VL
C′×S
× [ (∑ Zi[cations]i + ∑ Zi[anions]i i  i ) − B]  (Supplementary Equation 4) 
Where VL is the lysosomal volume in units of L; Faraday’s constant (F) which equals 96485 
Coulomb/mol and is used to convert the lysosomal ion content in units of moles to units of 
Coulomb; C’ is the specific membrane capacitance per unit area of a biological membrane4, 
which is experimentally approximated to be 1μF/cm2 and is multiplied by the lysosomal surface 
area S represented in units of cm
2
 to obtain the total lysosomal membrane capacitance; Zi is 
valence for ion i; [cation] the concentration of cation i at a given time t in units of Molar; [anion] 
is the concentration of anion i at a given time t in units of Molar; B is the Donnan particles in 
units of Molar, which are impermeable lysosomal contents defined by initial lysosomal ion 
concentrations and net change in the intrinsic surface potentials, supplementary equation (5). In 
the model and simulations communicated herein, the initial lysosomal ions consist of proton, 
potassium, sodium, and chloride with their respective charge (+ or -1) represented as a 
coefficient of their respective concentration, which is denoted by the square brackets, 
supplementary equation (5). 
B =  [H+]L,initial + [K
+]L,initial +  [Na
+]L,initial −  [Cl
−]L,initial −
C×S
F×VL
× {(Ψin −Ψout) +
Ψinitial}        (Supplementary Equation 5) 
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Where Ψin and Ψout are the intrinsic inner and outer surface potentials, respectively, in units of 
mV, which contribute to the change in ion concentration at membrane surface as described later, 
Ψinitial is the initial lysosomal membrane potential which is set to zero mV in order to maintain 
initial lysosomal membrane electroneutrality.  
 
A.1.4.   Modeling chloride influx.  
V-ATPase mediated proton influx into the lysosome is followed by lysosomal membrane 
potential increase which consequentially arrests further proton influx. Thus, to lower the 
membrane potential for the continuation of V-ATPase proton-pumping activity, which is 
essential to lower lysosomal pH to physiological pH, the removal of lysosomal cation or the 
insertion of lysosomal anion is required. Accordingly, CLC7 is considered as the primary 
membrane potential dissipating protein which transports two chloride ions from the cytoplasm to 
the lysosome for every proton it transports from the lysosome to the cytoplasm
5
. The rate (JCl, 
HClC7) at which the ion transportations occur was empirically derived from a current-voltage 
experimental data
3
 as a function of chemical (ΔpH, ΔCl) and electric potential gradients, (ΔΨ), 
as detailed in supplementary equations (6) and (7). This rate was multiplied by the total number 
of CLC7 molecules per lysosome (NClC7) in order to obtain the total amount of proton and 
chloride molecules transported across the lysosomal membrane through CLC7, as follows:  
HCLC7 =  NCLC7 × JCl,HCLC7(ΔpH,ΔCl,ΔΨ)  (Supplementary Equation 6) 
ClCLC7 =  2 × NCLC7 × JCl,HCLC7(ΔpH,ΔCl,ΔΨ)  (Supplementary Equation 7) 
Where ΔCl is the chloride gradient comprised of the luminal chloride (ClL) and the cytoplasmic 
chloride (ClC). Moreover, the coefficient 2 in supplementary equation (7) defines the 2:1 
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stoichiometric relationship between the chloride and proton ions transported by CLC7 across the 
lysosomal membrane.  
 
A.1.5.   Modeling proton efflux.  
In addition to CLC7, the passive diffusion of protons across the lysosomal membrane can 
also contribute to the dissipation of membrane potential in order to facilitate the proton pumping 
activity of V-ATPase. This  passive proton leak  is modeled by supplementary equation (8), 
which is derived from the Goldman-Hodgkin-Katz (GHK) ion flux equation
6
 that is commonly 
used to describe the passive diffusion of a given ion across a biological membrane, assuming a 
linear potential gradient across a lipid membrane
3
.   
Hleak =  (S × PH+ × Y × Z ×
10−pHL   −  (10−pHC  ×  e−Z×Y)
1− e−Z×Y
 ) × Nav    
        (Supplementary Equation 8) 
Where S is the total lysosomal surface area in units of cm
2
 used to obtain the total amount of 
proton which passively diffuses across the lysosomal membrane; PH
+
 is the lysosomal membrane 
proton permeability in units of cm/s; Z is the valence of the ion (i.e. +1 for proton); pHL is the 
luminal pH used to calculate the total free lysosomal proton based on the logarithmic relationship 
of pH and free proton (pHL = -log[H
+
]); pHc is the cytoplasmic pH used to calculate the total free 
cytoplasmic proton based on the logarithmic relationship of pH and free proton (pHC = -log[H
+
]); 
Nav is Avogadro’s number used to convert the amount of transported protons in unit of moles to 
unit of molecules; Y is used to convert proton transportation in unit of charge per second to 
moles per second and is defined as: Y =
ΔΨ×F
R×T
, where R is universal gas constant, F is Faraday’s 
constant, and T is absolute temperature. Moreover, for cells at room temperature (25 °C), RT/F 
167 
 
equals 25.69 mV
4
, and is used for normalizing the lysosomal membrane potential communicated 
in this report. 
 
A.1.6.   Modeling the effect of membrane leaflet potentials on ions.  
In order to account for the effects of intrinsic external (Ψi,out) and internal (Ψi,in) leaflet 
potentials of the lysosomal membrane on cytoplasmic and lysosomal ion i concentrations, 
respectively, the individual cytoplasmic and lysosomal ion concentrations are computed using 
the following relationships, supplementary equations (9 and 10), derived from the GHK equation 
for a single ion concentration gradient, by setting net current flow equal to zero.  
ΔΨi,in =  
−Z×R×T
F
ln
Ci,in
Ci,L
      (Supplementary Equation 9) 
ΔΨi,out =  
−Z×R×T
F
ln
Ci,out
Ci,C
     (Supplementary Equation 10) 
Where Ci,in is the internal concentration of a given ion (i) at the membrane surface facing the 
lysosomal compartment, Ci,L is the concentration of the ion (i) inside the lysosome, Ci,out is the 
external concentration of the ion (i) at the membrane surface facing the cytoplasmic 
compartment, Ci,C is the concentration of the ion (i) inside the cytoplasm. All units are molar. 
 
A.1.7.   Governing equations.  
Supplementary equations (3-10) were used in supplementary equations (11-13) to further 
define the ion movements as a function of time, in units of molecules per second. 
 
dH+
dt
=  Hpump − HCLC7 −   Hleak −  Hsequestered  (Supplementary Equation 11) 
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dCl−
dt
= 2 × NCLC7 × JCl,HCLC7  (ΔpH ,ΔCl,ΔΨ) −  Clsequestered    
        (Supplementary Equation 12) 
Moreover, extending supplementary equation (11), we can denote the change in lysosomal pH 
with respect to time by following the relationship between the lysosomal lumen buffering 
capacity (β) of the Donnan particles, which sequester non-free lysosomal protons, and free 
lysosomal protons which give rise to lysosomal pH as follows:   
 
dpH
dt
=  
(−Hpump+HCLC7+  Hleak+ Hsequestered)
V×Nav×β
   (Supplementary Equation 13) 
Where V is the lysosomal volume and is multiplied by Nav to convert the unit of molecules per 
second to molar per second, where the inverse of β is in units of pH units per molar. 
 
A.1.8.   Numerical analysis.  
Supplementary equations (11-13) were solved by numerical integration in Berkeley 
Madonna® using Rosenbrock stiff solver as a numerical integrator. 
 
A.1.9.   Data visualization.  
Multiple individual 2D datasets associated with the parametric simulations performed to 
generate simultaneous inhibitions of various lysosomal parameters were obtained. The datasets 
associated with each simultaneous inhibitions of lysosomal parameters were exported from 
Berkeley Madonna and compiled into three separate matrices in a MS-Excel spreadsheet, such 
that the first rows and columns of the matrix correspond to the two parameters simultaneously 
varied in the model simulations to obtain the final lysosomal readout values (lysosomal pH, Cl
-
, 
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and membrane potential), where each makes up the rest of the rows and columns of a single 
matrix. 
 
A.1.10. Model script. 
METHOD STIFF 
STARTTIME = 0 
STOPTIME =86400 
DT = 0.02 
DTMAX = 100 
TOLERANCE = 1e-6 
 
{Baseline Input Parameter List------------------------------------------------------------------------------} 
{Baseline Lysosomal Dimensions Assuming Spherical Geometry} 
R = 0.34                                      {Radius [microns]} 
V = 1.65e-16        {Volume [liters]} 
SA = 1.45e-8                                  {Surface area [cm^2]} 
 
{Baseline Cytosolic Volume} 
Vc = 1.65e10                                 {Volume [liters]-arbitrarily chosen to result 
in almost constant cytoplasmic ion concentration} 
 
{Intrinsic Surface Potentials-- used for calculating surface charges of each ion} 
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psi_out = -50              {Outer surface potential- used as outer 
resting membrane potential [mV]} 
psi_in = 0                    {Inner surface potential - used as inner 
resting membrane potential [mV]} 
 
{Fixed Standard Constants} 
mole = 6.02e23                        {Avogadro's Number [1/mol]} 
RTF = 25.69     {RT/F membrane potential for cells at room 
temperature[mV]} 
F = 96485     {Faraday's Constant that converts unit of membrane 
potential [Coulomb/mol]} 
cap_0 = 1e-6     {Capacitance per unit area of the lysosomal 
membrane [Farad/cm
2
]} 
cap = cap_0*SA/1000    {Total capacitance per lysosome [Farad]} 
  
{Baseline Cytosolic Concentrations} 
initpHbulk = 7.2                             {pH [pH units]}  
Kbulk = 0.145     {K+ [M]} 
initclbulk = 0.01    {Cl- [M]} 
Nabulk = 0.01                            {Na+ [M]} 
initHbulk = 0                               {Total H+ [M]} 
 
{Baseline Luminal Concentrations} 
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initpH = 7.4     {pH [pH units]} 
initk = 0.005     {K+ [M]} 
initcl = 0.11     {Cl- [M]} 
initna = 0.145     {Na+ [M]} 
initH = 0.00     {Total H+ [M]} 
 
{Donnan Particles [M]: constitute the initial impermeant luminal ions that give rise to Donnan 
potential to balance the negatively charged proteins in the luminal matrix} 
B = initk+initna+initH-initcl - cap/F/V*(psi_in - psi_out) - initpsi_total*cap/F/V                 {[M]} 
 
{Set Initial Total Membrane Potential [mV]} 
initpsi_total = 0 
beta = 0.04     {Buffering capacity [M/pH unit] of the luminal 
matrix that sequesters protons from solution} 
beta_bulk = 0.04    {Buffering capacity [M/pH unit] of the cytoplasm 
that sequesters protons from solution} 
 
{Baseline Input Kinetic Parameters-------------------------------------------------------------------------} 
P = 6e-5     {Membrane H+ permeability. Experimentally 
determined- Ishida et al 2013} 
N_VATP = 300    {Number of V-ATPases per lysosome. 
Experimentally estimated- Ishida et al 2013} 
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N_CLC7 = 5000    {Number of ClC7 antiporters per lysosome. 
Estimated- Ishida et al 2013} 
CLC_Cl = 2     {CLC7 Cl- Stoichiometry. Experimentally 
determined- Graves et al 2008} 
CLC_H = 1     {CLC7 H+ Stoichiometry. Experimentally 
determined- Graves et al 2008} 
 
{ODE- Time Dependent Ion Flows-------------------------------------------------------------------------} 
d/dt (pH) = ((NH_entrapment-Hpump - Hleak - (CLC_H*CLC7))/V/mole)/beta               
     INIT pH = initpH     {Lysosomal pH as a function of time [pH unit/sec]} 
d/dt (NCl) = -CLC_Cl*CLC7-NCl_entrapment                                                
     INIT NCl = initcl*V*mole  {Lysosomal Cl as a function of time [Cl-/sec]} 
d/dt (NH) = -NH_entrapment+Hpump + Hleak + (CLC_H*CLC7)                                
     INIT NH = initH*V*mole   {Total lysosomal H+ as a function of time 
[H+/sec]} 
d/dt (pHbulk) = ((-NH_entrapment+Hpump + Hleak + (CLC_H*CLC7))/Vc/mole)/beta_bulk               
     INIT pHbulk = initpHbulk   {Cytoplasmic pH as a function of time [pH 
unit/sec]} 
d/dt (NHbulk) = NH_entrapment- Hpump- Hleak - (CLC_H*CLC7)                       
     INIT NHbulk = initHbulk*Vc*mole {Cytoplasmic H+ as a function of time [H+/sec]} 
d/dt (NClbulk) = +CLC_Cl*CLC7 + NCl_entrapment  
     INIT NClbulk = initclbulk*Vc*mole {Cytoplasmic Cl as a function of time [Cl-/sec]}                                         
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{Ion Flows Through Lysosomal Membrane Channels and Pumps-------------------------------------} 
 
{Proton Pump} 
JH_VATP = #protonpump2 (pH,psi)  {Proton pump [H+/sec] by a single V-ATPase 
molecule as a function of luminal pH gradient and membrane potential. Surface dataset 
("protonpump2") imported from Matlab as a call-in function} 
Hpump = N_VATP*JH_VATP                    {Total proton pump flow [H+/sec] by a total number 
of VATPases per lysosome} 
 
{ClC7 Antiporter: Membrane Potential Dissipation} 
clc7f = (CLC_Cl+CLC_H)*psi + RTF*(2.3*(pHe - pHi) + CLC_Cl*LOGN(Cle/Cli))             
{Transmembrane H+ and Cl- motive force across lysosomal membrane that drives CLC7 
antiporter's function- Ishida et al 2013} 
G1 = -0.3*clc7f     {0.3 was determined by experimental fitting- Ishida 
et al 2013. Linear function for positive "psi"} 
G3 = -1.5E-5*clc7f^3    {1.5 was determined by experimental fitting- Ishida 
et al 2013. Cubic function for negative "psi"}                
S = 0.5+0.5*TANH((clc7f+250)/75)  {Switching function that ranges 0 to 1 depending on 
the sign of "psi"} 
JCLC7 = S*G1+ (1-S)*G3   {Single CLC7 antiporter turnover. Function 
switches from linear to a 3-degree polynomial function depending on "S" to empirically fit 
experimental data- Ishida et al 2013} 
CLC7 = N_CLC7*JCLC7   {Total ClC7 antiporter turnover [1/sec]} 
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{Define Terms for Goldman-Hodgkin-Katz Flux (GHK) Equation} 
gg = IF abs(psi) > .01 THEN psi/(1-exp(-psi/RTF))/RTF ELSE  
          1/(1 - (psi/RTF)/2 + (psi/RTF)^2/6 - (psi/RTF)^3/24 +(psi/RTF)^4/120)         {IF THEN 
statement to avoid computational error when psi = 0. Taylor series expansion about a point = 
(psi/RTF) when psi is less than RTF} 
 
{Passive Flows Across Lysosomal Membrane Modeled According to GHK Flux Equation} 
Hleak = P*SA*(10^(-pHe)*exp(-psi/RTF)-10^(-pHi))*gg*mole/1000                                             
{[H+/sec]} 
NCl_entrapment = (a)*mole        
a = (1e-16)/86400    {Rate of CLDI formation = 0.01 picomol/day in the 
cell = 0.0001 picomol/day in the lysosome} 
NH_entrapment = NCl_entrapment 
      
{Functions/Conversions--------------------------------------------------------------------------------------} 
{Membrane Potentials} 
psi = F*(V*(H+initk+initna- Cl - B))/cap     {Membrane potential [mV] dictated 
by the net change in lysosomal ions, lysosomal membrane capacitance, buffering capacity, and 
Donnan Particles, characteristics of the luminal matrix. Valence of each ion (plus or minus 1) is 
implicitly considered} 
psi_total = psi + psi_out-psi_in             {Total membrane potential [mV]} 
 
{Luminal Concentrations} 
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Cl = NCl/V/mole                               {[M]} 
H = NH/V/mole                                 {Total H+ [M]} 
 
{Luminal Content [mol]} 
Cl_mol = Cl*V                               {Cl [mol]} 
H_mol = H*V                                 {Total H+ [mol]} 
 
{Cytosolic Concentrations} 
Clbulk = NClbulk/Vc/mole                   {Cl [M]} 
Hbulk = NHbulk/Vc/mole                     {Total H+ [M]} 
 
{Cytosolic Content [mol]} 
Clbulk_mol = Clbulk*Vc                    {Cl [mol]} 
Hbulk_mol = Hbulk*Vc                      {Total H+ [mol]} 
 
{Modified Cytoplasmic Surface Concentrations Dictated by Surface Potential- Derived from 
GHK for a single ion in the case of zero net current flow; also known as Nernst equation} 
Cle = Clbulk*exp(psi_out/RTF)                {[M]} 
Ke = Kbulk*exp(-psi_out/RTF)                 {[M]} 
Nae = Nabulk*exp(-psi_out/RTF)               {[M]} 
pHe = (pHbulk+psi_out/(RTF*2.3))             {[pH units]} 
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{Modified Luminal Surface Concentrations Dictated by Surface Potential - Derived from GHK 
for a single ion in the case of zero net current flow; also known as Nernst equation} 
Cli = Cl*exp(psi_in/RTF)                      {[M]} 
Ki = initK*exp(-psi_in/RTF)                  {[M]} 
Nai = initNa*exp(-psi_in/RTF)                {[M]} 
pHi = (pH+psi_in/(RTF*2.3))                  {[pH units]} 
 
A.2. Supplementary Figures 
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Figure A.1 Fluorescence Microspectroscopy and (inset, i = brightfield, ii = green fluorescence, 
iii = far-red fluorescence) Epifluorescence Microscopy of CFZ-H
+
Cl
-
 crystals indicating the lack 
of green fluorescence while being fluorescent in the far-red fluorescence range. The excitation 
wavelength (nm, Ex) and emission wavelength (nm, Em) are shown on the X-axis and Y-axis, 
respectively. The normalized fluorescence yield is shown by a contour plot that was normalized 
using a control slide first and then to the maximum measured fluorescence yield. The colors as 
shown represent contour levels from 0-1 in steps of 0.2. The green, red, and far-red fluorescence 
bandwidths are overlaid on top of the normalized fluorescence spectra. 
 
 
178 
 
 
 
Figure A.2 Epifluorescence microscopy of RAW264.7 cells when incubated with CFZ (10 μM), 
Lysotracker® Blue (LB, 1 and 20 μM) at t = 1 hour. Scale bar, 10 μm. At 1 hour, green 
fluorescence spots indicative of CFZ are visible as mild diffuse staining rather than punctate 
staining observed at t = 24 hours. Vesicular staining pattern of LB, visible as blue punctate spots 
when incubated on its own, are absent when co-incubated with CFZ at both LB = 1 and 20 μM. 
The control images were taken at t = 24 hours post initiation of experiments. 
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Figure A.3 Pearson’s Colocalization Coefficient for multiple cell ROIs (n = 70) as obtained post 
epifluorescence microscopy of RAW264.7 cells incubated with CFZ (10 μM) at t = 24-72 hours. 
Fluorescence channel description is provided in Table A.2. The scatter distribution is further 
annotated with four horizontal lines denoting the Mean ± S.E. (same color lines as the 
distribution), Mean (green line) and the Median (black line) of the distribution. * -p < 0.005. 
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Figure A.4 Viability of RAW264.7 cells treated with a) BafA1 and b) NPPB in the presence of 
CFZ (0-10 μM). Data was collected at n = 6 with * - p < 0.05, ** - p < 0.01, *** - p < 0.001. 
Each point is compared in a pair-wise independent Student t-test.  
 
 
 
 
 
 
Figure A.5 Model and simulation of the effects of V-ATPase and cytoplasmic chloride on 
the lysosomal accumulation of CFZ-H
+
Cl
-
.  
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a, V-ATPase inhibition showed a more substantial effect than cytoplasmic chloride inhibition on 
the accumulation of CFZ-H
+
Cl
-
 at the rate of 0.01 picomol/cell/day, as reflected by the changes 
in the lysosomal pH, Cl
-
, and membrane potential values of the CFZ-H
+
Cl
-
 containing lysosome 
from that of the CFZ-H
+
Cl
-
 free lysosome. b, V-ATPase inhibition generally showed a more 
substantial effect than cytoplasmic chloride inhibition although the simultaneous inhibition of 
both parameters showed even more pronounced effect on the physiological accumulation of 
CFZ-H
+
Cl
-
 at the rate of 0.01 picomol/cell/day, as reflected by the changes in the lysosomal pH, 
Cl
-
, and membrane potential values of the CFZ-H
+
Cl
-
 containing lysosome from respective 
baseline physiological values. Arrow signs represent values outside of the axes plot range. 
 
 
 
 
 
 
Figure A.6 Model and simulation of the effects of V-ATPase and cytoplasmic chloride on 
the lysosomal accumulation of CFZ-H
+
Cl
-
 at a higher dose.  
a, V-ATPase inhibition showed a more substantial effect than cytoplasmic chloride inhibition on 
the accumulation of CFZ-H
+
Cl
-
 at the rate of 0.1 picomol/cell/day, as reflected by the changes in 
the lysosomal pH, Cl
-
, and membrane potential values of the CFZ-H
+
Cl
-
 containing lysosome 
from that of the CFZ-H
+
Cl
-
 free lysosome. b, V-ATPase inhibition generally showed a more 
substantial effect than cytoplasmic chloride inhibition although the simultaneous inhibition of 
both parameters showed even more pronounced effect on the physiological accumulation of 
CFZ-H
+
Cl
-
 at the rate of 0.1 picomol/cell/day, as reflected by the changes in the lysosomal pH, 
Cl
-
, and membrane potential values of the CFZ-H
+
Cl
-
 containing lysosome from respective 
baseline physiological values. Arrow signs represent values outside of the axes plot range. 
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A.3. Supplementary Tables 
Table A.1 Model Parameters 
Symbol Description Baseline Input Value Range of Input Value Units 
pHC Cytosolic pH 7.2 Fixed pH Unit 
pHL Luminal pH 7.4 Fixed pH Unit 
[Cl
-
]C 
Cytosolic chloride 
concentration 10 1x10
-5
 - 10 mM 
[Cl
-
]L 
Luminal chloride 
concentration 110 Fixed mM 
[Na
+
]L 
Luminal sodium 
concentration 145 Fixed mM 
[K
+
]L 
Luminal potassium 
concentration 5 Fixed mM 
[H
+
]L 
Luminal proton 
concentration 0 Fixed mM 
PH
+
 
Membrane proton 
permeability 6x10
-5
 Fixed cm/s 
V Lysosomal volume 1.65x10
-16
 Fixed L 
S Lysosomal surface area 1.45x10
-8
 Fixed cm
2
 
C' 
Specific bilayer 
capacitance 1 Fixed μFarad/cm2 
β Buffering capacity 40 Fixed mM/pH unit 
NVATP V-ATPase number 300 1x10
-4
 - 300 
 
NCLC7 CLC7 number 5000 1x10
-4
 - 5000 
 
Ψout Outer surface potential -50
b
 Fixed mV 
Ψin Inner surface potential 0
b
 Fixed mV 
CLC_Cl CLC7 Cl
-
 stoichiometry 2 Fixed 
 
CLC_H CLC7 H
+
 stoichiometry 1 Fixed 
 
R Gas constant 8.314 Fixed J.K
-1
.mol
-1
 
T Absolute temperature 0 Fixed Kelvin 
F Faraday's constant 96485 Fixed J/Volt 
Nav Avogardro's number 6.02x10
23
 Fixed molecules/mol 
a 
Rate of proton and 
chloride sequestration by 
CFZ to form CFZ-H
+
Cl
-
 0 1.16x10
-21
 - 1.16x10
-20
 Moles/day 
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a 
Baseline input values are literature values
7-11
 representing physiological lysosomes and are in agreement 
with previously published model
2,3
.  
b 
Estimated intrinsic surface potentials for inner (Ψin) and outer (Ψout) leaflets of the lysosomal membrane 
accounted for when modeling membrane transporter mediated dynamic lysosomal and cytoplasmic ion 
concentrations at the membrane surface
2
.  
 
Table A.2 Fluorescence in RAW264.7 cells.  
(Channels (Ex/Em)) – Blue (350/405 nm), Green (490/510 nm), Red (590/610 nm), and Far-Red 
(640/670 nm). 
 Blue Green Red Far-Red 
CFZ - + + - 
CFZ-H
+
Cl
-
 - - + + 
Lysotracker® Blue + - - - 
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Appendix B 
 
Supporting Information for Chapter 3 
 
 
B.1. Additional Experimental Methods: 
 
B.1.1.   Lysosomal ion transport model description. 
The transportation of ions to and from the lysosome induces charge, ΔQ, and membrane 
potential difference, ΔΨ, between the lysosome and the cytoplasm. By definition, membrane 
potential difference, which simply is referred hereon as membrane potential, across a given 
membrane is the difference between the potential of one side of the membrane and that of the 
other side of the membrane (i.e. the lysosome and the cytoplasm in our case). It can be calculated 
using the following relationship between the charge of a given ion(s) and capacitance, assuming 
that the lipid bilayer of lysosomal membrane can serve as a parallel plate capacitor:  
            ΔΨ =  
ΔQ
C′
         (1) 
Where C’ is the specific bilayer capacitance of the lysosomal membrane per unit area of the 
lysosomal surface area, which represents the measure of the net charge transported, ΔQ, in units 
of Coulomb, from one side of the membrane to the other resulting in membrane potential, ΔΨ, 
across the membrane, in units of mV. For biological membranes, C’ has been experimentally 
approximated to 1μF/cm2 1,2.  
Charge on a mole of a monovalent ion is represented by Faraday’s constant, F, which 
equals 96485 Coulomb/mol. Moreover, depending on the charge and valence, Zi, of the 
monovalent ion “i", F will be + or -; where the earlier is for a cation and the latter for an anion. 
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Thus, using F we can obtain the charge of the ions in the cytoplasm and the lysosome 
from the cytoplasmic and lysosomal ion concentration, respectively, in units of Coulomb.  
ΔQ = F × ( ∑ Zii × [i]C × VC − ∑ Zii × [i]L × VL)    (2) 
With [iC] and [iL] being the net concentration in the cytoplasm and lysosome in units of Molar, 
respectively. Both terms are multiplied by their respective compartmental volume to convert the 
units of Molar to mol. In both compartments, the net concentration comprises of permeable and 
impermeable ions.  
Furthermore, we utilize a physiological sign convention that the membrane potential is 
more positive or negative if there is more cation or anion, respectively, in the internal 
compartment (i.e. lysosome, in our case), than in the external compartment (i.e. cytoplasm, in 
our case). Thus, equation 2 is re-written as: 
ΔQ = F × (∑ Zii × [i]L × VL − ∑ Zii × [i]C × VC)    (3) 
More specifically, the following relationship is obtained to define the ion content in the 
cytoplasmic compartment:           
   ∑ [i]C × VCi = ∑ ([i]C × VC)fi −  ∑ ([i]C × VC)oi     (4) 
Where the subscript f denotes the final value of the permeable ions in units of mole, and the 
subscript o denotes the initial value of the impermeable ions in units of mole. However, because 
the cytoplasmic volume is comparatively big, we assume that the concentration of cytoplasmic 
ions remains more or less constant. Thus, we set:  ∑ ([i]C × VC)oi = 0 
Similar to equation 4, we have the following relationship for the case of lysosomal ion content: 
  ∑ [i]L × VLi = ∑ ([i]L × VL)fi − ∑ ([i]L × VL)oi     (5) 
Thus, by substituting the terms in equation 3 with those in equations 4 and 5, we obtain; 
    ΔQ = F × (∑ Zii × ([i]L × VL)f − ∑ Zii × ([i]L × VL)o)   (6) 
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In addition, because we treat the lysosomal volume as a parameter, equation 6 can be re-written 
as:              
   ΔQ = F × VL × ((∑ Zii × [i]L)f − ∑ Zii × ([i]L)o)    (7) 
Moreover, for the purpose of distinguishing notations, ∑ Zii × ([i]L)o) is replaced by “B”. This 
term is known as Donnan particles, which is represented in units of Molar. Thus, equation 7 is 
re-written as:            
   ΔQ = F × VL × ((∑ Zii × [i]L)f − B)      (8) 
Thus, by plugging equation 8 into equation 1, membrane potential is equated as; 
 ΔΨ =  
F×VL
C′
×  ((∑ Zii × [i]L)f − B)      (9) 
As previously mentioned, because the capacitance is a measurement per unit area of the 
lysosomal surface, equation 9 must be multiplied by the total lysosomal surface area (S), in units 
of cm
2
, to obtain total capacitance per lysosome, hence the total membrane potential. 
ΔΨ =  
F×VL
C′×S
∗ ((∑ Zii × [i]L)f − B)      (10) 
Furthermore, the final luminal ion concentrations [iL]f can be classified into cations and anions:  
ΔΨ =  
F×VL
C′×S
∗ [ (∑ Zi × [cations]i + ∑ Zi × [anions]i ii ) − B]  (11) 
In addition, the Donnan particles (B), in units of Molar, are explicitly defined using the initial 
lysosomal contents, including the net change in the intrinsic surface potential: 
B =  [H+]L,initial + [K
+]L,initial +  [Na
+]L,initial −  [Cl
−]L,initial −
C′×S
F×VL
× {(Ψin − Ψout) +
Ψinitial}            (12) 
With the subscript (initial) denoting the fixed initial luminal content, (Ψin) and (Ψout) being the 
intrinsic surface potentials for inner and outer leaflets in units of mV, respectively, of the 
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lysosomal membrane, as estimated in the literature
3
, (Ψinitial) being the initial membrane 
potential, which is set to 0 mV for the purpose of maintaining initial electroneutrality. 
Substituting equation 12 into equation 11 will give: 
ΔΨ =  
F×VL
C′S
× {[H+]L,final − [Cl
−]L,final −  [H
+]L,initial +  [Cl
−]L,initial} +  Ψin − Ψout} 
           (13)                 
With the subscript (final) denoting the luminal contents at a given time “t”.   
 
B.1.2.   Modeling ion transportation.  
Briefly, in this model, V-ATPase is an electrogenic proton pump which lowers the 
lysosomal pH by working against a proton motive force build-up that arises from membrane 
potential and proton concentration gradient. To capture this phenomenon, the rate of proton 
influx, JHVATP, by a single V-ATPase molecule per lysosome per second was incorporated to the 
model based on the instantaneous transmembrane pH gradient, ΔpH, and membrane potential, 
ΔΨ, (equation 14). This rate was multiplied by the total number of active V-ATPase molecules 
in a lysosome, NVATP 
3,4
 to obtain the total number of protons inserted into the lysosome in units 
of molecules per second (Hpump), (equation 14). 
Hpump = NVATP × JHVATP(ΔpH , ΔΨ)     (14) 
Following proton pump by the V-ATPase, membrane potential would increase in the 
absence of some other mechanism that dissipates the increment. Physiologically, membrane 
potential is dissipated by the efflux of cations from the lysosomes, or the influx of anions. In this 
regard, CLC7 plays a dominant role 
4
. Accordingly, the model represents the rate of proton 
removal per second, JCl,H_CLC7, as well-elaborated in a previously published model 
3
, by a single 
CLC7 molecule per lysosome as a function of chloride concentration gradient dictated by 
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cytoplasmic and lysosomal chloride concentrations, ClC and ClL, respectively, and electrical 
gradient dictated by ΔΨ, (equation 15). This rate was multiplied by the total number of CLC7 
molecules per lysosome, NClC7, 
3
 in order to obtain the total amount of protons removed in units 
of molecules per second by CLC7, HClC7,(equation 15).    
HClC7 =  NClC7 × JCl,HClC7(ΔpH, ClL , ClC , ΔΨ)    (15) 
In addition to CLC7, membrane potential dissipation is also facilitated by the process of 
proton transportation from the lysosome to the cytoplasm.  In order to capture the passive 
diffusion of protons across the semi-permeable lysosomal membrane, the Goldman-Hodgkin-
Katz (GHK) flux equation 
5
 was used. GHK flux equation was derived to model the flux of an 
ion “i”, ji, dictated by chemical, dC/dX, and electrical potential, dΨ/dX, gradients across a 
biological membrane: 
ji =  −Zi × ui × R × T × (
dC
dX
+  Zi × C ×
F
R×T
×  
dΨ
dX
)   (16) 
Where Z is charge and valence of the ion, “i”, C is the ion concentration, R is gas constant, T is 
absolute temperature, i.e. 0 Kelvin, and ui is the electro-kinetic ion mobility and is further related 
to the diffusion coefficient, Di, of the ion by the following Einstein relation: 
ui =  Di ×
Zi× F
R×T
        (17) 
Assuming a constant electric field across a homogenous membrane with thickness of l, the above 
equation is integrated at steady state to give the flux of ion “i" across the membrane using 
boundary conditions where at x = 0, the ion concentration = C0 (i.e. ion concentration before 
transportation at one side of the membrane) and at x = l, the ion concentration = C1 (i.e. ion 
concentration following transportation to the other side of the membrane): 
ji =
ui
l
× ΔΨ ×
Co−(C1×e
−Z×Y)
1−e−Z×Y
       (18) 
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Where Y is ΔΨ normalized by RT/F (equation 19) for cells at room temperature, 25°C, which 
equals 25.69 mV 
6
: 
Y =
ΔΨ×F
R×T
         (19) 
Thus, substituting terms in equation 18 by the ones in equations 17, we obtain: 
ji =
Di×Zi×F
R×T×l
× ΔΨ ×
Co−(C1×e
−Z×Y)
1−e−Z×Y
      (20) 
Moreover, equation 20 can be further simplified using the relationship in equation 19: 
ji =
Di×Zi×Y
l
 ×
Co−(C1×e
−Z×Y)
1−e−Z×Y
       (21) 
Furthermore, the diffusion coefficient can be written in terms of the permeability of the ion 
across the membrane using the following equation:  
Pi =  
Ki×Di 
l
         (22) 
Where Ki is the water-membrane partition coefficient of the ion “i" and measures the solubility 
of the ion in lipids. This term is set to 1 for either a co-ion or a counterion since the pore size of 
an ion membrane transporter is generally large and the partition coefficient of an ion in a pore 
approaches 1 as the pore size increases 
7
. 
Thus, by substituting equation 22 into equation 21, we obtain: 
ji = Pi × Y × Z ×
Co−(C1×e
−Z×Y)
1−e−Z×Y
      (23) 
Because equation 23 gives the ion flux over a single area in units of Molar per second, the rate is 
multiplied by the total lysosomal surface area, S, to determine the total ion flux, as follows:  
ji = S × Pi × Y × Z ×
Co−(C1×e
−Z×Y)
1−e−Z×Y
      (24) 
Accordingly, the total amount of free proton that can be transported from the lysosome to the 
cytoplasm, Hleak, in units of Molar per second (which is further converted into molecules per 
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second by multiplying it by Avogardo’s number, Nav) follows the derivation of equation 24 and 
thus, can be written as: 
Hleak =  (S × PH+ × Y × Z ×
10−pHL   −  (10−pHC  × e−Z×Y)
1− e−Z×Y
 ) × Nav  (25) 
With pH
+
 being the proton permeability in units of cm/s, pHL is the lysosomal luminal pH in 
units of pH units used to calculate the free lysosomal proton, 10
-pHL, in units of Molar, pHc is the 
cytoplasmic pH in units of pH units used to calculate the free cytoplasmic proton, 10
-pHC, in units 
of Molar, Z, S, and Y are the same terms as previously described. 
 
B.1.3.   Modeling the effect of membrane leaflet potentials on ions.  
Using an equation derived from the previously defined GHK flux equation, the 
concentrations of the transported ions are further modified based on the surface membrane 
potential exposed to either the cytoplasm or the lysosomal compartment 
6
. In the case where net 
current flow is zero, the GHK equation that defines the membrane potential, which in this case is 
also defined as Nernst potential, ΔΨi, of a given ion “i”, is presented as: 
ΔΨ =  ΔΨi =  
−Z×R×T
F
× ln
Ci,0
Ci,1
      (26) 
With Ci being the concentration of the ion “i" in units of Molar and the position of the ion are 
denoted by the subscripts 0 and 1.  
Thus, by inserting the intrinsic internal leaflet potential, Ψin, in units of mV into equation 26, the 
concentration of a given ion at the membrane surface facing the lysosomal compartment is 
calculated according to the following relationship:  
ΔΨi,in =  
−Z×R×T
F
× ln
Ci,in
Ci,L
       (27) 
192 
 
With Ci,in being the internal concentration of a given ion at the membrane surface facing the 
lysosomal compartment in units of Molar, and Ci,L is the concentration of the same ion in the 
non-membrane region of the lysosomal compartment in units of Molar. 
Similarly, by inserting intrinsic external or outer leaflet potential, Ψout, in units of mV into 
equation 26, the concentration of a given ion at the membrane surface facing the cytoplasmic 
compartment is calculated according to the following relationship: 
ΔΨi,out =  
−Z×R×T
F
× ln
Ci,out
Ci,C
       (28) 
With Ci,out being the external concentration of a given ion at the membrane surface facing the 
cytoplasmic compartment in units of Molar, and Ci,c is the concentration of the same ion in the 
non-membrane region of the cytoplasmic compartment in units of Molar.   
 
B.1.4.   Governing equations.  
The aforementioned ion flux equations are used to generate a kinetic model to monitor 
the time-dependent changes in lysosomal proton and chloride molecules per second as described 
by equations 29 and 30: 
dH+
dt
=  Hpump − HClC7 −   Hleak      (29)                                                                                                           
dCl−
dt
= 2 × NClC × JCl,HClC7(ΔpH , ClL, ClC, ΔΨ)    (30) 
The coefficient “2” in equation 30 indicates that CLC7 transports chloride and proton across the 
lysosomal membrane in 2:1 stoichiometric ratio, which was used in published model 
3
 based on 
analysis of experimental studies
4
.  
We can further define the time-dependent change in pH by converting the total amount of 
lysosomal proton in units of molecules per second (equation 29) into units of Molar per second 
by dividing the terms in equation 29 by lysosomal volume and Avogadro’s number. Moreover, 
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the Molar per second unit is converted into units of pH unit per second by dividing the entire 
term by the buffering capacity, β, which is represented in units of Molar per pH unit:                                                                    
dpH
dt
=  
(−Hpump+HClC7+  Hleak)
V×Nav×β
       (31) 
The lysosomal lumen buffering capacity of the Donnan particles entraps protons and thus, 
dictates lysosomal pH. It is experimentally measured by introducing a strong acid or base (in 
units of Molar) that can induce change of 1 pH unit. Thus, the physiological accumulation of 
weakly basic compounds, such as cationic amphiphilic and lysosomotropic drugs, will have 
insignificant effect on the buffering capacity, at least in theory, as the amount of proton they 
sequester from the lysosome will be fully released upon the hydration of the protonated drug, 
thereby maintaining mass-balance mediated physiological lysosomal pH. Although the buffering 
capacity varies with pH, for simplicity purpose, it was set to a constant according to literature 
values
3,8
.  
 
B.1.5.   Numerical analysis.  
The set of differential equations 29-31 was solved by numerical integration in Berkeley 
Madonna® using Rosenbrock stiff solver as a numerical integrator. 
 
B.1.6. Model script 
METHOD STIFF 
STARTTIME = 0 
STOPTIME =86400 
DT = 0.02 
DTMAX = 100 
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TOLERANCE = 1e-6 
 
{Baseline Input Parameter List------------------------------------------------------------------------------} 
 
{Baseline Lysosomal Dimensions Assuming Spherical Geometry} 
R = 0.34                                     {Radius [microns]} 
V = 1.65e-16       {Volume [liters]} 
SA = 1.45e-8                                 {Surface area [cm^2]} 
 
{Baseline Cytosolic Volume} 
Vc = 1.65e10                                {Volume [liters]-arbitrarily chosen to result in 
almost constant cytoplasmic ion concentration} 
 
{Intrinsic Surface Potentials-- used for calculating surface charges of each ion} 
psi_out = -50       {Outer surface potential- used as outer resting 
membrane potential [mV]} 
psi_in = 0                  {Inner surface potential - used as inner resting 
membrane potential [mV]} 
 
{Fixed Standard Constants} 
mole = 6.02e23                       {Avogadro's Number [1/mol]} 
RTF = 25.69     {RT/F membrane potential for cells at room 
temperature [mV]} 
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F = 96485                                    {Faraday's Constant that converts unit of membrane 
potential [Coulomb/mol]} 
cap_0 = 1e-6                                 {Capacitance per unit area of the lysosomal 
membrane [Farad/cm^2]} 
cap = cap_0*SA/1000                    {Total capacitance per lysosome [Farad]} 
  
{Baseline Cytosolic Concentrations} 
initpHbulk = 7.2                             {pH [pH units]}  
Kbulk = 0.145                           {K+ [M]} 
initclbulk = 0.01                                {Cl- [M]} 
Nabulk = 0.01                            {Na+ [M]} 
initHbulk = 0                               {Total H+ [M]} 
 
{Baseline Luminal Concentrations} 
initpH = 7.4                                 {pH [pH units]} 
initk = 0.005                               {K+ [M]} 
initcl = 0.11                                {Cl- [M]} 
initna = 0.145                               {Na+ [M]} 
initH = 0.00                                 {Total H+ [M]} 
 
{Donnan Particles [M]: constitute the initial impermeant luminal ions that give rise to Donnan 
potential to balance the negatively charged proteins in the luminal matrix} 
B = initk+initna+initH-initcl - cap/F/V*(psi_in - psi_out) - initpsi_total*cap/F/V                 {[M]} 
196 
 
{Set Initial Total Membrane Potential [mV]} 
initpsi_total = 0 
beta = 0.04                               {Buffering capacity [M/pH unit] of the luminal 
matrix that sequesters protons from solution} 
beta_bulk = 0.04                        {Buffering capacity [M/pH unit] of the cytoplasm 
that sequesters protons from solution} 
 
{Baseline Input Kinetic Parameters-------------------------------------------------------------------------} 
P = 6e-5                                 {Membrane H+ permeability. Experimentally 
determined- Ishida et al 2013} 
N_VATP = 300                            {Number of V-ATPases per lysosome. 
Experimentally estimated- Ishida et al 2013} 
N_CLC7 = 5000                           {Number of ClC7 antiporters per lysosome. 
Estimated- Ishida et al 2013} 
CLC_Cl = 2                              {CLC7 Cl- Stoichiometry. Experimentally 
determined- Graves et al 2008} 
CLC_H = 1                               {CLC7 H+ Stoichiometry. Experimentally 
determined- Graves et al 2008} 
 
{ODE- Time Dependent Ion Flows-------------------------------------------------------------------------} 
d/dt (pH) = ((-Hpump - Hleak - (CLC_H*CLC7))/V/mole)/beta       
     INIT pH = initpH    {Lysosomal pH as a function of time [pH unit/sec]} 
d/dt (NCl) = -CLC_Cl*CLC7                                                  
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     INIT NCl = initcl*V*mole  {Lysosomal Cl- as a function of time [Cl-/sec]} 
d/dt (NH) = +Hpump + Hleak + (CLC_H*CLC7)                               
     INIT NH = initH*V*mole   {Total lysosomal H+ as a function of time 
[H+/sec]} 
d/dt (pHbulk) = ((+Hpump + Hleak + (CLC_H*CLC7))/Vc/mole)/beta_bulk               
     INIT pHbulk = initpHbulk   {Cytoplasmic pH as a function of time [pH 
unit/sec]} 
d/dt (NHbulk) = -Hpump- Hleak - (CLC_H*CLC7)                            
     INIT NHbulk = initHbulk*Vc*mole {Cytoplasmic H+ as a function of time [H+/sec]} 
d/dt (NClbulk) = +CLC_Cl*CLC7                                              
     INIT NClbulk = initclbulk*Vc*mole {Cytoplasmic Cl
-
 as a function of time [Cl-/sec]}                                         
 
{Ion Flows Through Lysosomal Membrane Channels and Pumps-------------------------------------} 
 
{Proton Pump} 
JH_VATP = #protonpump2 (pH, psi) {Proton pump [H
+
/sec] by a single V-ATPase 
molecule as a function of luminal pH gradient and membrane potential. Surface dataset 
("protonpump2") imported from Matlab as a call-in function} 
Hpump = N_VATP*JH_VATP                     {Total proton pump flow [H+/sec] by a total 
number of VATPases per lysosome} 
 
{ClC7 Antiporter: Membrane Potential Dissipation} 
clc7f = (CLC_Cl+CLC_H)*psi + RTF*(2.3*(pHe - pHi) + CLC_Cl*LOGN(Cle/Cli))              
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{Transmembrane H+ and Cl- motive force across lysosomal membrane that drives CLC7 
antiporter's function- Ishida et al 2013} 
G1 = -0.3*clc7f                             {0.3 was determined by experimental fitting- Ishida 
et al 2013. Linear function for positive "psi"} 
G3 = -1.5E-5*clc7f^3                        {1.5 was determined by experimental fitting- Ishida 
et al 2013. Cubic function for negative "psi"}                
S = 0.5+0.5*TANH((clc7f+250)/75)           {Switching function that ranges 0 to 1 depending on 
the sign of "psi"} 
JCLC7 = S*G1+ (1-S)*G3                      {Single CLC7 antiporter turnover. Function 
switches from linear to a 3-degree polynomial function depending on "S" to empirically fit 
experimental data- Ishida et al 2013} 
CLC7 = N_CLC7*JCLC7                        {Total ClC7 antiporter turnover [1/sec]} 
 
{Define Terms for Goldman-Hodgkin-Katz Flux (GHK) Equation} 
gg = IF abs(psi) > .01 THEN psi/(1-exp(-psi/RTF))/RTF ELSE  
          1/(1 - (psi/RTF)/2 + (psi/RTF)^2/6 - (psi/RTF)^3/24 +(psi/RTF)^4/120)         {IF THEN 
statement to avoid computational error when psi = 0. Taylor series expansion about a point = 
(psi/RTF) when psi is less than RTF} 
 
{Passive Flows Across Lysosomal Membrane Modeled According to GHK Flux Equation} 
Hleak = P*SA*(10^(-pHe)*exp(-psi/RTF)-10^(-pHi))*gg*mole/1000                                         
{[H
+
/sec]} 
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{Functions/Conversions--------------------------------------------------------------------------------------} 
{Membrane Potentials} 
psi = F*(V*(H+initk+initna- Cl - B))/cap     {Membrane potential [mV] dictated 
by the net change in lysosomal ions, lysosomal membrane capacitance, buffering capacity, and 
Donnan Particles, characteristics of the luminal matrix. Valence of each ion (plus or minus 1) is 
implicitly considered} 
psi_total = psi + psi_out-psi_in             {Total membrane potential [mV]} 
 
{Luminal Concentrations} 
Cl = NCl/V/mole                               {[M]} 
H = NH/V/mole                                 {Total H+ [M]} 
 
{Luminal Content} 
Cl_mol = Cl*V                               {Cl-} 
H_mol = H*V                                 {Total H+} 
 
{Cytosolic Concentrations} 
Clbulk = NClbulk/Vc/mole                   {Cl [M]} 
Hbulk = NHbulk/Vc/mole                     {Total H+ [M]} 
 
{Cytosolic Content} 
Clbulk_mol = Clbulk*Vc                    {Cl-} 
Hbulk_mol = Hbulk*Vc                      {Total H+} 
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{Modified Cytoplasmic Surface Concentrations Dictated by Surface Potential- Derived from 
GHK for a single ion in the case of zero net current flow; also known as Nernst equation} 
Cle = Clbulk*exp(psi_out/RTF)                {[M]} 
Ke = Kbulk*exp(-psi_out/RTF)                 {[M]} 
Nae = Nabulk*exp(-psi_out/RTF)               {[M]} 
pHe = (pHbulk+psi_out/(RTF*2.3))             {[pH units]} 
 
{Modified Luminal Surface Concentrations Dictated by Surface Potential - Derived from GHK 
for a single ion in the case of zero net current flow; also known as Nernst equation} 
Cli = Cl*exp(psi_in/RTF)                      {[M]} 
Ki = initK*exp(-psi_in/RTF)                  {[M]} 
Nai = initNa*exp(-psi_in/RTF)                {[M]} 
pHi = (pH+psi_in/(RTF*2.3))                  {[pH units]} 
 
B.2. Supplementary Figures 
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Figure B.1 The effects of individual lysosomal chloride transportation stressors on the 
physiology of spherical versus tubular lysosomes.  
(A) Modeling the effect of varying CLC7 number on lysosomal pH, Cl
-
, and membrane potential 
with respect to different lysosomal morphology. Maximum depletion of CLC7 has a slightly 
more pronounced effect on spherical lysosomal physiology than on tubular lysosomal 
physiology, as reflected by the maximum increment in membrane potential (> 250 mV, 
represented by the black arrow). (B) Modeling the effect of varying cytoplasmic chloride 
concentration on lysosomal pH, Cl
-
, and membrane potential with respect to different lysosomal 
morphology. Maximum depletion of cytoplasmic chloride induced maximum increment in 
membrane potential (up to 248.3 mV), with minimal changes in lysosomal pH and Cl
- 
accumulation.  
202 
 
 
 
Figure B.2 The effect of a simultaneous CLC7 inhibition and membrane proton 
permeabilization on the physiology of spherical versus tubular lysosomes.  
(A) Lysosomal dimensions used to generate spherical and tubular lysosomes. (B) Modeling the 
effect of simultaneous variations of CLC7 number and membrane proton permeability on 
lysosomal pH, Cl
-
, and membrane potential. The simultaneous maximum depletion of CLC7 
number and increment in membrane proton permeability (> 6x10
-3
 cm/s in the case of the effect 
on lysosomal pH and Cl
-
, and > 6 x10
-5
 cm/s in the case of the effect on lysosomal membrane 
potential) induces > 4 pH unit increment in lysosomal pH, > 150 mM reduction in lysosomal Cl
-
 
accumulation, and > 250 mV increment in membrane potential, as indicated by the black arrows. 
Although the overall effect of these stressors is very similar in both spherical and tubular 
lysosomal physiology, the effect is slightly more pronounced on spherical lysosomal physiology.  
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Figure B.3 The effect of a simultaneous cytoplasmic chloride inhibition and membrane 
proton permeabilization on spherical versus disc-shaped lysosomal physiology.  
Cytoplasmic chloride concentration and membrane proton permeability were simultaneously 
varied in spherical and different sized disc-shaped lysosomes to observe their combined effects 
on lysosomal pH, Cl
-
, and membrane potential. Simultaneously increasing the cytoplasmic 
chloride inhibition (> 80%) and membrane proton permeability (> 0.06 cm/s) induced > 4 pH 
unit increment in lysosomal pH and > 150 mM reduction in lysosomal Cl
-
 accumulation, 
represented by the black arrows. For all lysosomal morphologies, maximum increment in 
membrane potential (> 250 mV, represented by the black arrows) is observed at maximum 
cytoplasmic chloride inhibition. However, the perturbation in lysosomal physiology was 
generally pronounced as the lysosomal radius and surface area expansions were increased.   
 
  
B.3. References 
1 Fricke, H. The Electric Capacity of Suspensions with Special Reference to Blood. J Gen 
Physiol 9, 137-152 (1925). 
204 
 
 
2 Fenwick, E. M., Marty, A. & Neher, E. Sodium and calcium channels in bovine 
chromaffin cells. J Physiol 331, 599-635 (1982). 
 
3 Ishida, Y., Nayak, S., Mindell, J. A. & Grabe, M. A model of lysosomal pH regulation. J 
Gen Physiol 141, 705-720, doi:10.1085/jgp.201210930 (2013). 
 
4 Graves, A. R., Curran, P. K., Smith, C. L. & Mindell, J. A. The Cl-/H+ antiporter ClC-7 
is the primary chloride permeation pathway in lysosomes. Nature 453, 788-792, 
doi:10.1038/nature06907 (2008). 
 
5 Weiss, T. F. Cellular Biophysics: Transport.  (MIT Press, 1996). 
 
6 Hille, B. Ionic Channels of Excitable Membranes. 2nd Edition.  607 (Sinauer Associates, 
Inc. , 1992). 
 
7 Buyukdagli, S., Manghi, M. & Palmeri, J. Variational approach for electrolyte solutions: 
from dielectric interfaces to charged nanopores. Phys Rev E Stat Nonlin Soft Matter Phys 
81, 041601, doi:10.1103/PhysRevE.81.041601 (2010). 
 
8 Gekle, M. & Silbernagl, S. Comparison of the buffer capacity of endocytotic vesicles, 
lysosomes and cytoplasm in cells derived from the proximal tubule of the kidney 
(opossum kidney cells). Pflugers Arch 429, 452-454 (1995). 
 
9 Alberts B, J. A., Lewis J, Raff M, Roberts K, Walter P. Molecular Biology of the Cell. 
4th edition. New York: Garland Science; 2002. Transport into the Cell from the Plasma 
Membrane: Endocytosis. Available from: 
https://www.ncbi.nlm.nih.gov/books/NBK26870/. 
 
 
 
 
 
